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I 
 
Abstract 
 
Schizophrenia is a severe, chronic and debilitating psychiatric disorder.  Current 
therapies have no efficacy in treating the cognitive impairments which are 
largely responsible for the poor quality of life of schizophrenia patients and 
contribute to the massive economic burden that is associated with the disorder. 
 
Although it is known that schizophrenia is highly heritable, the underlying 
genetic basis is still poorly understood due to the complex polygenetic nature of 
the disorder.  Several candidate genes which are thought to increase risk for the 
incidence of schizophrenia have been identified.  Two such schizophrenia 
candidate genes are neuregulin 1 (NRG1) and v-erb-a erythroblastic leukaemia 
viral oncogene homolog 4 (ERBB4).  As well as the genetic evidence from genetic 
association studies, studies of animal models and the endogenous biological 
functions of NRG1 and ERBB4 in the CNS suggest that these genes may play an 
important role in the pathophysiology of schizophrenia.  However, very little is 
known about the functions of these genes in specific brain regions in adulthood 
with respect to cognition.   
 
To address this, I have utilised recombinant adeno-associated viral particles 
(rAAVs) as a vehicle to mediate knockdown of the expression of Erbb4 
specifically within the medial prefrontal (mPFC) cortex of adult rats.  This allows 
for a spatially and temporally controlled investigation of the role that Erbb4 
signalling may play in prefrontal cortex-dependent behaviours in adulthood.   
 
Following initial in vitro and in vivo validation of the functionality of the rAAVs, 
further in vivo studies confirmed that, five weeks after stereotaxic injection of 
rAAVs encoding a short hairpin sequence corresponding to Erbb4 (shErbb4.rAAV), 
into the mPFC of rats, there was significant Erbb4 protein knockdown, as 
analysed by ELISA.  Subsequent western blot analysis revealed that Erbb4 
knockdown consequently increased the level of Nrg1 expression and decreased 
the activity of Akt signalling, but had no effect on Erk signalling.   
 
Erbb4 knockdown specifically within the mPFC increased performance accuracy 
in the 5-choice serial reaction time task at 5 weeks post-surgery. Furthermore, 
viral mediated Erbb4 knockdown specifically within the mPFC heightened the 
II 
 
sensitivity to the locomotor inducing effects of amphetamine.  There were, 
however, no effects of Erbb4 knockdown on pre-pulse inhibition at any time 
points assessed.  These results indicate that Nrg1-Erbb4 signalling in the PFC 
modulates cognitive performance but not sensorimotor gating, and that 
dopaminergic transmission may be regulated by Nrg1-Erbb4 signalling.  
 
In conclusion, this study highlights the ability of viral mediated gene 
manipulation to investigate regionally specific roles of schizophrenia candidate 
genes in adulthood in terms of cognition and downstream signalling pathways.  
This may translate to a better understanding of how these genes may exert 
potentially pathophysiological effects in patients and ultimately lead to 
improved treatments.   
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1.1 Schizophrenia 
Schizophrenia is a chronic and debilitating psychiatric disorder in which, unlike 
many other neurological diseases, the onset of symptoms generally manifest in 
late adolescence/early adulthood.  The causes of the disorder are unclear but 
mostly likely result from genetic and environmental factors which impact on 
neurotransmitter systems in particular brain circuits.  Emil Kraepelin, a German 
psychiatrist, first described schizophrenia in 1893 and termed the disorder, 
Dementia Praecox, to differentiate it from other forms of dementia.  However 
Dementia Praecox-meaning early dementia- was somewhat misleading as not all 
people with schizophrenia experience dementia.  Later, the psychiatrist Eugene 
Bleuler renamed Dementia Praecox and coined the term “schizophrenia” in 
1908, and made the observation that schizophrenia appeared to be a group of 
diseases as it had multiple effects on personality, thought, cognition and 
motivation.  A recent systematic review of the epidemiology of schizophrenia 
indicates that approximately 7 per 1000 individuals will develop schizophrenia 
during their lifetime (McGrath et al., 2008).   Furthermore, men are at a slightly 
higher risk than women for developing schizophrenia, with a male:female risk 
ratio of 1.4:1 being identified in multiple studies (Aleman et al., 2003; McGrath 
et al., 2008).  With the lifelong duration of schizophrenia, the economic burden 
of the disorder is a huge cost to UK society, with an estimated cost of £6.7 
billion in 2004/5 in England alone (Mangalore & Knapp, 2007).   
 
1.1.1 Symptoms of schizophrenia 
Diagnosis of schizophrenia is carried out according to guidelines set by the 
Diagnostic and Statistical Manual of Mental Disorders IV (DSM IV) in the USA and 
the International Classification of Diseases 10th revision (ICD-10) in Europe.  Both 
guidelines state that in order to diagnose a patient with schizophrenia they must 
have a specific number of symptoms, which have been presented for a specific 
duration of time.  For example DSM IV states that the patient must have two or 
more of the “characteristic” symptoms of schizophrenia, present for a 
significant portion of time during a one month period.  Schizophrenia is thought 
of as a spectrum disorder with many subtypes of schizophrenia being classified 
based on severity and presence of symptoms, including paranoid schizophrenia, 
3 
catatonic schizophrenia, residual schizophrenia and undifferentiated 
schizophrenia (ICD-10).  
 
The symptoms of schizophrenia have been broadly categorised into three groups 
including positive symptoms, negative symptoms and cognitive deficits.  Positive 
symptoms of schizophrenia are clinical features that are normally absent in the 
general population, for example hallucinations most commonly of an auditory 
nature, delusions, thought disorder and disorganised speech (ICD-10).  Unlike 
positive symptoms, which reflect an excess of normal functions, negative 
symptoms of schizophrenia are observed as a loss of thoughts, feelings or 
emotions normally present in the general population.  For example negative 
symptoms include the loss of motivation, withdrawal from society, inability to 
experience pleasure (anhedonia), blunted emotions and apathy. It is these 
symptoms that are associated with the staggeringly high co-morbidity seen in 
schizophrenia with ~10% schizophrenics committing suicide (Meltzer et al., 
2002).  
 
The third classification of symptoms of schizophrenia is cognitive deficits, which 
are now widely recognised as a core feature of the disorder.  Seven cognitive 
domains have been identified to be deficient in patients with schizophrenia 
including; working memory, processing speed, visual and verbal learning and 
memory, social cognition and attention and vigilance (Nuechterlein et al., 2004).  
Moreover, the importance of cognitive deficits in schizophrenia has been 
emphasised by studies showing cognitive performance correlates with functional 
outcome in schizophrenia patients (Green, 1996, Green, 2006).  Poor cognitive 
performance, likely in combination with the effects of negative symptoms may 
explain why it is estimated that almost 80% of schizophrenia patients are 
unemployed (Mangalore & Knapp, 2007). 
 
1.1.2 Neuropathology of schizophrenia 
Unlike other disorders of the brain where distinct neuropathologies are evident 
with disease progression, such as amyloid plaques and neurofibrillary tangles in 
Alzheimer’s disease, schizophrenia is not associated with gross neuroanatomical 
changes.  Instead, subtle morphological and cytoarchitectural changes have been 
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identified in the post-mortem studies of brains of patients that had 
schizophrenia.   
Lateral ventricular enlargement has been reported in schizophrenia since 1976 
(Johnstone et al., 1976). A review of MRI studies revealed that the median 
increase in ventricular size in schizophrenia is 40% (Lawrie & Abukmeil, 1998). 
This review also revealed this enlargement was accompanied by reduction in 
brain volume of an average of 3%, with medial temporal structures being 
affected.  The morphology of other brain regions has also been implicated in 
being affected by schizophrenia.  The temporal lobe has been implicated in 
particular as a loss in size of this region, particularly the superior temporal 
gyrus, has been correlated to the extent of auditory hallucinations (Shenton et 
al., 1992). Similarly, Wible et al., (1995) found a correlation between the 
reduction in frontal lobe volume and the extent of negative symptoms.  
However, studies have been confounded due to the use of post-mortem tissue 
from patients who have undergone treatment with antipsychotics for long 
periods of time and also the variables between donors of the tissues e.g. age, 
period of antipsychotic treatment, and extent of clinical symptoms.  However, 
magnetic resonance imaging (MRI) studies in first episode schizophrenia patients 
have also shown global brain volume reductions (Steen et al., 2006; Vita et al., 
2006). 
 
There have also been cytoarchitectural abnormalities found in schizophrenia; for 
example there is a decrease in cellular size of neurones in the dorsolateral 
prefrontal cortex and hippocampus (Harrison, 1999).  This study also suggested 
that there is accompanying increase in neurone density in these brain regions.  
Dendritic spine and synapse densities have also been shown to be affected in cell 
subtypes in schizophrenia (Selemon & Goldman, 1999; Chen et al., 2008).  These 
cytoarchitectural changes may lead to a lack of connectivity between brain 
regions, possibly leading to the manifestation of positive, negative or cognitive 
symptoms of schizophrenia.  Further evidence for dysconnectivity of brain 
regions in schizophrenia stems from reports showing deficits in myelination, 
resulting from myelin sheath or oligodendrocyte abnormalities (Konrad & 
Winterer, 2008).  
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Many of these findings have led to the development of the neurodevelopmental 
theory of schizophrenia.  This theory posits that an as yet unidentified pre- or 
neonatal insult to the brain, disrupts the function of late maturing brain regions 
such as the PFC that ultimately manifests as behavioural abnormalities later in 
life (Weinberger, 1987). 
 
1.2 Hypotheses of schizophrenia 
The underlying causes of the symptoms of schizophrenia are thought to be due 
to an imbalance of neurotransmitter levels in distinct brain regions.  However, it 
is common opinion that due to the complex nature of schizophrenia not a sole 
neurotransmitter pathway is affected.  Instead it is thought that alterations in 
multiple neurotransmitter systems converge and have feedback effects on each 
other. 
1.2.1 The dopamine hypothesis 
The dopamine (DA) hypothesis of schizophrenia was originally based upon the 
observations of Carlsson and Lindquist (1963), who proposed that hyperactivity 
of DA transmission was linked to the positive symptoms of schizophrenia.  
Furthermore, all typical antipsychotic drugs, which are somewhat effective in 
managing positive symptoms, have high affinity for the DA D2 receptor which is 
predominantly expressed in subcortical regions of the brain (Seeman, 2004).  In 
addition amphetamine, which enhances DA release, worsens positive symptoms 
of schizophrenia patients (Angrist et al., 1974) and induces schizophrenia-like 
symptoms in unaffected individuals (Janowsky & Risch, 1979).  From these 
studies it is thought that over-activity of subcortical dopamine DA systems is 
responsible for the positive symptoms of schizophrenia.  Moreover a series of 
studies have shown increased D2 receptor binding in mesolimbic regions of the 
brains of schizophrenia patients (MacKay et al., 1982; Seeman et al., 1984; 
Crawley et al., 1986) 
 
In contrast, D1 receptors are predominantly expressed in cortical regions (Davis 
et al., 1991).  It is thought that a hypodopaminergic state in this prefrontal 
cortical region may be responsible for the cognitive deficits of schizophrenia, as 
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D1-mediated transmission is required for optimal PFC activity and thus 
performance in cognitive tests (Goldman-Rakic, 2000).  This is supported by the 
fact that current antipsychotic treatments, which predominantly act by 
antagonising D2 receptors have little efficacy in the treatment of cognitive 
deficits.  The imbalance between mesocortical dopamine deficiency and 
mesolimbic dopamine over-activity may then explain all three symptom domains 
of schizophrenia.  
 
1.2.2  Glutamate hypothesis 
There is growing support for the hypothesis of glutamatergic dysfunction in 
schizophrenia.  This was primarily proposed due to non-competitive N-Methyl-D-
asparate (NMDA) receptor antagonists, for example ketamine and phencyclidine 
(PCP), producing effects similar to positive, negative and cognitive symptoms of 
schizophrenia in healthy humans (Krystal et al., 1994; Ardler et al., 1999; Lahti 
et al., 2001).  Moreover, administration of these antagonists can exacerbate 
symptoms in schizophrenia patients (Luby et al., 1959; Allen et al., 1978; Lahti 
et al., 2001).  In line with these findings, it is thought that schizophrenia may 
involve NMDA receptor hypofunction.  This is supported by evidence for reduced 
NMDA receptor subunit GRIN1 (NR1) mRNA levels in post-mortem brains of 
schizophrenia patients (Law & Deakin, 2001) and reductions in markers for 
glutamate transport for example vesicular glutamate transporter-1 
(SLC32A1/VGAT1) (Reynolds and Harte, 2007).   
 
In agreement with NMDA receptor hypofunction, GABAergic neurotransmission is 
thought to be affected in schizophrenia.  NMDA receptors are particularly 
concentrated on parvalbumin-containing GABA interneurones, loss of function of 
these NMDA receptors impacts GABAergic dysregulation (Morris et al., 2005).  
Reductions in parvalbumin-positive GABA-ergic interneurones in frontal and 
hippocampal regions have been observed in schizophrenia (Benes et al., 2000; 
Reynolds et al., 2004).  Glutamic acid decarboxylase (GAD)-67 (GAD1) an enzyme 
important in the conversion of glutamate to GABA is also thought to be down-
regulated in schizophrenia (Lipska et al., 2003). 
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1.2.3  Other hypotheses 
Other neurotransmitters have also been implicated in the pathology of 
schizophrenia, for example serotonin (5HT).  5-HT involvement in schizophrenia 
was first prompted by the observation that lysergic acid diethylamide (LSD), 
which binds with high affinity to 5HT receptors, induces psychosis-like symptoms 
(Hemmings & Hemming, 1978).  The serotonin hypothesis was also strengthened 
by the observation that the antipsychotic clozapine, which was found to have 
higher efficacy in treating symptoms, with fewer extra-pyramidal side effects 
(EPS), had an ability to block 5HT2A receptors (Baldessarini & Frankenburg, 
1991).  This implies that schizophrenia may be partly due to an over-activation 
of 5HT receptors. 
 
1.3  Treatments of schizophrenia 
Although there is, as of yet, no cure for schizophrenia, there are drugs available 
for the life-long management of positive symptoms, and to a lesser extent 
negative symptoms.  However, there is to date no significantly effective 
treatment for the cognitive deficits.  Some of the earlier treatments for 
schizophrenia resulted in unwanted side effects; nevertheless, with better 
pharmacological knowledge, more effective, safer antipsychotic drugs are being 
produced. 
 
1.3.1  Typical antipsychotics 
Typical antipsychotics, also referred to as first generation antipsychotics, 
include haloperidol, chlorpromazine, thioridazine and flupenthixol.  These drugs 
have a high affinity for D2 receptors and are linked to a number of serious side 
effects.  These side effects include dry mouth, muscle stiffness, tremors and 
extra-pyramidal symptoms (EPS).  EPS are a group of side effects caused by 
hypodopaminergic transmission in the nigrostriatal pathway and resemble 
symptoms of Parkinson’s disease.  These include dystonia (muscle spasms), 
tardive dyskinesia (involuntary movement of muscles, usually in the face) and 
akathisia (restlessness).  Moreover, although there is high D2 receptor blockade, 
some patients are resistant to typical antipsychotic treatment.  Importantly 
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these drugs also have no effect on negative symptoms or cognitive deficits (Abi-
Dargham & Laruelle, 2005).   
 
1.3.2 Atypical antipsychotics 
Schizophrenia treatment was revolutionised with the introduction of clozapine in 
the early 1990s.  This drug was found to be better in treating positive symptoms 
in treatment-resistant schizophrenia patients and also produced fewer EPS.  This 
reduction in EPS may be due to the drug having a different pharmacological 
profile from typical antipsychotics, with a lower blockade of DA receptors.  
Clozapine however does cause alternative side-effects such as weight gain, and 
more seriously, agranulocytosis.  Therefore it is mainly prescribed to treatment-
resistant schizophrenia patients.  Other atypical antipsychotics, such as 
olanzapine, risperidone and amisulpride, like clozapine, do not act solely by 
antagonising D2 receptors, but have a wide range of affinities including 5HT 
receptors, other DA receptor subtypes and histamine receptors (Abi-Dargham & 
Laruelle, 2005).  Despite this relatively broad tropism, Clinical Antipsychotic 
Trials of Intervention effectiveness (CATIE) studies and Cost Utility of the Latest 
Antipsychotic drugs in Schizophrenia Study (CUtLASS) failed to find atypical 
antipsychotics significantly more effective than their predecessors (Lieberman et 
al., 2005; Jones et al., 2006).  Furthermore, cognitive deficits are poorly treated 
by atypical antipsychotics.   
 
1.3.3 Developing therapies 
With multiple hypotheses of the potential underlying neurotransmission deficits 
involved in schizophrenia now generally accepted, there has been a rapid 
development of drugs which target these alternative neurotransmitter systems.  
These drugs include metabotropic glutamate receptor 5 (mGluR5/GRM5) 
activators which enhance NMDA receptor function.  However, there are 
difficulties in producing drugs which act specifically at subtypes of mGluRs, as 
their binding sites are very similar.  Due to the complex genetic nature of 
schizophrenia, which most likely leads to the heterogeneity observed in 
symptom severity, it is probable that patients with symptom clusters or specific 
polymorphisms will respond better to more targeted treatments.  However, the 
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causal genetics and neurotransmitter impairments in schizophrenia are too 
poorly understood for the development of such drugs at this time. 
 
1.4  Risk factors implicated in schizophrenia 
Schizophrenia is a very complex disorder and it is thought that there are several 
causative factors that can increase the risk of subsequent development of the 
condition.  However, the complexity of schizophrenia suggests that there is not 
one individual underlying causative factor.  Instead it is feasible to say that 
additive or interactive effects between several candidate genes and several 
environmental factors are responsible.  
 
1.4.1 Illegal substances 
One such risk factor associated with schizophrenia is the use of illegal 
substances, in particular cannabis.  Cannabis use is known to produce effects on 
the CNS that reflect some of the symptoms of schizophrenia such as impairments 
in memory and attention, anxiety and hallucinations.  Moreover, long term heavy 
use of cannabis has been associated with long term cognitive deficits (Hall & 
Solowij, 1998); however, this has been the subject of much debate.  
Furthermore, there is evidence for increased cannabinoid receptor, CB1 (CNR1), 
expression in multiple brain regions of schizophrenia patients including the 
dorsolateral prefrontal cortex (Dean et al., 2001).  There have been many 
studies investigating the link between cannabis use and increased risk to 
schizophrenia development; however the results of these studies have been 
variable.  In 2005 a meta-analysis of these studies showed that cannabis 
consumption is related to doubling the risk of schizophrenia (Henquet et al., 
2005).  It has also been reported that the age of onset of cannabis use affects 
the risk factor.  Arseneault et al., (2002), demonstrated this by reporting that 
people who regularly used cannabis by early adolescent years (15 years old) 
were four times more likely to be diagnosed with schizophrenia or a 
schizophrenia-like-disorder by the age of 26 than controls (people who had never 
used cannabis or had used it once or twice as an adolescent).  
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1.4.2  Environmental factors 
Environmental risk factors have also been associated with increased risk of 
schizophrenia.  It has been reported that risk of schizophrenia is altered by 
whether birth and childhood upbringing took place in an urban or rural 
environment.  There is an increased risk of schizophrenia in people who are born 
in urban areas, and this risk is increased relative to the length of time spent in 
this environment (Pedersen and Mortensen, 2001).  The reason for this change in 
risk level is unknown; however, differences in diet, exposure to toxins and 
infections as well as social class have all been suggested as an explanation.  In 
addition to area of birth, time of birth has been proposed as a risk factor for 
developing schizophrenia.  It has been shown in both Northern and Southern 
hemisphere countries that people born in winter and spring months compared to 
other seasons are more likely to develop schizophrenia (Torrey et al., 1997). 
 
1.4.3  Intrauterine environmental factors 
The environment during prenatal life is also an important causative risk factor 
for schizophrenia.  There is an increased risk of schizophrenia in people whose 
mother was malnourished during pregnancy.  A well documented case of this is 
the Dutch Hunger Winter during 1944-45, where people conceived during the 
famine were later shown to have a two fold higher risk of schizophrenia than 
people conceived in the country in years previous to the famine (Hoek et al., 
1998).  This increase in risk was replicated in another study investigating the 
Chinese famine of 1959-61 (St Clair et al., 2005).  The most accepted reasoning 
behind this increase in risk is that intrauterine nutrients are necessary for 
normal foetal development including development of the brain.  Other 
complications during pregnancy can also lead to the delivered child having an 
increase in the risk of developing schizophrenia, for example obstetric 
complications during labour (Cannon et al., 2001)  and viral infections during 
pregnancy such as Influenza (Limosin et al., 2003), Rubella (Brown et al., 2001) 
and Herpes Simplex (Buka et al., 2001). 
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1.4.4  Genetic factors 
Schizophrenia is known to be a highly heritable disorder and there is a high 
incidence running through families.  The concordance rate of schizophrenia is 
80% (Cannon et al., 1998; Cardno et al., 1999; Sullivan et al., 2003).  In 
monozygotic twins, who share 100% genetic material, if one twin has 
schizophrenia the other twin has a 40-50% risk of also developing schizophrenia 
(Gottesman et al. 1987; Sullivan et al., 2003).  This risk drops to approximately 
15% in dizygotic twins or siblings who share 50% genetic material (Gottesman et 
al. 1987; Sullivan et al., 2003).  Although the concordance rate of schizophrenia 
is very high, it is not 100%, which suggests schizophrenia is not purely a genetic 
disorder.   
1.4.5 Gene x environment interaction 
It is now widely accepted that other factors other than genes (as described in 
sections 1.4.1, 1.4.2, 1.4.3) are capable of subtly increasing risk for 
schizophrenia, and in recent years attention has turned to investigating 
potential interactions between genetic and environmental risk factors.  
However, these studies are difficult to carry out due to their longitudinal 
requirements. 
 
To date the most successful gene x environment studies have been those 
investigating the interaction between genes and cannabis use.  One such 
example of this additive effect is that adolescents who smoke cannabis and have 
a specific single nucleotide polymorphism (SNP) in the gene Catechol-O-methyl 
transferase (COMT), which encodes an enzyme which degrades catecholamines 
(involved in dopamine catabolism), have a greater risk for schizophrenia than an 
adolescent individual that solely smokes cannabis or solely has the COMT gene 
polymorphism (Caspi et al., 2005).  This result however, was not confirmed in a 
similar subsequent study (Zammit et al., 2007).  Another gene, Neuregulin 1 
(NRG1), has also been recently linked to having a potential interaction with 
cannabis, as mice with a mutation in the Nrg1 gene show a heightened response 
to the psychoactive component of cannabis, -9-tetrahydrocannabinol (THC) 
(Boucher et al., 2007). 
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1.5 Identification of schizophrenia candidate genes 
Although it is known that schizophrenia runs in families, it is also known that 
schizophrenia is not inherited in a Mendelian inheritance pattern, and the 
precise mechanism of inheritance in schizophrenia remains unknown.  Over the 
past few decades, as advances in molecular biology have significantly 
progressed, many genes have been identified that may be associated with 
increased liability to schizophrenia.  Advances in technology have facilitated the 
identification of these schizophrenia candidate genes. 
 
1.5.1 Structural chromosomal studies 
Several schizophrenia candidate genes have been identified via studies 
investigating changes in chromosome structure.  Deletion of the chromosomal 
region 22q11 has been found to lead to velo-cardio-facial-syndrome (VCFS).  This 
microdeletion syndrome is estimated to affect 1:2500-1:4000 live births, and is 
associated with a 30-fold increase in the risk of affected individuals with VCFS to 
develop schizophrenia (Murphy et al., 2002; Gothelf et al., 2007).  Deletion of 
this chromosomal region will affect the expression of multiple genes, however.   
Two of these are of particular interest in terms of schizophrenia.  COMT which 
encodes an enzyme initiating the degradation of catecholamines such as the 
neurotransmitter dopamine by catalysing their methylation, and Proline 
dehydrogenase (PRODH) which encodes an enzyme which initiates the 
degradation of proline: an amino acid important in the synthesis of glutamate 
(Harrison & Weinberger, 2005).  Since several aspects of schizophrenia have 
been linked to the manifestation of altered dopaminergic and glutamatergic 
states in specific brain regions, COMT and PRODH are likely candidate genes for 
schizophrenia. 
 
An autosomal balanced translocation involving chromosomes 1q42.1 and 11q14.3 
was identified in a large Scottish family that were found to have a very high 
incidence of schizophrenia, bipolar disorder and major depression (St Clair et 
al., 1990).  Subsequent sequencing of the 1q42 and 11q14.3 breakpoints led to 
the finding of two novel genes disrupted by the previous mutation, DISC1 and 
DISC2, with only DISC1 having the ability to encode protein (Millar et al., 2000).  
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DISC1 is a promising schizophrenia candidate gene as it has many functions which 
relate to the pathophysiology of the disorder, with Morris et al., (2003) 
concluding that “DISC1 is a multifunctional protein whose truncation may 
contribute to schizophrenia susceptibility by disrupting intracellular transport, 
neurite architecture, and/or neuronal migration”.  
 
More recent studies have shifted from looking at gross chromosomal structural 
changes to more focussed studies of sub-microscopic copy number variants 
(CNVs) - microdeletions or microduplications of small stretches of DNA.  Several 
studies utilising genome wide searches for CNVs have found CNVs are more 
abundant in schizophrenia patients (Kirov et al., 2008; Walsh et al., 2008; Xu et 
al., 2008). Genes which appear to be affected by these deletions or duplications 
include those previously implicated in schizophrenia including Neurexin (NRXN1) 
and ERBB4 (Kirov et al., 2008; Walsh et al., 2008; St Clair, 2009).  These 
chromosomal aberrations are highly penetrant variants, which are thought to 
exist in combination with other genetic variants to increase the genetic risk for 
schizophrenia. 
 
1.5.2 Linkage studies 
The aim of linkage analysis studies, which are carried out using samples from 
affected families, is to identify regions of the genome which are shared between 
affected family members but not among unaffected family members (I.e. 
inherited genetic variation).  Many linkage studies have implicated “risk regions” 
of the genome that appear to be linked with schizophrenia.  Meta-analyses of 
over 30 schizophrenia linkage studies found that chromosomal regions 8p21-22 
and 22q11-12 are likely to contain potential schizophrenia candidate genes 
(Badner & Gershon, 2002; Lewis et al., 2003).  Although linkage studies do not 
identify individual candidate genes they do narrow down regions in which these 
genes may be positioned; further studies within these regions can then identify 
individual genes.  Several plausible schizophrenia candidate genes have been 
identified from these aforementioned “risk regions” such as NRG1 which is 
located on 8p21-22 (see section 1.8).   
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1.5.3 Association studies 
Unlike linkage studies, association studies can be carried out on unrelated 
individuals, and aim to investigate if SNPs within a specific gene are associated 
with disease.  SNPs represent common genetic variations which, individually, 
have low penetrance.  Support for many schizophrenia candidate genes has been 
strengthened by positive findings of association studies, including dystrobrevin 
binding protein (also known as dysbindin) (DTNBP1) (Straub et al., 2002).  A 
useful resource for the overview of association studies of schizophrenia 
candidate genes is SZGene (www.schizophreniaforum.org/res/sczgene) which 
lists both positive and negative findings for many genes.  From these findings 
SZGene composes a list of the current top schizophrenia genetic risk factors 
(based on genetic evidence only), the top schizophrenia candidate gene as of 
1/12/2010 is PRSS16 which encodes a serine protease.  Often negative findings 
of previously positively associated genes are found, this may be due to 
limitations in sample size, ethnicities tested and which SNPs were investigated. 
Genome wide association studies (GWAS) utilise a similar approach to the 
aforementioned association studies.  However, instead of investigating SNPs in 
an individual gene, genotypes of cases and controls for half a million to a million 
SNPs are simultaneously tested on a chip.  Because of the large number of 
statistical comparisons required in such studies, the risk of false positive findings 
is increased by using this method.  Therefore the threshold for a significant 
finding of a difference in genotype frequency between cases and controls has to 
be set much higher than that of regular association studies.  Several 
schizophrenia GWAS scans have been carried out since 2007 with many 
interesting genes being identified, such as the zinc finger gene, ZNF804A 
(O’Donovan et al., 2008).  However, three meta-analyses of GWAS scans only 
found converging results for the major histocompatibility region on chromosome 
6 being associated with schizophrenia (Purcell et al., 2009; Shi et al., 2009; 
Stefansson et al., 2009).  
Although converging evidence is emerging for genetic risk factors for 
schizophrenia, the polygenic nature of the disorder makes the identification of 
the underlying genetic risks very complex.  It has been suggested that the 
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complex genetic risk of schizophrenia is due to low penetrance variations in 
1000s of individual genes (Purcell et al., 2009).  However, it is also likely that it 
is a combination of multiple common polymorphisms in schizophrenia candidate 
genes and rare de novo mutations that contributes to the risk of schizophrenia.  
With the ongoing development of new technologies, such as next generation 
sequencing, the genetic burden of schizophrenia will be better understood.    
1.6 Measuring cognition in rodents 
Cognitive deficits are now considered to be a core symptom domain of 
schizophrenia, with cognitive performance being closely correlated with 
functional outcome in patients (Green, 1996; Green, 2006).  Unfortunately 
current antipsychotic therapies are inefficient at treating these cognitive 
deficits (Harvery & Keefe, 2001; Keefe et al., 2007).  Therefore, an initiative 
was developed to identify the cognitive symptoms that have unmet therapeutic 
need, called the Measurement and Treatment Research to Improve Cognition in 
Schizophrenia (MATRICS) initiative.  This initiative identified seven domains of 
cognition that are affected in schizophrenia 1) attention/vigilance 2) working 
memory 3) reasoning and problem solving 4) processing speed 5) visual learning 
and memory 6) verbal learning and memory 7) social cognition (Marder et al., 
2004).  
Preclinical assessment that maps onto these symptom domains in rodents may 
allow the discovery and selection of potentially useful therapies for treating the   
cognitive deficits of schizophrenia.  For example attention/vigilance and 
processing speed can be measured in the 5-choice serial reaction time task (5-
CSRTT), a preclinical equivalent to the continuous performance task (CPT) in 
humans (Robbins, 2002). Problem solving and reasoning can be assessed by the 
attentional set-shifting task which is analogous to the Wisconsin Card Sorting 
Task (WCST) used in humans (Birell & Brown, 2000).  Other tasks such as social 
recognition and social interaction allow assessment of social cognition, whereas 
working memory can be assessed by the radial arm maze and odour span tests 
(Young et al., 2009). 
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1.7 Animal models 
With the complexity of schizophrenia come limitations to the creation of animal 
models of the disorder.   Although it is unlikely that animal models are capable 
of encapsulating all aspects of the disorder, it is possible to model components 
of schizophrenia.  To date animal models have allowed a better understanding of 
the underlying neurotransmitter systems that are likely to be dysfunctional in 
schizophrenia.  They also allow preclinical testing of potential new therapies for 
schizophrenia.  There are several different mechanisms by which animal models 
of schizophrenia have been generated, each mechanism generating models 
reflecting slightly different aspects of schizophrenia, with their own distinct 
advantages and disadvantages.   
1.7.1 Pharmacological models 
Pharmacological animal models of schizophrenia are based upon the current 
knowledge of the alterations in neurotransmitter systems that are thought to 
lead to the symptoms of schizophrenia.  For example, based on the glutamate 
hypothesis of schizophrenia (section 1.2.2), administration of PCP to rats has 
been shown to result in not only biochemical changes but also behavioral deficits 
that reflect those observed in schizophrenia patients.  Previous studies from our 
laboratory have shown that repeated PCP administration to rats led to reduced 
parvalbumin (Pvalb) mRNA and Kv3.1 (Kcnc1) potassium channel mRNA, which 
are both expressed in GABAergic interneurones (Cochran et al., 2002; Cochran et 
al., 2003).  Additionally, PCP causes reduced metabolic activity in PFC and 
reduces network connectivity (Cochran et al., 2003; Dawson et al., 2010).  
Furthermore, transcriptome analysis of PFC tissue, from rats chronically treated 
with PCP, showed that PCP treatment altered the expression of many genes with 
functions related to the glutamate and GABA systems (Catherine Winchester, 
personal communication).  These alterations included genes located on 
chromosomal loci that have been previously implicated in schizophrenia 
including 8p22-21 (Winchester et al., 2007).  In addition PCP treatment in rats 
has resulted in deficits in behaviours that are dysfunctional in schizophrenia, 
including sensorimotor gating (Egerton et al., 2005), executive function as 
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assessed by set-shifting (Egerton et al., 2003; Egerton et al., 2005; Dawson et 
al., 2010) and attention, vigilance and processing speed (Thomson et al., 2010).  
Other pharmacological substances, including toxins, have also been utilized to 
generate animals which resemble some of the aspects of schizophrenia.  For 
example prenatal exposure of rats to the mitotoxin methylazoxymethanol (MAM) 
decreases cortical mass, causes deficits in PPI, heightened locomotor response 
to amphetamine and deficits in working memory (Moore et al., 2006). 
1.7.2 Environmental models 
As described in section 1.4.2, environmental factors have also been implicated 
in increasing the risk to schizophrenia.  Rodents with environmental insults show 
biochemical and behavioral changes that resemble those of schizophrenia.  Rats 
or mice that are moved into social isolation post-weaning show deficits in 
prepulse inhibition, locomotor activity and object recognition (Jones et al., 
2010) along with decreased cortical and hippocampal synaptic plasticity (Comery 
et al., 1995; Silva–Gomez et al., 2003). 
1.7.3 Genetic models 
Genetic association studies have identified polymorphisms within many genes 
that increase risk for schizophrenia; in addition numerous genes have been 
identified/hypothesised as functional candidate genes based on their 
endogenous roles within the CNS which are known to be dysfunctional in 
schizophrenia.  However, to date no causative genes have yet been identified.  
Therefore, in order to understand further the functions of these genes and to 
gain a better insight into how they may be potentially pathophysiological in 
schizophrenia, animal models have been generated with altered forms of 
schizophrenia candidate genes.   
 
For example animal models with deletion of chromosome 22q11.2 show 
sensorimotor gating and working memory deficits that reflect aspects of 
schizophrenia (Paylor et al., 2001).  Targeted mutation of selected 
schizophrenia genes in rodents has permitted a greater understanding of how the 
gene of interest may play a role in structural and biochemical changes of 
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schizophrenia.  Animal studies of Disc1 show a strong link between the gene and 
schizophrenia.  For instance Kamiya et al., (2005) demonstrated that loss of 
expression of Disc1 by RNAi (quantified by western blot) resulted in impaired 
cerebral cortex development,  whereas another study demonstrated that Disc1 
dysfunction in schizophrenia may lead to altered glycogen synthase kinase 3 
(GSK3) signalling (Mao et al., 2009).  In addition functions of Nrg1 and Erbb4 
have been better understood by animal models of these genes (see section 
1.9.3).   
 
1.8 Neuregulin-Erbb signalling  
1.8.1 Neuregulin 1 (NRG1) nomenclature and structure 
Neuregulins are a family of four growth factor genes (NRG1-4) that mediate 
important roles in a number of different organs by activating receptor tyrosine 
kinases.  Human NRG1 (also known as heregulin) was first identified in the early 
1990’s (Holmes et al., 1992), with the identification of NRG2, NRG3 and NRG4 
occurring in subsequent years (Carraway et al., 1997; Zhang et al., 1997; Harari 
et al., 1999).  Of the neuregulins, NRG1 has been most widely studied due to its 
important roles in CNS and cardiac development.  However, recently there has 
been a surge of interest in NRG3 as it is the only neuregulin with expression 
restricted to the brain and its binding ability restricted to specific receptor 
tyrosine kinase sub-types (Zhang et al., 1997), making NRG3 a potentially 
attractive molecule to study in terms of neurological disorders.   
 
The structure of the human NRG1 gene has been widely investigated since its 
discovery.  NRG1 is a large gene (1.4 megabases (Mb)) located on chromosome 
8p12.21, and due to multiple promoter transcription start sites and alternative 
splicing there are approximately 31 transcript isoforms (Mei & Xiong, 2008). The 
nomenclature of these isoforms is based upon four structural characteristics: 1) 
The N-terminal encoded sequence determines the “type” of NRG1, with six 
distinct types of NRG1 (NRG1 type I-VI) having been identified to date.  Types I, 
II, IV and V are similar in that they possess an immunoglobulin (Ig) domain 
whereas type III possesses a cysteine rich domain (CRD).  Type VI NRG1 lacks the 
exons that encode for Ig and CRD domain and so little is known about its 
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processing and signalling capabilities. 2) All NRG1s contain an epidermal growth 
factor (EGF)-like domain; however there are three types of EGF-like domains 
termed ,  and 3) The linker region between the EGF-like encoding domain 
and the C-terminal transmembrane encoding domain (TMD) is also subject to 
alternative splicing, resulting in four variants (1-4) of the linker region.  4) The 
C-terminal domain can consist of a cytoplasmic tail of type a, b or c (Falls, 2003; 
Mei & Xiong, 2008).  These isoform defining characteristics determine the 
function and regional expression of NRG1, for example NRG1 isoforms with a 
EGF-like domain and a type “a” cytoplasmic tail are the most prominently 
expressed in the brain (Falls, 2003).  A simplified summary of the NRG1 
nomenclature is shown in Figure 1-1.   
 
The NRG1 gene encodes a membrane bound pro-protein which is susceptible to 
cleavage by proteases. Tumour necrosis factor- converting enzyme (ADAM17, 
TACE), -amyloid precursor protein cleaving enzyme (BACE) and meltrin  
(ADAM19) act at a juxtamembrane site close to the EGF-like domain (Loeb & 
Fischbach, 1995; Sunnarborg et al., 2002; Yokozeki et al., 2007).  This cleavage 
results in the release of the bioactive extracellular fragment of NRG1 that can 
then initiate signalling cascades via binding to receptor tyrosine kinases 
expressed on the same cell type (autocrine signalling) or other cell types 
(paracrine signalling).  Type III NRG1 is unique in that not only is it the only 
NRG1 type to consist of a CRD but also because its transmembrane domain is 
located within the N-terminal domain.  Thus cleavage of the type III pro-protein 
does not result in release of a bioactive extracellular fragment, but instead 
exposes the bioactive EGF-domain as a tethered ligand still membrane bound.  
Type III NRG1 isoforms are therefore thought only to be capable of juxtacrine 
signalling.   
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Figure 1.1 Neuregulin-1 isoform nomenclature.  NRG1 isoforms arise from 
combinations of type (I-VI), presence of Ig or CR domain, or EGF domain, 
linker region (1-4), cytoplasmic tail a, b or c.* Type VI Nrg1 does not contain either 
Ig or CR domain.  # Type III Nrg1 has an additional TMD located within the N-
terminal domain.  Ig: Immunoglobulin, CRD: cysteine rich domain, EGF: epidermal 
growth factor, TMD: transmembrane domain. 
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1.8.2 NRG1 expression in the CNS 
NRG1 is widely expressed in the adult human brain, including the prefrontal 
cortex, hippocampus, cerebellum and substantia nigra- areas which have been 
linked to being important in schizophrenia (Law et al., 2004; Bernstein et al., 
2006).  Similarly, in the adult rat brain Nrg1 expression has been shown in these 
structures (Chen et al., 1994; Kerber et al., 2003).  NRG1 isoform expression in 
the brain appears to be spatially and temporally controlled.  Where types I, II 
and III NRG1 are expressed in the cortex of adult human and rat brain (Kerber et 
al., 2003; Hashimoto et al., 2004), type IV NRG1 appears to be brain specific and 
is restricted to human expression (Steinhorsdottir et al.,2004; Tan et al., 2007).  
Moreover NRG1 isoform expression changes during development.  Type IV NRG1 
is expressed 3.5 fold times higher in foetal human brain than that of the adult 
(Tan et al., 2007).  Moreover, in rodents Nrg1 protein expression in the 
hippocampus, cerebellum and cortex is lower in adulthood than in foetal tissues 
(Chen et al., 1994).  In mice the first embryonic expression of Nrg1 is type III 
NRG1 expression, which is followed by the expression of type I then type III, 
suggesting the isoforms have distinct roles during different stages of 
development. 
NRG1 mRNA has been shown to be clearly expressed in cortical pyramidal 
neurons and interneurones of the adult human cortex and hippocampus, and in 
Golgi and Purkinje cells of the cerebellum (Law et al., 2004; Bernstein et al., 
2006).  In agreement, Kerber et al., (2003) found Nrg1 protein expression in 
granular and Purkinje cells of cerebellum in adult rat (Kerber et al., 2003).  
Type II NRG1 is expressed in oligodendrocytes, microglia and astrocytes of the 
adult human brain (Cannella et al., 1999).  Subcellular location of NRG1 has 
been shown to be predominantly in the neuronal cell body and synapse rich 
regions, with clustering at cell membranes (Chaudhury et al., 2003; Law et al., 
2004). 
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1.8.3 ERBB4 nomenclature and structure 
ERBB4 is one of four members of the ERBB receptor tyrosine kinase (RTK) family.  
ERBB1-4 are located on human chromosomes 7, 17, 12 and 2, respectively, and 
encode type 1 receptor tyrosine kinases ERBB1 (epidermal growth factor 
receptor; EGFR), ERBB2, ERBB3 and ERBB4 (Ullrich et al., 1984; Yamamoto et 
al., 1986; Kraus et al., 1989; Plowman et al., 1993).  Human ERBB4, like NRG1, 
is a large gene of approximately 1.15Mb, consisting of 28 exons (Mei & Xiong, 
2008).  The ERBB4 gene is also subject to alternative splicing, and as a result 
four isoforms of ERBB4 have been identified.  JMa ERBB4 isoforms contain exon 
16 but not exon 15, while JMb isoforms contain exon 15 but not 16, consequently 
these isoforms differ structurally in their juxtamembrane sequence affecting 
their susceptibility to proteolytic cleavage (Elenius et al., 1997a).  CYT isoforms 
differ in their cytoplasmic tail sequence, with CYT1 isoforms containing exon 26 
and thus a 16 amino-acid sequence that is the binding site for PI3-K.  CYT2 
isoforms lack exon 26 and therefore activation of CYT2 containing ERBB4 
receptors by NRG1 does not activate the PI3-K signal transduction pathway 
(Elenius et al., 1999). A very recent study has identified novel ERBB4 transcripts 
with alternative splicing of exon 3.  These isoforms have been termed del.3 and 
appear to exist only in CYT2 transcripts (i.e. not containing exon 26) (Tan et al., 
2010).  It is unlikely that these are the only naturally occurring ERBB4 isoforms, 
and indeed further novel isoforms have been identified in rare forms of cancers 
termed JMc and JMd (Gilbertson et al., 2001).  The nomenclature for ERBB4 
isoforms is diagrammatically shown in Figure 1-2. 
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Figure 1.2 Partial exon structure of ERBB4 isoforms JMa, JMb, CYT1 and 
CYT2 produced by alternative splicing.  JMa and JMb isoforms resulting from 
the inclusion of exon 16 or 15, which in turn renders them sensitive or insensitive 
to proteolytic cleavage by presenilin dependent secretase respectively.  CYT1 
and CYT2 isoforms result from the inclusion or exclusion of exon 26, respectively, 
resulting in the ability or inability to activate the PI3-K transduction pathway.  
Therefore four combinations of receptor are possible, JMa/CYT1, JMa/CYT2, 
JMb/CYT1 or JMb/CYT2. Dashed line indicates continuation of exons not shown in 
diagram. Exons are numbered and represented as boxes, with intronic DNA 
represented by dashed lines (size is not to scale).  
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1.8.4 ERBB4 expression in the CNS 
Human ERBB4 is highly expressed in the heart, kidney and neuronal tissues 
(Plowman et al., 1993).  The levels of ERBB4 isoform expression appears to be 
tissue dependant, with JMa isoforms being solely expressed in the kidney, 
whereas the heart only expresses JMb ERBB4 isoforms (Elenius et al., 1997a).  In 
addition ERBB4 CYT2 isoforms are predominantly expressed in neural and renal 
tissues while CYT1 is predominantly expressed in the breast and heart (Elenius et 
al., 1999).  
ERBB4 is expressed in most regions of the adult human brain, and in all cortical 
areas with intense expression specifically in cortical layers II and V (Bernstein et 
al., 2006).  This general expression pattern is also seen in the brains of non-
human primates (Thompson et al., 2007).  To date the regional expression of 
ERBB4 isoforms is unknown, however it has been shown that all four isoforms 
(JMa, JMb. CYT1 and CYT2) are expressed to some extent in cortical and 
hippocampal tissues of human brain (Law et al., 2006).  In the adult rat brain 
Erbb4 is widely expressed in the cortex, amygdala, hippocampus, reticular 
thalamic nucleus and cerebellum (Steiner et al., 1999; Gerecke et al., 2001).   
All isoforms of ERBB4 including the newly identified del.3 transcript are 
expressed in the foetal brain (Tan et al., 2010). Erbb4 expression in rats has 
been shown to increase with development (Mechawar et al., 2007).  The 
subcellular location of Erbb4 has been identified.  In general Erbb4 expression 
has been identified as somatodendritic, with Erbb4 immunoreactivity or mRNA 
expression localising to the cytoplasm and/or plasma membrane (Gerecke et al., 
2001; Mechawar et al., 2007).  However, the expression has also been observed 
within the nucleus of cortical and hippocampal cells (Mechawar et al., 2007).  
The complex proteolytic processing of ERBB4 may explain this diffuse cellular 
expression. 
Moreover, ERBB4 is expressed in many cell types.  ERBB4 has been identified in 
interneurones in human brain (Bernstein et al., 2006), and rat brain (Steiner et 
al., 1999; Mechawar et al., 2007).  More recently Erbb4 protein expression has 
been shown to be in GABAergic interneurones (Yau et al., 2003; Fishan et al., 
2009; Vullhorst et al., 2009; Neddens & Buonanno, 2010).   ERBB4 has also been 
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identified in pyramidal neurons (Berstein et al., 2006; Mechawar et al., 2007; 
Thompson et al., 2007).  However, this pyramidal cell expression has been 
subject to debate recently as studies utilising newly synthesised antibodies 
generated against Erbb4 have found no expression of Erbb4 in pyramidal cells of 
the mouse hippocampus (Vullhorst et al., 2009; Neddens & Buonanno, 2010).  
Expression of ERBB4 in glia is also somewhat unclear with studies showing 
presence (Ma et al., 1999; Bernstein et al., 2006) and absence (Mechawar et al., 
2007) of co-localisation of ERBB4 with glial markers.  Erbb4 has also been shown 
to be expressed in dopaminergic neurons of the substantia nigra and ventral 
tegmental area (Steiner et al., 1999).  
1.8.5 NRG-mediated ERBB4 activation 
All ERBB receptors are alike in that they contain four domains; an ectodomain 
containing two cysteine rich domains, a single transmembrane domain, 
intracellular juxtamambrane domain and a carboxy-terminal tail (Mei & Xiong, 
2008). Ligand binding to the ectodomain triggers receptor dimerisation and 
subsequent auto and trans-phosphorylation of the intracellular tyrosine kinase 
residues on the receptor, which serve as docking sites for various adaptor 
proteins.  These proteins then activate numerous intracellular signalling 
cascades. 
Each type of ERBB receptor has a distinct ligand binding profile.  There are 
seven known ligands that bind with high affinity to ERBB4, including three known 
ERBB1 ligands; betacellulin (Riese et al., 1996), heparin binding epidermal 
growth factor (Elenius et al., 1997b) and epiregulin (Komurasaki et al., 1997) as 
well as neuregulins 1-4 (NRG1-4) the most potent being NRG1-1 (Tzahar et al., 
1994).  Upon activation, receptor dimerisation can be homodimerisation, where 
two ERBB receptors of the same type come together, or heterodimerisation, 
where two differing ERBB receptors form a complex.  ERBB4 receptors are 
capable of homodimerisation (i.e. ERBB4/ERBB4), whereas, ERBB3 lacks an 
enzymatically active tyrosine kinase domain and so requires heterodimerisation 
with ERBB2 as a co-receptor for signalling (Guy et al., 1994).  ERBB2 itself is 
thought to be an orphan receptor as no ligands have been identified; instead 
ERBB2 forms heterodimers with the other ERBB receptors, activating signalling as 
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ERBB2 does have an active tyrosine kinase domain.  ERBB2/ERBB4 heterodimers 
are thought to potentiate ERBB4’s signalling capacity by increasing the affinity 
of the ligand binding site, thus accentuating the signalling response to ligand 
binding (Graus-Porta et al., 1997; Wang et al., 1998; Jones et al., 1999). 
 
Following ligand binding and ERBB4 dimerisation, phosphorylation of the 
intracellular domains generates docking sites for adapter proteins such as SHC 
(Culouscou et al., 1995) and GRB7 (Fiddes et al., 1998).  This initiates mitogen-
activated protein kinase (MAPK) and phosphoinositide-3 kinase (PI3-K) signalling 
cascades (Puricelli et al., 2002).   
 
Like NRG1, the ERBB4 receptor is susceptible to proteolytic cleavage.  Cleavage 
of the juxtamembrane domain of JMa containing ERBB4 isoforms by TACE 
releases an extracellular fragment containing the ligand binding site (Elenius et 
al., 1997a; Cheng et al., 2003).  This extracellular fragment can then bind to 
pro-protein membrane bound NRG’s or type III NRG1, to initiate intracellular 
signalling.  Furthermore, the remaining 80kDa membrane bound fragment of 
ERBB4 can be further cleaved by -secretase to release an intracellular fragment 
(Ni et al., 2001; Vidal et al., 2005).  This intracellular fragment can translocate 
to the nucleus where it has been shown to interact with transcriptional factors 
which may regulate gene expression (Omerovic et al., 2004; Linggi & Carpenter, 
2006).  This backwards signalling has also been proposed for NRG1, which can 
also be cleaved by -secretase.  This intracellular fragment can also translocate 
to the nucleus and has been shown to regulate the promoter of post synaptic 
density 95 (PSD95) (Bao et al., 2004). 
 
1.9 Evidence for aberrant NRG1-ERBB4 signalling in 
schizophrenia  
NRG1 and ERBB4 have both been implicated as strong candidate genes for 
increasing the risk to schizophrenia due to evidence from studies of their 
endogenous functions in the CNS, genetic studies and animal models.  Based on 
the evidence from genetic studies, NRG1 is currently at position 26 in the 
SZGene database. 
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1.9.1 Biological functions related to schizophrenia 
NRG1 signalling has been shown to have central functions in the regulation and 
development of several organs including those of the cardiovascular system 
(Erickson et al., 1997; Rentschler et al., 2002; Kuramochi et al., 2006) and 
breast tissue (Yang et al., 1995; Jones et al., 1996; Li et al., 2002), however, it 
is the important roles that NRG1 plays in the CNS that have linked it to 
schizophrenia. 
 
NRG1 plays central roles in systems that are affected in schizophrenia (for 
example the regulation of oligodendrocytes and myelination, which appears to 
be abnormal in schizophrenia) (Hakak et al., 2001; Hof et al., 2002; Flynn et al., 
2003; Tkachev et al., 2003).  In addition, studies of ERBB4 have identified many 
important functions including mediating axonal navigation between the thalamus 
and neocortex (Lopez-Bendito et al., 2006), regulation of neuroblast chain 
migration, orientation and organisation (Anton et al., 2004), promotion of 
proliferation and organisation of neuronal precursors in the sub ventricular zone 
(Ghashghaei et al., 2006), and regulation of neuronal migration along radial glial 
fibres (Rio et al., 1997).   These actions appear to be dysfunctional in 
schizophrenia and are a potential explanation for the loss of synaptic 
connectivity observed in the disease, which could implicate ERBB4’s role in the 
cognitive deficits seen in schizophrenia.   
 
NRG1-ERBB4 signalling has also been implicated in regulating the expression of 
neurotransmitter receptor subunits, indicating NRG1-ERBB4 signalling 
dysfunction may affect neurotransmitter systems that have previously been 
proposed to be altered in schizophrenia.  For example, ERBB4 appears to have 
distinct interactions with GABA receptors: ERBB4 signalling through activation by 
immunoglobulin-domain containing isoforms of Nrg1 increases the expression of 
the GABAA receptor 2 subunit as well as increasing the number of functional 
GABAA receptors in cerebellar granule cells (Rieff et al., 1999).  However, Okada 
et al., (2004), found that Ig-NRG, which was in close proximity to ERBB4 
receptors, down-regulated the expression of GABAA receptor  subunits in 
hippocampal slices.  It is probable to assume that this effect of NRG1, 
hypothetically through ERBB4 receptors, is brain region and/or GABAA subunit 
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dependent.  Flames et al., (2004), showed that NRG1/ERBB4 signalling has an 
important role in the development and migration of GABAergic interneurons, as 
loss of the functionality of either NRG1 or ERBB4 resulted in a decrease in the 
number of GABAergic interneuron’s migrating to the cortex. Therefore this 
creates a direct link between dysfunction of NRG1/ERBB4 signalling and 
defective GABA neurotransmission as seen in schizophrenia (Lewis et al., 2000; 
Benes & Berretta 2001).  In addition NRG1 signalling, particularly through type III 
NRG1, regulated neuronal acetylcholine receptor expression (Yang et al., 1998; 
Liu et al., 2001).  NMDA subunit expression is also regulated by NRG1 (Ozaki et 
al., 1997). 
 
NRG1-ERBB4 signalling has been further linked to regulating NMDA 
neurotransmission.  Huang et al., (2000) reported that ERBB4 is co-localised with 
PSD95, and more recently it has been shown both NRG1 and ERBB4 bind to PSD95 
through the PDZ domain of their C termini (Fujikawa et al., 2007).  Altering the 
level of PSD95, by over-expression or inhibition, enhanced or attenuated 
activation of ERK by means of NRG1 (Huang et al., 2000).  Furthermore, PSD95, 
ERBB4 and NMDA receptors co-localise at excitatory synapses, offering potential 
that there is an interaction between these proteins (Garcia et al., 2000).  
Following these studies Gu et al., (2005) found that Nrg1 decreased NMDA 
receptor currents in both cultured rat PFC neurons and rat PFC tissue slices, and 
that this decrease was attenuated by inhibiting Erbb receptors as well as 
blockers of downstream molecules.  The authors suggest that the decrease in 
NMDA receptor currents is due to an increase in receptor internalisation.  
However, as the inhibitors were non-specific for all Erbb receptors, it is unclear 
as to which were responsible.  A direct link between NRG1/ERBB4/PSD95 and 
schizophrenia was made by Hahn et al., (2006), who showed that in human 
schizophrenic post-mortem prefrontal cortex tissue slices there was an increase 
in PSD95-ERBB4 interaction versus tissue from unaffected individuals.  This study 
also showed that although there were no significant changes in the levels of 
NRG1 or ERBB4 between groups, there was enhanced NRG1-ERBB4 signalling in 
the tissue from schizophrenic patients and that this enhanced signaling led to a 
greater reduction of NMDA receptor function in schizophrenia.  This observation 
directly links with the hypothesis that NMDA receptor function is reduced in 
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schizophrenia, and thus alterations in NRG1-ERBB4 signalling caused by a genetic 
deficit in schizophrenia may contribute to this hypofunction.   
 
Because of the findings that ERBB4 and NRG1 are enriched at the post synaptic 
density, in recent years the role NRG1-ERBB4 signalling may play in regulating 
synaptic plasticity has been investigated.  NRG1-ERBB4 has been shown 
constitutively to regulate long term potentiation (LTP) (Kwon et al., 2005; 
Pitcher et al., 2008) through a dopamine dependent mechanism (Kwon et al., 
2008). 
 
Another connecting factor linking NRG1’s biological function to schizophrenia is 
that NRG1 is important in the onset of puberty and sexual development (Toyoda-
Ohno et al., 1999).  Mice that have dysfunctional NRG1 signalling have delayed 
onset of puberty and reproductive development due to levels of reproductive 
hormones being reduced (Prevot et al., 2003).  As these hormones are of utmost 
importance at the time of the onset age of schizophrenia, this indicates that if 
indeed there was a link between schizophrenia and NRG1 signalling dysfunction, 
it could be viable that the neurodevelopmental abnormality is due to a change in 
levels of these critical hormones.   
 
1.9.2 Genetic evidence for NRG1-ERBB4 dysfunction in 
schizophrenia 
NRG1 and ERBB4 are located at 8p21-22 and 2q33.3-34, respectively, regions 
highlighted as risk regions in one or both of the aforementioned meta-analyses 
of linkage studies (Badner & Gershon, 2002; Lewis et al. 2003).  There have been 
several lines of research strengthening the association of both NRG1 and ERBB4 
with schizophrenia.   A major breakthrough came from an Icelandic familial 
study when Stefansson et al. (2002) reported that there was significant linkage 
between a core haplotype of NRG1, consisting of five single nucleotide 
polymorphisms (SNPs) and two microsatelites, and schizophrenia. This 
association between NRG1 and schizophrenia has been subsequently replicated 
in 20 case control studies and a further 9 family based studies in multiple 
populations including those of European, American and Asian origins. However, 
there have also been several studies finding no association in these populations.  
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A summary of all of the schizophrenia association studies carried out on NRG1 to 
date can be found on SZGene 
(http://www.szgene.org/geneoverview.asp?geneid=311).  
 
Several association studies have strengthened the link of ERBB4 as a risk gene for 
schizophrenia.  In a large case/control study from the UK and Ireland, 
association was found between variants in ERBB4 with an increased risk of 
schizophrenia, and this association may be through the interaction with the 
Icelandic NRG1 haplotype (Norton et al., 2006).  This association was replicated 
by two further studies (Silberberg et al., 2006; Law et al., 2007), where both 
found association of three intronic SNPs; rs7598440, rs839523 and rs707284, 
which form a core risk haplotype in exon 3 of ERBB4, in linkage disequilibrium in 
three separate populations.  Further association studies have positively 
associated ERBB4 with schizophrenia; however, as with NRG1, negative findings 
have also been documented.  A summary of all of the schizophrenia association 
studies carried out on ERBB4 to date can be found on SZGene 
(http://www.szgene.org/geneoverview.asp?geneid=273).  In addition, in a study 
of rare structural variants in schizophrenia a novel deletion in ERBB4 was found 
(Walsh et al., 2008). 
  
1.9.3 Biochemical evidence for NRG1-ERBB4 dysfunction in 
schizophrenia 
A number of studies in human post-mortem brain tissue have shown an 
alteration in the expression of NRG1 in schizophrenia.  Hashimoto et al., (2004) 
found that in the human dorsolateral prefrontal cortex (DLPFC) there was a 23% 
increase in NRG1 type I mRNA in tissue from schizophrenia patients compared to 
samples from unaffected individuals, with no alterations in expression of the 
other NRG1 subtypes.  These findings were also replicated in the hippocampus 
(Law et al., 2006); however this study did not find small decreases in subtype 
ratios that were observed by Hashimoto et al., (2004).  More recently NRG1 
protein levels were found to be increased selectively within the PFC of 
schizophrenia patients (Chong et al., 2008). Conversely, a study by Hahn and 
colleagues (2006), found no alteration in the expression of NRG1 in the DLPFC of 
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post-mortem human schizophrenic samples in comparison to unaffected control 
samples.  
  
Furthermore, there is also evidence of altered expression of ERBB4 in 
schizophrenia.  Two studies have found that ERBB4 expression in the DLPFC is 
increased in schizophrenia, and that these increases are due to significant 
increases in JMa and CYT1 splice isoforms (Silberberg et al., 2006; Law et al., 
2007).  Additionally Law et al., (2007) observed that this increase was not 
present in the hippocampus but appeared to be specific to the PFC, and was 
associated with specific SNP allelic expression of ERBB4.  Although no changes in 
ERBB4 protein expression have been identified in one study (Hahn et al., 2006), 
the previous findings of increased ERBB4 in schizophrenia have been supported 
by two recent studies (Chong et al., 2008; Law et al., in press).  
 
It should be noted however, that several studies have suggested that Nrg1 and 
Erbb4 expression is altered in rats chronically treated with anti-psychotic drugs 
(Wang et al., 2008; Chana et al., 2009), although these results were not 
replicated in a recent study (Law et al., in press).  Therefore, changes in 
expression of these genes in schizophrenia may be partly attributable to long-
term exposure to antipsychotic treatments.   
 
1.9.4 Animal models of aberrant Nrg1-Erbb4 signalling 
In addition to the association and expression studies, animal models have also 
provided positive evidence for NRG1 and ERBB4 as functional candidate genes for 
schizophrenia.  Heterozygous Nrg1 knockout mice have shown open field 
hyperactivity (Gerlai et al., 2000; Stefansson et al., 2002; O’Tuathaigh et al., 
2005; Karl et al., 2007).  However, with the complexity of the NRG1 gene it is 
not surprising that this behavioural phenotype was not observed in other mouse 
models with mutated Nrg1 (Rimer et al., 2005; Erlichman et al., 2009).  
Sensorimotor gating has also been shown as dysfunctional in some Nrg1 mouse 
models (Stefansson et al., 2002; Chen et al., 2008; Deakin et al., 2009) but not 
in others (Erlichman et al., 2009).  Other behaviours more representative of the 
cognitive deficits have been observed in Nrg1 mouse models, such as disrupted 
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latent inhibition (Rimer et al., 2005), fear conditioning and novel object 
recognition (Duffy et al., 2010).   
 
In agreement that NRG1 signalling is dysfunctional in schizophrenia, mutations in 
the Erbb4 gene in mice result in similar behavioural deficits reflective of 
schizophrenia.  These behaviours include hyperactivity (Stefansson et al., 2002; 
Golub et al., 2004; Wen et al., 2010), dysfunctional pre-pulse inhibition 
(Stefansson et al., 2002; Wen et al., 2010), social interaction (Roy et al., 2007) 
and working memory deficits (Golub et al., 2004; Wen et al., 2010). 
Furthermore, Gerlai et al., (2000) showed that the schizophrenia-related 
behavioural phenotype seen in heterozygous Erbb4 rodents was specific and not 
observed in heterozygous mutants of Erbb2 or Erbb3.  Although there has been a 
recent advance in animal modelling of these two genes, to date these studies 
have been limited to mice, and investigate the effect of gene dysfunction 
throughout the entire brain.  
 
As well as behavioural changes, animal models of Nrg1 and Erbb4 have allowed 
the elucidation of other neurobiological roles of these genes within the CNS.  For 
example Nrg1 mutant mice have impaired short and long term potentiation 
(Bjarnadottir et al., 2007) and alterations in the expression of serotonin-related 
genes (Dean et al., 2008).  Moreover mice with alterations in Erbb4 show 
reduced dendritic spine density (Barros et al., 2009) and altered GABAergic 
neurotransmission (Wen et al., 2010).  
 
1.10   Regulating gene expression 
For several decades the genetic composition of rodents has been manipulated to 
allow the understanding of the underlying function of the targeted genes.  
Knockout animals have been successfully bred and are an invaluable tool in 
scientific research; however, as in the case of Nrg1 and Erbb4 homozygous mice, 
knockout can be lethal (Gassmann et al., 1995; Seshadri et al., 2010).  
Heterozygous “knockouts” of schizophrenia candidate genes are commonly bred 
where only one copy of the endogenous gene is deleted or manipulated, 
permitting the gene expression to be significantly reduced but still allowing 
viability of the animal.  One of the major problems with knockout animals is that 
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the effect of the mutation is not regional but is widespread throughout the 
entire body.  In the past 10 years it has come to light that there are alternative 
approaches to regulating the expression levels of specific genes.  One such 
approach is RNA interference (RNAi).   
 
1.10.1  RNAi 
This method of endogenous gene silencing allows for double stranded RNA 
(dsRNA) with a sequence complementary to the gene of interest to be 
introduced into cell cultures or organisms, where it recognises and causes 
initiation of the RNAi pathway, knocking down transcription of the target gene.  
The RNAi pathway can be effectively induced in vitro and in vivo by the 
application of short interfering RNAs (siRNA) or by the expression of short hairpin 
RNAs (shRNA) via viral or non-viral vectors. 
 
The term RNAi was coined in 1998 by Fire and colleagues who discovered that 
injecting dsRNA into the body or gonad of nematode Caenorhabditis elegans 
resulted in silencing of a gene with sequence complementary to that of the 
dsRNA (Fire et al., 1998).  This phenomenon had already been observed in plants 
(Napoli et al., 1990) and fungi (Romano and Macino, 1992), where the 
phenomenon observed was termed posttranscriptional gene silencing (PTGS) and 
quelling, respectively.   
 
1.10.2  RNAi pathway 
When long dsRNA enters the cell, it is recognised by a dsRNA-specific 
endonuclease called Dicer.  This protein cleaves the dsRNA into short dsRNAs of 
around 21 to 23 nucleotides with 2 nucleotide long 3 prime (3’) overhangs.  
These siRNAs then form a complex with several proteins including Argonaut, this 
complex is termed the RNAi silencing complex (RISC).  RISC causes unwinding of 
the ds siRNA sequence leaving one single antisense strand of complementary RNA 
bound to the RISC, which binds to the target mRNA in a sequence specific 
manner.   
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Binding of the siRNA-RISC to the target mRNA results in the target mRNA being 
cleaved in the middle of the siRNA complementary sequence.  The cleaved 
mRNA is recognised by the cell as foreign material and is digested by nucleases. 
mRNA cleavage prevents translation into the target protein thus silencing gene 
function (Hoyer, 2007). 
 
1.10.3  RNAi applications 
RNAi has been used as an effective tool for investigating the function of several 
schizophrenia candidate genes including DISC1, DTNBP1 and CAMK2 (Numakawa 
et al., 2004; Babcock et al., 2005; Duan et al., 2007).  Several studies have 
observed the behavioral outcome following specific knockdown of the gene of 
interest in rodents, for example behavioral testing of: nociception (Tan et al., 
2005), auditory processing and spatial learning (Threlkeld et al., 2007), 
Alzheimer’s related behavioural deficits (Singer et al., 2005), exploratory 
behaviour (Babcock et al., 2005) and motor performance deficits (Hommel et 
al., 2003).   
 
1.11 Hypotheses and aims  
It is well established from genetic associations, expression studies, and animal 
models that NRG1 and ERBB4 are promising candidate genes for schizophrenia, 
yet the understanding of how these genes function in distinct regions of the 
brain in adulthood, and the relation of these functions to cognition and 
schizophrenia-related behaviors, is poor. Therefore we sought to investigate the 
function of Nrg1-Erbb4 signalling within a distinct brain region of the adult rat, 
the mPFC, by utilising recombinant adeno-associated viral particles designed to 
knockdown the expression of Erbb4. 
We hypothesised that by knocking down expression of Erbb4 within the mPFC of 
rats, a brain region highly associated with the cognitive deficits of 
schizophrenia, we would initiate changes in schizophrenia-related behaviours 
and in particular measures of cognition.  In addition, it was also hypothesised 
that as ERBB4 signals as part of a regulated signal transduction pathway, 
dysregulation of Erbb4 expression would have a knock-on effect on the levels of 
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other components of this pathway-which may be reflective of biochemical 
changes that are pathophysiological in schizophrenia. 
By validating in vivo viral-mediated knockdown of Erbb4 and measuring the 
downstream effects of this knockdown on behavioural and biochemical function 
in rats, we aimed to gain a greater knowledge of the function of Erbb4 within 
the mPFC in adulthood, and overcome the spatial and temporal restrictions of 
previous animal models of Nrg1-Erbb4 dysfunction.  We propose that 
investigating Nrg1-Erbb4 signalling in this way will potentially lead to a greater 
understanding of how Nrg1-Erbb4 may be pathophysiological in schizophrenia, 
and could give a greater insight in to prospective therapeutic targets for treating 
the cognitive deficits of schizophrenia.   
In addition we also aimed to validate a neuronal cell line NG108-15 as a 
potential in vitro model for investigating Nrg1-Erbb4 signalling.  Thus as an 
alternative to in vivo studies this model system would allow a reduction in the 
numbers of animals required, and also enable validation of recombinant adeno-
associated viral particles to be tested on a cell line before being utilised in more 
physiologically relevant tissues.   
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2 Materials and Methods 
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2.1 Materials 
Recombinant adeno-associated viral particles (rAAVs) were produced by the 
University of Pennsylvania, Penn Vector Core facility, USA. Three types of rAAVs 
were supplied expressing either: enhanced green fluorescent protein (eGFP) only 
(rAAV.eGFP), eGFP and a hairpin sequence corresponding to rat Erbb4 
(rAAV.shErbb4.eGFP) or eGFP and a scrambled version of the hairpin sequence 
corresponding to rat Erbb4 which does not correspond to any known gene 
(rAAV.scr.eGFP).  The shErbb4 sequence specifically targets a 19 nucleotide 
sequence of exon 28 of the rat Erbb4 gene: TGG AGA CCT TCA AGC TTT A 
whereas the scrambled hairpin sequence: AGT TCA TGA GTG TCA CAT C is not 
known to target any gene.  In brief, the recombinant replication deficient AAV 
vectors were produced by the co-transfection of HEK293 cells with plasmids that 
encoded 1) shRNA driven by the U6 promoter and/or eGFP driven by the CMV 
promoter 2) AAV ori proteins of serotype 2 and rep and cap proteins of serotype 
9 and 3) adenoviral “helper” proteins VA, E2a and E4.  The constructs encoded 
additional elements to aid viral packaging and transduction properties including 
the SV40 intron, woodchuck posttranscriptional regulatory element (WPRE) and 
bovine growth hormone polyadenylation signal. The viral particles were supplied 
with titres quantified as genome copies (gc)/ml. 
 
Phencyclidine hydrochloride (PCP) and d-amphetamine sulphate were purchased 
from Sigma-Aldrich, Poole, UK.  Human recombinant NRG1 was purchased from 
R&D Systems, Abingdon, UK and reconstituted in 0.1% BSA (w/v)/1xPBS.  0.5M 
ethylenediaminetetraacetic acid (EDTA, C10H16N2O8) solution pH8 and all cell 
culture media (Neurobasal, Dulbecco’s Modified Eagle Medium (DMEM, 4500mg/L 
D-Glucose), Minimum Essential Medium (MEM) and Opti-MEM® I Reduced Serum 
Medium) were purchased from GIBCO®, Invitrogen, Paisley, UK.   
Several chemicals were routinely used in the preparation of buffers described 
within this section.  Table 1 lists these routinely used chemicals and the source 
from which they were purchased.  The source of all other materials and 
equipment used in this study is stated in brackets in the appropriate section of 
the description of methods. 
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Ringers solution was composed by diluting one quarter-strength Ringers Solution 
tablet (Oxoid, Cambridge, UK) in 500ml distilled H2O.  10x Phosphate Buffered 
Saline (PBS) consisted of a final concentration of 1.3M NaCl, 70mM Na2HPO4, 
30mM NaH2PO4.2H2O in diethylpyrocarbonate (DEPC) treated-H2O, and was 
diluted to a 1x solution in distilled H2O before use.   
Table 2-1 List of chemicals routinely used and their source  
Chemical Chemical formula Source 
Potassium phosphate KH2PO4 Fisher Scientific, Leicestershire, 
UK Sulphuric acid H2SO4 
Tris Base C4H11NO3 
Glycerol C3H8O3 
BDH, Poole, UK Potassium chloride KCl 
Sodium chloride NaCl 
Sodium hydrogen phosphate Na2HPO4 
Calcium chloride dihydrate CaCl2.2H2O 
Sigma-Aldrich, Poole, UK 
D-Glucose C6H12O6 
Magnesium sulphate 
heptahydrate 
MgSO4.7H20 
Methanol CH3OH 
Sodium azide NaN3 
Sodium bicarbonate NaHCO3 
Sodium deoxycholate C24H39NaO4 
Sodium dodecyl sulphate 
(SDS) 
CH3(CH2)11OSO3N
a 
Sodium orthovanadate Na3VO4 
Sodium phosphate dihydrate NaH2PO4.2H2O 
Triton® X-100 (C4H4O)nC14H22O 
Tween®-20 C58H114O26 
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2.2 Cell culture 
2.2.1 NG108-15 cell culture 
Mouse neuroblastoma x rat glioma NG108-15 cells (European Collection of Cell 
Cultures, ECACC) were maintained in DMEM (4500mg/L D-Glucose) supplemented 
with 10% (v/v) Foetal Bovine serum (FBS, Sigma-Aldrich), 100 units/ml penicillin 
and 0.1mg/ml streptomycin (Invitrogen).  Cells were grown in 25cm2/75cm2 flat 
bottomed plates (Corning® CoStar®, Sigma-Aldrich) and incubated at a constant 
temperature of 37˚C in air containing 5% C02.  Once cells were at approximately 
75-80% confluency they were detached from the plate surface with 0.05% (v/v) 
trypsin/ 1xEDTA (Sigma-Aldrich) and resuspended in fresh supplemented DMEM.  
The cells were then replated into 75cm2 plates or counted using a 
haemocytometer and plated at a specific density into 6/12 well flat bottomed 
plates (Corning® CoStar®, Sigma-Aldrich). 
 
2.2.2 Primary dissociated cortical cultures 
Dissociated cortical cultures were prepared from postnatal day 1/2 rat pups 
using a dissection surface and surgical equipment sterilised with 70% (v/v) 
ethanol.  The pups were euthanised by a 100l intraperitoneal (i.p.) injection of 
Euthatal (Merial, Harlow, UK), followed by decapitation.  The brains were 
removed and placed in MEM that had been chilled to 4°C, the hemispheres were 
separated and the cortical tissue dissected out.  The cortical tissue was then cut 
with a size 10 scalpel blade into small pieces and incubated in 1.5mg/ml papain 
(Sigma-Aldrich)/preparation buffer (116mM NaCl, 5.4mM KCl, 26mM NaHCO3, 
1.3mM NaH2PO4.2H2O,  1mM  MgSO4.7H2O, 1mM CaCl2.2H2O, 0.5mM EDTA pH8, 
25mM D-Glucose) for 30 minutes at 37°C to disrupt the cortical tissue 
enzymatically. 
The cortical tissue was then removed from the papain and transferred into 
10mg/ml BSA (Sigma-Aldrich)/ preparation buffer pre-warmed to 37°C.  The 
tissue was then gently triturated using a plastic Pasteur pipette.  Next, the 
dissociated tissue was centrifuged in a Sigma 2K15 refrigerated centrifuge 
(Sigma-Aldrich) at 4°C, 2000rpm for 3 minutes, the supernatant removed and 
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the tissue resuspended in Neurobasal® media supplemented with 2% (v/v) B27 
(Invitrogen), 100 units/ml penicillin and 0.1mg/ml streptomycin (Invitrogen) and 
2mM L-Glutamine (Invitrogen).  The cells were then plated out into 8-well 
chamber slides or 6/12 well flat bottom plates pre-coated with 4mg/ml poly-D-
lysine (Sigma-Aldrich)/DEPC treated H2O.  Two days after plating half the 
medium was removed from the wells to remove any dead cells or debris and 
replaced with fresh supplemented Neurobasal® medium. 
The cells were then left to culture for a further 4 days before any treatments 
were carried out.   
2.2.3 NRG1 stimulation 
NG108-15 cells were grown in 6-well flat bottom plates as described in section 
2.2.1 for 24 hours before their cell culture media was removed and replaced 
with serum free DMEM.  The cells were left to culture for a further 24 hours 
before being treated with vehicle (0.1% BSA (w/v)/1xPBS) or NRG1 at final 
concentrations ranging from 10ng/ml-200ng/ml.  The cells were then incubated 
for 10, 30 or 60 minutes at a constant temperature of 37˚C in air containing 5% 
C02 before protein was isolated (section 2.12) from the cells.  Phosphorylated 
ERBB4 levels or levels of other proteins of interest were assessed by ELISA 
(section 2.14) or western blotting (section 2.13) respectively, following NRG1 
application. 
2.3 RNAi in vitro 
2.3.1 siRNA transfection 
NG108-15 cells at a density of 1.5x105 cells/ml were plated into 6 or 12 well flat 
bottomed  plates (Corning® CoStar®, Sigma-Aldrich) and incubated at a constant 
temperature of 37˚C in air containing 5% C02 for 24 hours before transfection 
with siRNAs.  Lipofectamine™ RNAiMAX transfection reagent (Invitrogen) was 
allowed to come to room temperature and then diluted in Opti-MEM® I reduced 
serum medium according to the manufacturer’s protocol. Custom Silencer® 
select siRNA for mouse Erbb4 and Silencer® siRNA for Gapdh and a non-targeting 
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sequence (Ambion, Austin, TX, USA) were diluted to required concentrations in 
Opti-MEM® I and incubated at room temperature for 5 minutes.  Equal volumes 
of diluted Lipofectamine™ RNAiMAX and diluted siRNA were incubated together 
at room temperature for 20 minutes to allow complexes to form.  Following 
incubation, the siRNA/transfection reagent complex was added to the plated 
NG108-15 cells.  For each experiment control wells were included which 
contained untreated NG108-15 cells (no transfection reagent or siRNA) and cells 
treated with transfection reagent only (mock transfection, no siRNA). Cells were 
incubated at a temperature of 37˚C in air containing 5% C02 until further 
processing.   
The target sequence of the Erbb4 siRNA was the mouse equivalent of the hairpin 
sequence used in the shErbb4 recombinant adeno-associated viral particles.   
2.3.2 rAAV transfection 
24 hours (NG108-15 cells) or 4 days (dissociated cortical cultures) after plating, 
cells were treated with recombinant adeno-associated viral particles.  Viral 
particles were allowed to thaw on ice before being diluted in the appropriate 
cell culture media (DMEM or Neurobasal®).  The correct volumes of diluted 
particles were applied directly into the well to give the desired amount of 
genome copies (gc).  For each experiment wells were included that were treated 
with 3% (w/v) sucrose/PBS to control for the effect of viral particles alone.  
Following rAAV treatment, cells were incubated at a temperature of 37˚C in air 
containing 5% C02 until further processing.   
2.4 In vivo studies 
2.4.1 Animals 
All experimental procedures were carried out in accordance with the UK Animal 
(Scientific Procedures) Act, 1986.  Male Hooded Lister rats (Harlan, UK) weighing 
260-280g upon arrival were dual housed at a maintained temperature and 
humidity of 20-22˚C and 55%, respectively.  Following a one week quarantine 
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period the rats were ready to begin training or undergo surgery as described in 
the following sections.  Three individual in vivo studies were performed.   
1) 9 rats were used to study the location of injection sites and at which titre 
to use rAAV particles.  There were two treatment groups in this study: the 
first group of 3 rats received a 2l injection into the medial prefrontal 
cortex (mPFC) of vehicle (3% (w/v) sucrose/PBS) in one hemisphere and a 
2l injection of “high titre” 1x109gc/l rAAV.eGFP into the contralateral 
hemisphere.  The second group of 6 rats received a 2l injection into the 
mPFC of “low titre” 1x108gc/l rAAV.eGFP in one hemisphere and a 2l 
injection of “high titre” 1x109gc/l rAAV.eGFP into the contralateral 
hemisphere (surgeries were performed as described in section 2.4.2).  
Rats then underwent transcardial perfusion (see section 2.4.3) at 1, 3 or 8 
weeks following surgery (1 veh/high titre rat and 2 low/high titre rats at 
each time point).  The prefrontal cortex (PFC) was sectioned and then 
stained to detect the presence of multiple proteins (see section 2.15.2) 
2) 24 rats were used to study the effect of viral particles on schizophrenia-
related behaviours and to quantify mRNA and protein levels of members 
of the Nrg1-Erbb4 signalling pathway.  This study included 3 treatment 
groups of 8 rats receiving 2l bilateral injections into the mPFC of vehicle 
(3% (w/v) sucrose/PBS), 1x109gc/l rAAV.scr.eGFP or 1x109gc/l 
rAAV.shErbb4.eGFP (surgeries were performed as described in section 
2.4.2).  Rats were then allowed to recover for one week before being 
tested in the open field and prepulse inhibition (PPI) behavioural tasks (as 
described in sections 2.5 and 2.6, respectively).  The tasks were repeated 
at 3 weeks and 5 weeks post-surgery, after which the rats were 
euthanised by cervical dislocation and the PFC tissue collected (see 
section 2.4.4).  The mRNA expression of genes of interest was analysed in 
this tissue by qRT-PCR (see section 2.11), while protein expression of 
members of the Nrg1-Erbb4 signalling pathway was analysed by western 
blot and ELISA (see sections 2.13 and 2.14, respectively). 
3) 36 rats were used to study the effect of viral particles on performance in 
the 5-choice serial reaction time task.  First rats were trained in the task 
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(see section 2.7.3) then split into three treatment groups based on 
performance at baseline testing (see section 2.7.4).  This study included 
three treatment groups of 12 rats receiving 2l bilateral injections into 
the mPFC of vehicle (3% (w/v) sucrose/PBS), 1x109gc/l rAAV.scr.eGFP or 
1x109gc/l rAAV.shErbb4.eGFP (surgeries were performed as described in 
section 2.4.2).  At one, three and five weeks post-surgery the rats were 
tested in the task (see section 2.7.5). 
2.4.2 Stereotaxic surgery 
Rats were initially anaesthetised in a clear acrylic chamber via the inhalation of 
isoflurane (Isoflo®, Abbot Animal Health, Maidenhead, UK) set at level 5.  
Oxygen and nitrous oxide were continuously supplied at 0.3L/min and 0.7L/min, 
respectively, throughout the duration of the surgical procedure.  Once no pedal 
or corneal reflexes were present the fur from the level of the eyes to muscular 
band of the neck was shaved using a small set of clippers.  Next, the rat was 
transferred to a heat mat (Fine Science Tools, Inc, Cambridge, UK) and 
positioned in front of the stereotaxic frame (David Kopf Instruments, Tujunga, 
CA, USA).  The level of anaesthesia was reduced to 3 and the rat was then 
secured into the frame using atraumatic ear bars (David Kopf Instruments), the 
incisor bar was set to 3.3mm below the ear bars to achieve flat skull position 
(Paxinos & Watson, 2007).   
The shaved area was swabbed with 70% (v/v) ethanol and a single incision was 
made with a sterile scalpel from between the eyes to between the ears.  Next, 
the skull was exposed by blunt dissection and Bregma located.  The flat skull 
position was confirmed by checking the dorso-ventral (DV) co-ordinates of 
Bregma and Lambda were the same, if not the incisor bar was adjusted.  From 
Bregma the location of the prelimbic area of the mPFC (prL) in each hemisphere 
was identified and marked on the skull using the co-ordinates +3.2mm anterior-
posterior (AP), +/- 2mm medio-lateral (ML) (Paxinos & Watson, 2007).  Using a 
dental drill with a small 1mm dental burr attached (Royem Scientific Ltd, 
Bedfordshire, UK) small burr holes were made at these co-ordinates.  Next the 
5l Hamilton syringes fitted with Hamilton needles (Hamilton Company, Reno, 
NV, USA) were secured to both arms of the stereotaxic frame at an angle of 20°, 
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and lowered through the burr holes to 4mm below the surface of the skull 
(injections were performed at an angle to reduce the chance of disturbing blood 
vessels running along the midline of the brain).  2µl bilateral injections of 
vehicle (PBS/3% (w/v) sucrose), rAAV.eGFP, rAAV.scr.eGFP or 
rAAV.shErbb4.eGFP were then performed over a 10 minute time period; 
following completion of the injection the needle was left in place for a further 5 
minutes to reduce the chance of back-flow of injected material.  The needle 
was slowly retracted and the incision site closed using Vicryl™ sutures (Ethicon® 
coated Vicryl™ 4.0, Dunlop Veterinary Supplies, Dumfries, UK). 
Following surgery the rats were removed from the stereotaxic frame and placed 
single housed in one warmed paper-lined cage per rat.  The following day the 
cage bedding was changed back to sawdust and the rats were kept separate for a 
further 48 hours to prevent damage to the incision wound.  The rats’ were then 
re-housed with their cage mates from before surgery and allowed to recover for 
another 4 days before any further experimental procedures were performed.  
Rats’ weights were closely monitored to check for post-surgical weight changes.   
2.4.3 Transcardial perfusion 
Rats were removed from their home cage and given a lethal i.p. injection of 
Euthatal (Merial).  Once no pedal or corneal reflexes were present the chest 
cavity was exposed and a needle was inserted into the left ventricle of the 
heart.  The right atrium was then cut and 1x Ringer’s/PBS solution was then 
pumped into the heart until the liver had paled.  250ml freshly made 4% (w/v) 
paraformaldehyde (PFA, prilled form, Sigma-Adrich)/PBS was then pumped 
through the heart, at a slow rate until complete fixation had taken place 
(approximately 30 minutes).  The whole brain was then dissected out and placed 
in 20% (w/v) sucrose/PBS and stored at 4°C for cryoprotection purposes.   
2.4.4 Cervical dislocation and PFC dissection 
Rats that were involved in studies 2 and 3 (see section 2.4.1) were euthanised by 
cervical dislocation.   The whole brain was immediately removed and brains 
from rats in study 3 were snap frozen in isopentane (VWR International Ltd, 
Poole, UK) cooled to -42°C on dry ice and stored at -80°C until further 
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processing (data not shown in thesis).  Brains from rats in study 2 were 
transferred to an ice cold tile and the whole PFC dissected out.  The PFC tissue 
was exposed by the initial removal of the olfactory bulb tissue; a coronal slice of 
approximately 1.5mm was then collected.  Diagonal cuts were then made with a 
size 10 scalpel blade through the cingulum of this coronal slice, isolating the 
prefrontal cortical tissue.  All dissections were carried out by the same 
individual to minimise variation in sample collection.  Each hemisphere was 
individually stored in ribolyser tubes (Lysing Matrix D, Qbiogene, Cambride, UK) 
at -80°C until being used for mRNA or protein expression analysis. 
2.5 Open Field 
2.5.1 Open field apparatus 
The open field test apparatus consisted of two 100cmx100cmx40cm infra-red 
translucent acrylic plastic arenas situated on top of infra-red light boxes and 
positioned directly under a ceiling mounted infra-red sensitive camera.  The 
camera was linked to a computer in an adjacent room where distance travelled 
was analysed using EthoVision Pro, Version 3.0 video tracking software (Noldus 
Information Technology, The Netherlands).  All locomotor experiments were 
carried out in the same room with lighting level fixed at 190 Lux. 
2.5.2 Habituation to open field 
Rats were removed from their home cages and individually housed in the room 
where the locomotor activity was to be assessed.  The rats were habituated to 
the open field arenas for 30 minutes prior to locomotor activity assessment. 
2.5.3 Amphetamine challenge 
The effect of an amphetamine challenge on locomotor activity was assessed in 
the rats that had previously undergone stereotaxic surgery.   In a cross-over 
design rats received subcutaneous injections in the flank of vehicle (0.9% (w/v) 
saline) or d-amphetamine sulphate (1mg/kg) on the first day of locomotor 
testing.  The following day the alternative treatment was administered to the 
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rats (e.g. vehicle day 1, amphetamine day 2).  In brief, the rats were removed 
from the arena following the 30 minute habituation period and administered the 
appropriate drug treatment. They were then immediately placed back into the 
same arena as where the habituation had been monitored to assess locomotor 
activity over a 60 minute period.  Arenas were cleaned with disinfectant 
between rats. 
2.6 Prepulse inhibition 
2.6.1 PPI apparatus 
The effect of stereotaxic surgery on PPI was carried out using three identical 
sound-attenuated chambers (MED Associates, St. Albans, VT, USA) and the 
magnitude of startle responses recorded by MED Associates Startle Software 
(SOF-825).  
2.6.2 Habituation to PPI 
The day prior to the PPI testing (and at least 2 hours after locomotor activity 
assessment) rats were habituated to the PPI procedure.  PPI experimental 
procedure was as follows, rats were placed into restrainers connected to a 
platform measuring the extent of movement.  The restrained rats were firstly 
acclimatised for 5 minutes to a background noise of 65 decibels (dB).  They were 
then tested in three blocks of trials, in all of which the interval between trials 
was on average 15 seconds.  Blocks 1 and 3 consisted of 6 stimulus-alone trials of 
120 dB pulses of white noise lasting 40 milliseconds (ms).  Block 2 consisted of 52 
trials 12 of which were stimulus alone trials, 10 of which were 40ms trials of 
background noise (no-stimulus), and 30 of which were 40ms 120 dB pulses 
preceded by a 20ms lower amplitude "pre-pulse"  of 4, 8 or 16dB above 
background noise 100ms before the stimulus.    Each pre-pulse intensity was 
presented 10 times in a pseudorandom order.   
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2.6.3 PPI testing 
The next day (day 2) the rats were again exposed to this PPI procedure, this 
time the test data were acquired and PPI calculated from the trials in Block 2 for 
each pre-pulse amplitude using the following equation:  % PPI= 100x ((stimulus 
alone response)-(pre-pulse + stimulus response))/ (stimulus alone response).  
Startle per se was taken from the startle response to stimulus alone.    
2.7 5-choice serial reaction time task 
2.7.1 Animals 
36 Male Hooded Lister rats (Harlan) weighing 260-280g upon arrival were dual 
housed at a maintained temperature and humidity of 20-22˚C and 55%, 
respectively.  Following a one week quarantine period the rats were maintained 
at 85% of their free feeding weight by a strict daily food restriction regime of 25-
30g standard rat chow per cage.  All animals were allowed water ad libitum, 
except during the 30 minute training/testing periods.  The rats’ weights were 
monitored three times a week throughout the duration of the study (except the 
period following surgery, where the rats’ weights were monitored daily for a 
week).  This study was carried out in accordance with the UK animals (scientific 
procedures) Act 1986.   
 
2.7.2 Habituation phase 
For three days prior to the habituation to the apparatus, each rat was handled 
daily for approximately 5 minutes to allow familiarisation to being handled.  The 
day prior to the rats being introduced to the apparatus for the first time reward 
pellets (45mg, Sandown Scientific, Middlesex, UK) were placed in each cage to 
familiarise the rats to the rewards and thus prevent  neophobia.   
 
On the first day of habituation to the apparatus, the rats were placed within the 
operant box with reward pellets in the food hopper.  This purpose of this was 
two-fold 1) To accustom the rat to the operant box and 2) To build the 
association between the food hopper and reward collection.  This association 
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was strengthened on the second habituation day where reward pellets were 
again available in the food hopper, in addition each aperture was baited with a 
reward pellet to build the association between nose poking and food reward.    
 
2.7.3 Training of the 5-choice serial reaction time task  
Once the rats were familiarised with the apparatus and food rewards, training of 
the task began.  The rats were placed into the operant box and a nose-poke into 
the food hopper initiated the beginning of the task.  After a 5 second inter-trial 
interval (ITI) one of the five open apertures illuminated for a fixed period of 
time (stimulus duration, SD).  Responses into this illuminated aperture during 
the SD or within a specified duration of time afterwards (limited hold, LH) the 
rat would be rewarded with a food reward and a correct response was recorded.  
Responses into an incorrect aperture during SD or LH periods would be recorded 
as an incorrect response and the rat would be punished by a time out period of 
darkness of 5 seconds.  Time out punishments were also initiated if the rat made 
an omission - no response into any aperture during SD or LH, or a premature 
response – a response in an aperture within the ITI period.  The next trial was 
again initiated by a nose-poke in the food hopper.  This was repeated for 100 
trials or 30 minutes, whichever was completed first.   
 
Training of the five choice serial reaction time task was performed on weekdays.  
Training of the task initially involved the stimulus duration and limited hold 
being set at 60 seconds; these durations were gradually reduced once the rat 
had performed the task to criteria at that training level with an accuracy of 80% 
or more with less than 20% omissions.  Each rat was trained to the level of 
performing the task with an accuracy of 80% or more with less than 20% 
omissions with a stimulus duration of 0.6 seconds and limited hold duration of 5 
seconds.  As not all rats met criteria at level 12 at the same time, the rats that 
had met criteria at level 12 were reduced to 3 training sessions a week to 
prevent over-training.  The training levels are summarised in Table 2.    
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2.7.4 Baseline testing   
Once all rats had reached criteria at training level 12 their performance in 3 
variations of the 5-choice serial reaction time task was assessed.  Parameters of 
these tasks are summarised in Table 3.  Performance in the basic task was 
assessed on Monday, Tuesday and Thursday and an average performance over 
the three days was calculated.  Performance in the variable inter-trial interval 
task and variable stimulus duration task were assessed on Wednesday and Friday, 
respectively.  The rats were split into 3 groups of 12 with equal performance in 
all three task types based on the baseline testing period to ensure any 
differences following surgery was due to the surgical treatment carried out.   
2.7.5 Post-surgical testing 
Rats were re-tested in all three task types 1, 3 and 5 weeks post-surgery as 
described in Table 4. Again, an average performance in the basic task was 
calculated from three basic task sessions at each time point.  In the weeks 
between testing (weeks 2 and 4), the rats were exposed to the basic task three 
times a week to maintain their performance.   
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Table 2-2 Summary of 5-choice serial reaction time task training levels.  s, 
seconds 
Training 
level 
Stimulus 
duration (s) 
Inter-trial 
interval (s) 
Limited 
hold (s) 
Time 
out (s) 
1 60 5 60 5 
2 30 5 30 5 
3 20 5 20 5 
4 10 5 10 5 
5 5 5 5 5 
6 2.5 5 5 5 
7 1.5 5 5 5 
8 1 5 5 5 
9 0.9 5 5 5 
10 0.8 5 5 5 
11 0.7 5 5 5 
12 0.6 5 5 5 
 
Table 2-3 5-choice serial reaction time task types.  s, seconds 
Test 
type 
Stimulus 
duration (s) 
Inter-trial 
interval (s) 
Limited 
hold (s) 
Time 
out (s) 
Basic 0.5 5 5 5 
vITI 0.5 5 / 7 / 10 / 12 5 5 
vSD 0.5 / 0.4 / 0.2 / 0.1 5 5 5 
 
Table 2-4 Summary of 5-choice serial reaction time task testing post-
surgery. 
Day 5-choice test type Treatment 
0 - 
Stereotaxic injections into 
mPFC 
veh/scr.rAAV/shErbb4.rAAV 
W
E
E
K
 1
 7 Basic - 
8 Basic - 
9 vITI - 
10 Basic - 
11 vSD - 
W
E
E
K
 3
 21 Basic - 
22 Basic - 
23 vITI - 
24 Basic - 
25 vSD - 
W
E
E
K
 5
 35 Basic - 
36 Basic - 
37 vITI - 
38 Basic - 
39 vSD - 
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2.8 Total RNA isolation 
2.8.1 RNA isolation from cultured cells 
RNA was isolated from NG108-15 cells or dissociated cortical cultures 24 hours 
and 4 days, respectively after transfection using RNeasy mini kit (Qiagen, West 
Sussex, UK) according to the manufacturer’s protocol.  First the medium was 
removed from the wells and cells were subsequently washed with ice-cold 
Dulbecco’s phosphate-buffered saline (D-PBS, Invitrogen).  NG108-15 cells were 
then detached from the well surface using 0.05% (w/v) trypsin/ 1xEDTA pH8 
(Sigma-Aldrich) which was inactivated with DMEM.  The detached cells were 
transferred to an Eppendorf tube and pelleted by centrifugation in a Boeco M-24 
desktop centrifuge (Boeco, Germany) at 10,000rpm for 5 minutes at room 
temperature. The cell pellet was washed with ice cold D-PBS and centrifuged 
again at 10,000rpm for 5 minutes at room temperature.   
 
The cells were lysed (either directly in the plate for dissociated cortical cultures 
or as a cell pellet for NG108-15 cells) with 350µl buffer RDD+-mercaptoethanol 
(Sigma-Aldrich). Lysed cells were then transferred to a ribolyser tube (Lysing 
Matrix D, Qbiogene) and disrupted mechanically for 20 seconds at 6.5g (Hybaid 
Ribolyser, Hybaid Ltd, Middlesex, UK).  An equal volume of 70% (v/v) ethanol 
was then added to the lysed cells which were transferred to an RNeasy column 
and centrifuged at 10,000rpm for 15 seconds at room temperature. The total 
RNA, bound to the column matrix was washed with the kit wash buffers and 
treated with DNase to remove any genomic DNA from the sample.  Total RNA 
was eluted from the column with 30µl RNase free water.  Table 5 summarises 
the steps involved in total RNA isolation. 
 
2.8.2 RNA isolation from PFC tissue 
Total RNA was isolated from the PFC tissue (one hemisphere) using RNeasy mini 
kit (Qiagen) as described above with the following modifications.  Tissue was 
lysed with 350µl buffer RDD+-mercaptoethanol (Sigma-Aldrich) directly in the 
ribolyser tube and total RNA eluted with 50l RNase free H2O (Ambion).   
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Samples were stored at -80°C until further processing.  Table 5 summarises the 
steps involved in total RNA isolation. 
 
Table 2-5 Steps involved in total RNA isolation from cultured cells and PFC 
tissue. 
Step Buffer Volume Spin cycle 
1 RW1 350µl 15s, 10,000rpm 
2 RDD+DNase I* 80µl ----- 
3 RW1 350µl 15s, 10,000rpm 
4 RPE 500µl 15s, 10,000rpm 
5 RPE 500µl 2min, 10,000rpm 
6 - - 1min, 13,000rpm 
7 RNase free H2O 30/50l 1min, 10,000rpm 
 
  
2.8.3 Qualification and quantification of total RNA 
1.5µl isolated total RNA was used to quantify the concentration of total RNA in 
each sample by NanoDrop™ 1000 (Thermo Scientific, Leicestershire, UK) and 
quality of RNA in selected samples was checked using the RNA6000 Nano Chip Kit 
on the Bioanalyser 2100 (Agilent Technologies, Berkshire, UK). 
 
2.9 First strand cDNA synthesis 
First strand cDNA was synthesised from up to 2µg total RNA isolated from NG108-
15 cells, dissociated cortical culture cells, rat PFC tissue or rat and mouse brain 
total RNA (Ambion) using SuperScript®VILO™ cDNA synthesis kit (Invitrogen) 
according to the manufacturers instructions.  In a final volume of 20l first 
strand cDNA was synthesised using up to 2g total RNA 1xVILO™ reaction mix, 
1xSuperScript® III reverse transcriptase enzyme and nuclease free water 
(Ambion).  First strand cDNA was then generated by incubating the tube 
contents at 25˚C for 25 minutes, 42˚C for 60 minutes then terminating the 
reaction at 85˚C for 5 minutes (Veriti™ 96-well Thermal Cycler, Applied 
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Biosystems, Foster City, CA, USA).  Samples were stored at -20°C until they were 
further processed. 
2.10 Reverse transcriptase polymerase chain reaction 
(RT-PCR) 
2.10.1 Primer design 
RT-PCR primers specific for Erbb4 were purchased from Sigma-Genosys (Poole, 
UK).  Primers were designed so that the forward and reverse primers were 
located in different exons and therefore any product amplified from genomic 
DNA would have a much bigger amplicon length than that of a product amplified 
from intronless mRNA.  Mouse and rat Erbb4 exon sequences were taken from 
ENSEMBL (www.ensembl.org).  PCR primers were designed so that the resulting 
product amplified would include differences in sequence between rat and mouse 
Erbb4 or differences between Erbb4 isoforms.  Specificity of primers to Erbb4 
was confirmed by ensuring the primer sequences had no sequence identity to 
any other known genes using the Basic Local Alignment Tool 
(http://blast.ncbi.nlm.nih.gov/Blast.cgi). 
Sequences of PCR primers used in this study are shown in table 6.  It also shows 
the species and isoform specificity of the primers.   
2.10.2 Polymerase chain reaction 
KOD Hot Start DNA polymerase enzyme mixture (Novagen, Merck Chemical Ltd, 
Nottingham, UK) was used to amplify up to 2g 1st strand cDNA synthesised from 
NG108-15 cell RNA or total RNA from rat or mouse brain (Ambion).  A reaction 
mix was prepared containing a final concentration of: 1x KOD Hot Start PCR 
Buffer, 0.2mM dNTP mixture, 1mM MgSO4, 0.3M forward and reverse primer 
mix, 1-2l cDNA, 1U KOD Hot Start DNA polymerase, RNase free H2O up to 50l). 
The reaction mix was incubated in a thermocycler (Veriti™ 96-well Thermal 
Cycler, Applied Biosystems) 95°C for 2 minutes, followed by 35-40 cycles of 95°C 
for 20 seconds, 62-67°C for 10 seconds, 70°C for 10 seconds.   
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5-20l of PCR products were loaded with BlueJuice™ gel loading buffer 
(Invitrogen) into 2.5% (w/v) agarose gels stained with 0.01% (v/v) GelStar® 
Nucleic Acid Gel Stain (Lonza, Slough, UK) and electrophoresed at a constant 
supply of 80volts.  Products were then viewed by ultraviolet light and size 
confirmed by comparison to 1kb Plus DNA ladder (Invitrogen).   
 
2.10.3 Extraction and purification of PCR products 
The PCR product was then carefully cut out of the gel and the DNA fragments 
were extracted and purified using QIAquick Gel Extraction Kit (Qiagen) as 
recommended by the manufacturer’s protocol.  In brief, the product was 
weighed and added to an eppendorf tube with 6x v/w of buffer QG, the sample 
was heated at 50˚C for 10 minutes with brief vortexing every three minutes.  
Next an equal volume to product weight of isopropanol was added and the 
sample applied to spin column in 800µl intervals and centrifuged in a Boeco M-24 
desktop centrifuge (Boeco, Germany) at 13,000rpm/1min until the entire sample 
was used.  Next 500µl buffer QG was applied to the column and centrifuged 
again at 13,000rpm/1min.  750µl buffer PE was pipetted directly onto the 
column and incubated at room temperature for 1 minute before being 
centrifuged at 13,000rpm/1min.  The purified product was then eluted from the 
spin column with 30µl RNase free H20.  A small amount of the purified product 
was then electrophoresed on a 2.5% (w/v) agarose gel to ensure correct size was 
maintained.   
 
2.10.4 PCR product sequencing and sequence analysis 
Purified PCR products were sequenced using 3.2µM forward and reverse PCR 
primers (GeneService, Nottingham).   
 
The resulting sequence of the PCR product was analysed by aligning against 
human, mouse and rat genomes and transcripts (BLAST, 
http://blast.ncbi.nlm.nih.gov/Blast.cgi).   
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Table 2-6 Summary of RT-PCR primers used 
Primer ID Primer sequence (5’-3’) 
Species 
specificity 
Isoform 
specificity 
Exon location 
FwdM1 AGGCTACATGACTCCAATGC Mouse All 27 
FwdR1 AGGCTACATGACTCCCATGC Rat All 27 
RevRM1 TTCCAGTAGTCGGGGTTGTC Rat/Mouse All 28 
M/R JMa/b Fwd CCACCCTTGCCATCCAAA Rat/Mouse JMa/JMb 14 
M/R JMa/b Rev CCAATGACTCCGGCTGCAATCA Rat/Mouse JMa/JMb 17 
M CYT1/2 Fwd CAACATACCTCCTCCCATCTACAC Mouse CYT1/2 25 
M CYT1/2 Rev GCATTCCTTGTTGTGTAGCAAA Mouse CYT1/2 27 
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2.11 Quantitative real time RT-PCR (qRT-PCR) 
2.11.1 Plate set-up 
qRT-PCR was carried out using TaqMan® based chemistry (Applied Biosystems) in 
MicroAmp™ optical 96-well reaction plates (Applied Biosystems). Each 
experimental well contained up to 125ng 1st strand cDNA, 1x TaqMan®Gene 
Expression Master Mix (Applied Biosystems), 1x Gene expression assay (Applied 
Biosystems) and RNase free H2O in a final volume of 25l.  In each experiment, 
wells containing RNase free H2O instead of template were included to monitor 
for contamination.  Each sample or non-template control was performed in 
triplicate.  The reaction plate was then sealed with a piece of MicroAmp™ 
optical adhesion film (Applied Biosystems) and briefly centrifuged.  cDNA was 
amplified for 40 cycles of 95˚C/2min, 95˚/15sec, 60˚/1min using an ABI PRISM® 
7000 Sequence Detection System (Applied Biosystems).  Simultaneously, levels of 
gene expression were quantified in real time from the levels of excited 
fluorescent probe incorporated into the gene expression assay.  The gene 
expression assays used in this study are listed in table 7.   
Table 2-7 TaqMan® gene expression assays used in this study 
Gene expression assay Target gene Species 
Rn00665492_m1 Erbb4 Rat 
Mm01256803_m1 Erbb4 Mouse 
Mm00437762_m1 -2-m Mouse 
Mm99999915_g1 Gapdh Mouse 
Hs99999901_s1 r18s Human/rat/mouse 
Rn01482168_m1 Nrg1 Rat 
Rn00583646_m1 Akt1 Rat 
Mm00433800_m1 Grin1 Mouse 
 
 
2.11.2 Gene expression quantification 
The Comparative CT Method (CT Method - where the amount of target is 
normalised to an endogenous reference then expressed relative to a calibrator 
sample) was used to quantify changes gene expression.  The cycle at which 
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amplification begins was set as the end cycle of the baseline; this was 
determined for each gene expression assay in each experiment performed.  The 
threshold level of fluorescence was set to 0.3 in all experiments. The cycle at 
which the amount of fluorescence emitted from a given sample crosses the 
threshold value is recorded as that sample’s CT value.  The CT value of the non-
template wells was checked to ensure any amplification in experimental samples 
was not due to contamination, the CT values of each triplicate of each 
experimental sample were averaged (outliers were removed if the CT value was 
notably different from the other two replicates).   
The CT was calculated by subtracting the mean CT value of the endogenous 
control gene from the mean CT value of target gene.  For each sample, the CT 
value of a calibrator sample (e.g. untreated cells or vehicle treated rats) was 
then subtracted from the CT value of the test sample to give the CT value. 
The antilog (2-CT) of this value was then calculated to give a fold change in 
gene expression of the target gene. 
   
2.11.3 Gene expression assay validation 
To ensure the validity of using the Comparative CT Method (CT method), the 
amplification efficiencies of the TaqMan® Gene expression Assays used for 
endogenous control genes and target genes in this study were tested.  To test if 
the amplification efficiencies were relatively equivalent (and therefore valid for 
CT analysis) the amplification of endogenous control genes and target genes 
was quantified over a range of dilutions of template cDNA.   
cDNA synthesised from 200ng, 100ng, 40ng, 20ng, 10ng, 4ng and 2ng of rat brain 
or mouse brain total RNA (Ambion) using the protocol described in section 2.9 
was diluted 1/2.5 in RNase free H2O (Ambion).  The experiment was set-up as 
described in the previous section with the appropriate gene expression assay 
being used.  The CT was calculated for the target gene as described in the 
previous section.  An XY scatter plot was then created plotting CT for each 
sample against template amount, a linear regression was applied to this data to 
calculate the value of the slope.  If the value of the slope is less than 0.1 then it 
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is evident that the efficiency of the two assays tested were of equal efficiency 
and therefore the CT Method can be used to quantify changes in gene 
expression.   
2.12 Protein isolation 
2.12.1 Protein lysate isolation from cultured cells 
48 hours to 8 days post-treatment protein lysates were isolated from NG108-15 
cells and dissociated cortical cultures.  On ice the cell culture medium was 
removed from the wells and cells were washed with ice cold D-PBS.  125l-250l 
ice cold RIPA buffer (10mM Tris, pH7.4, 100mM NaCl, 1mM EDTA, 1mM EGTA, 
0.1% (w/v) SDS, 0.5% (w/v) sodium deoxycholate, 1% (v/v) Triton® X-100, 10% 
(v/v) glycerol) supplemented with 10µl/ml protease inhibitor cocktail (Sigma-
Aldrich), 1mM NaF and 2mM Na3VO4 was added to each well and incubated on ice 
for 5 minutes.  Lysed cells were scraped from the wells and transferred to an ice 
cold eppendorf tube and centrifuged in a Sigma 2K15 refrigerated centrifuge 
(Sigma-Aldrich)  at 4˚C for 10 minutes at 10,000rpm.  The supernatant was 
collected and stored at -80°C until further processing.  
2.12.2 Protein lysate isolation from PFC tissue 
The tissue from one hemisphere of the PFC, weighing 25-60mg, was allowed to 
thaw on ice.  Once thawed, 500l ice cold RIPA buffer supplemented with 
10µl/ml protease inhibitor cocktail (Sigma-Aldrich), 1mM NaF and 2mM Na3VO4 
was added to each sample.  The tissue was then mechanically disrupted and 
cells lysed three times at 3.5g for 20 seconds (Hybaid Ribolyser).  The lysates 
were then centrifuged in a Sigma 2K15 refrigerated centrifuge (Sigma-Aldrich)  
at 4°C for 10 minutes at 10,000rpm, before the supernatant was collected and 
stored at -80°C until further processing.   
2.12.3 Protein quantification 
The concentration of protein in each sample was determined using the 
Bradford’s colorimetric assay (Bradford, 1976).  In brief, BSA (Sigma-Aldrich) was 
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diluted in H2O to known concentrations of 250µg/ml, 125 µg/ml, 62.5 µg/ml and 
31.25µg/ml.  Each protein lysate sample (from cells or tissue) was diluted in H2O 
so that its concentration would be within the range of that of the BSA standards 
used (generally 1/10 or 1/20 dilution). As a standard for 0g/ml protein RIPA 
buffer was diluted to the same factor as the samples.   10µl of each BSA 
standard, lysis buffer and sample were pipetted, in triplicate, into a flat bottom 
96 well plate (Corning® CoStar®, Sigma-Aldrich).  200µl 5x Bradford’s reagent 
(BioRad, Hemel Hemstead, UK) diluted 1:4 in H2O was then added to each well 
and incubated at room temperature for 10 minutes to allow the dye to bind to 
protein and to convert colour.  
The plate was then inserted into a MRX microplate reader (Dynex Technologies, 
Ashford, UK) and the optical density of each well was measured at 630nm.  Using 
Revelation software v3.01 a linear regression of optical density vs. protein 
concentration was calculated using the optical density value from lysis buffer to 
represent 0µg/ml protein and the serial dilution of BSA as known protein 
concentration standards. The concentration of each sample was then calculated 
from the linear regression curve. The concentration of each sample was 
multiplied by the dilution factor (10 or 20) to give the final concentration.   
2.13 Western blotting 
2.13.1 Sample preparation 
Protein lysates from cells or tissue were prepared for western blotting by the 
addition of 4x NuPAGE® LDS sample buffer (Invitrogen) and 10x NuPAGE® 
reducing agent (Invitrogen) to the lysate sample.  This was then denatured at 
70°C for 10 minutes.  As the samples were further diluted by the addition of the 
sample buffer and reducing agent, the protein concentration quantified by 
Bradford’s assay was adjusted by multiplying by 0.65.  This final concentration 
was then used to determine the volume of sample required to give a desired 
amount of protein, so that the same amount of protein was used for each 
sample.  
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2.13.2 Electrophoresis 
Separation of proteins by molecular weight was achieved using 10% NuPAGE® 
Novex® Bis-Tris gels (Invitrogen).  In brief, the NuPAGE® gels were secured into 
the XCell SureLock® Mini-Cell system (Invitrogen) and the inner and outer 
chambers filled with 1x NuPAGE® SDS MES Running Buffer (Invitrogen).  The 
inner chamber was supplemented with NuPAGE® Antioxidant (Invitrogen) to 
maintain the state of the protein samples during electrophoresis.  Next, the 
correct volumes of the protein samples were pipetted into the wells of the 
NuPAGE® gel, in each experiment at least one well of each gel contained 5l 
Precision Plus Kailedescope™ ladder (BioRad) as a colorimetric marker of protein 
molecular weights.   
Samples were then electrophoresed at 200V for 35 minutes or until the loading 
dye had visibly reached the bottom of the gel. 
2.13.3 Protein transfer 
Following electrophoresis, the protein samples were then transferred to PVDF 
membrane (0.2m pore size, Invitrogen).  First, sponges, PVDF membranes (pre-
wet in 100% Methanol) and filter papers were pre-soaked in 1x NuPAGE® 
Transfer Buffer/ 10% (v/v) methanol/ NuPAGE® Antioxidant.  The gels were 
carefully removed from their cassettes and assembled on top of a piece of pre-
wet filter paper, and the pre-wet PVDF membrane was then placed on top of the 
gel and this was topped by another piece of pre-wet filter paper.  This gel-
membrane “sandwich” was then secured into the XCell II™ Blot Module 
(Invitrogen) with enough pre-wet sponges under the “sandwich” (on the cathode 
core) and on top of the “sandwich” (the anode core) until there was a tight fit 
and any trapped air bubbles were removed.   
The blot module was then filled with 1x NuPAGE® Transfer Buffer/ 10% (v/v) 
methanol/ NuPAGE® Antioxidant and the outer chamber filled with H2O to 
dissipate any heat during the transfer process. A supply of 30V was then passed 
through the blot module (from the cathode core to the anode core) for 1 hour to 
transfer proteins from the gel onto the PVDF membrane.   
61 
2.13.4 Antibody incubations 
Detection of proteins of interest was performed using several blocking, washes 
and antibody incubation steps. Initially, the PVDF membrane were incubated in 
TBS (20mM Tris, 137mM NaCl, pH 7.6)/ 0.1% (v/v) Tween-20/ 5% (w/v) dried milk 
powder (Marvel) for 2 hours at room temperature with agitation to block non-
specific binding of antibodies.  Next, the membrane was washed 5 times in 
TBS/0.1% (v/v) Tween®-20 for 5 minutes per wash at room temperature with 
agitation before being incubated in the appropriate primary antibody diluted to 
the correct concentration in TBS/0.1% (v/v) Tween®-20/ 5% (w/v) dried milk 
overnight at 4°C with agitation.  The list of antibodies and dilutions used are 
shown in table 8.   
The following day the membrane was washed as before, with an additional 10 
minute final wash.  The membrane was then incubated for 1-2 hours at room 
temperature with agitation in the appropriate HRP-conjugated secondary 
antibody diluted to the correct concentration in TBS/0.1% (v/v) Tween®-20/ 5% 
(w/v) dried milk.  When multiple proteins of different sizes were being detected 
from the same sample two primary and, if necessary, secondary antibodies were 
used in conjunction.  When the primary antibody was already conjugated to HRP 
and no secondary antibody necessary (e.g. Actin-HRP antibody), overnight 
incubation was not necessary, the membrane was simply incubated for 1-2 hours 
at room temperature in diluted HRP antibody then processed as if after 
secondary antibody incubation had taken place.  Next, the membranes were 
washed as before, with an additional 10 minute final wash. 
2.13.5 Visualisation and quantification of proteins 
The proteins were then detected using enhanced chemiluminescence (ECL) Plus 
reagents (Amersham, GE Healthcare, Buckinghamshire, UK).  The reagents were 
allowed to come to room temperature and then diluted as described in the 
manufacturer’s instructions (1ml Solution A + 50l Solution B per membrane) this 
was then pipetted onto the PVDF membrane and allowed to incubate for 5 
minutes at room temperature.  Next, the PVDF membrane was wrapped in 
Clingfilm, ensuring no air bubbles were present and taped inside an x-ray 
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cassette.  In complete darkness x-ray film (ECL Plus Hyperfilm, Amersham, GE 
Healthcare or Kodak) were placed against the membrane and exposed for 5 
seconds to 1 hour.  The film was then developed (X-O MAT) and protein levels in 
each sample were quantified by measuring the optical density of each sample 
(ImageJ, NIH, Bethesda, MD, USA). 
Each sample’s optical density was expressed as normalised to the optical density 
of actin, a protein for which the expression should not change with the 
treatments used in this study, and therefore can serve as a control for variations 
in the amount of sample initially loaded.  The same membrane was used several 
times to identify the levels of multiple proteins in the same sample.  To do this 
the antibodies were stripped from the membranes by incubating the membrane 
in pre-warmed stripping buffer (62.5mM Tris HCL (pH 6.7), 2% (w/v), 100mM -
mercaptoethanol) for 30 minutes at 50°C.  Membranes were then washed twice 
in TBS/0.1% (v/v) Tween-20 for 10 minutes before undergoing blocking, washes 
and antibody incubations as described above. 
2.14 Enzyme linked immunosorbant assay (ELISA) 
2.14.1 Plate preparation 
Protein levels of total ERBB4 (tERBB4) and phosphorylated ERBB4 (pERBB4) were 
quantified using DuoSet® IC Human total-ERBB4 ELISA and DuoSet® IC Human 
Phospho-ERBB4 ELISA (R&D Systems).  Firstly, wells of high bind polystyrene flat 
bottom 96-well microplates (R&D Systems) were coated with 100l 1g/ml 
(pERBB4) or 4g/ml (tERBB4) capture antibody diluted in PBS (137mM NaCl, 
2.7mM KCl, 8.1mM Na2HPO4, 1.5mM KH2PO4, pH 7.2) overnight at 4°C.   
2.14.2 Sample and Standard application 
The following day wells were washed five times with wash buffer (PBS, 0.05% 
(v/v) Tween®-20) then non-specific antibody binding was blocked with 300l 
blocking buffer (PBS, 1% (w/v) BSA, 0.05% (w/v) NaN3 pH 7.2) for 2 hours at 
room temperature after which the wells were washed again (as before). Next, 
Human tERBB4 standards of known concentration (31.25pg/ml-4000pg/ml) and 
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Human pERBB4 standards of known concentrations (46.875pg/ml-6000pg/ml) 
were diluted in IC Diluent#12 (R&D Systems) and pipetted in triplicate into the 
96-well plate.  NG108-15 cell, dissociated cortical cell or rat PFC tissue lysates 
were diluted 1/2 (for tERBB4 ELISA) or 1/4 (for pERBB4 ELISA) in IC Diluent#12 
(R&D Systems) and pipetted in duplicate or triplicate into the 96-well plate.  
Standards and samples were incubated at room temperature for 2 hours.  For 
each experiment triplicates of RIPA buffer diluted to the same factor as samples 
were included to serve as a 0pg/ml standard.  Wells including capture antibody 
only or detection antibody only were included to ensure specificity of antibodies 
(no optical densities were observed with these treatments).   
2.14.3 Antibody incubations 
The wells were again washed (as before) and then incubated with detection 
antibody (1x phosphotyrosine-HRP for pERBB4 ELISA or 1g/ml tERBB4 detection 
antibody) diluted in IC Diluent#14 (R&D Systems) for 2 hours at room 
temperature.  For the tERBB4 ELISA an additional antibody incubation step of 20 
minutes in 1x streptavidin-HRP diluted in IC Diluent#14 was required as the 
detection antibody used in this ELISA was not HRP-conjugated.   
2.14.4 Detection and quantification of proteins 
Following antibody incubations the wells underwent a final wash step (as before) 
then were incubated in Substrate solution (1:1 Solution A : Solution B, R&D 
Systems) for 30 minutes at room temperature.  The enzymatic reaction was 
stopped by the addition of 50% (v/v) H2SO4 to each well. The optical density of 
each well was measured on a MRX microplate reader (Dynex Technologies) at 
450nM.  A standard curve of the standards was generated plotting mean optical 
of each standard against standard concentration (pg/ml).  The levels of tERBB4 
or pERBB4 in the samples were then determined from this using linear regression 
analysis. 
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2.15 Immuno-fluorescent staining 
2.15.1 Immuno-fluorescent staining in cultured cells 
Cell culture media was removed from the wells of an 8-well chamber slide and 
cells were fixed in ice-cold 4% (w/v) PFA (prilled form, Sigma-Aldrich)/PBS for 20 
minutes at 4°C.  Following fixation, cells were washed twice in PBS for 3 
minutes at room temperature before being permeablised in PBS/0.5% (v/v) 
Triton® X-100.  Non-specific antibody binding was then prevented by incubating 
the cells in blocking buffer (PBS/15% (v/v) donkey serum) for 1 hour at room 
temperature.  The cells were then incubated in the correct primary antibody 
diluted in PBS/3% (v/v) donkey serum/0.5% (v/v) Triton-X-100 overnight at 4°C.   
The following day, the cells were washed three times in PBS before being 
incubated with the appropriate Alexa-Fluor conjugated secondary antibody 
diluted in 1xPBS/5% (v/v) donkey serum for 1 hour at room temperature.  The 
cells were again washed three times in PBS, the chamber removed from the slide 
and a coverslip being applied with VECTASHIELD® Mounting Medium with DAPI 
(Vector Laboratories, Burlingame, CA, USA).   
Immunofluorescent staining was then observed using the correct filter on a Nikon 
Eclipse E600 epifluorescent microscope and images were taken using a Nikon 
CoolPix 4500 camera mounted to the microscope.   
2.15.2 Immuno-fluorescent staining in PFC brain sections 
Once the brains from the transcardially perfused rats had sunk to the bottom of 
the 20% (w/v) sucrose/PBS solution they were believed to be cryoprotected.   
The brains were then snap frozen in isopentane (VWR International Ltd) cooled 
to -42°C on dry ice, then placed in the cryostat (Leica CM1850) to equilibrate to 
-20°C.  The brains were then cut into 20µm sections and mounted onto poly-L-
lysine (0.01%, Sigma-Aldrich) coated slides.  Using a hydrophobic barrier pen 
(Vector Laboratories), boundaries were drawn around each brain section.   
Firstly the sections were dehydrated in 50% (v/v) ethanol for 30 minutes at room 
temperature.  Next sections underwent three 10 minute washes in wash buffer 
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(2.5mM NaH2PO4.2H2O, 7mM Na2HPO4 , 0.3M NaCl) before being incubated in the 
correct primary antibody diluted in wash buffer/0.3% (v/v) Triton®- X-100 
overnight at 4°C.  The next day the sections were washed again 3 times for 10 
minutes in wash buffer before being incubated in the appropriate Alexa Fluor 
conjugated secondary antibody diluted in buffer/0.3% (v/v) Triton®- X-100 for 
two hours at room temperature.  For co-localisation studies combinations of 
primary and secondary antibodies were used together in the incubation stages, 
ensuring that the antibodies were raised in different species.  The list of 
antibodies used is shown in table 8.  After another series of washes (as before) 
the sections were allowed to air-dry then coverslips were mounted onto the 
slides with VECTASHIELD® Mounting Medium with DAPI. 
Immunofluorescent staining was then observed using the correct filter on a Nikon 
Eclipse E600 epifluorescent microscope and images were taken using a Nikon 
CoolPix 4500 camera mounted to the microscope.  For co-localisation studies 
further images were taken using a Leica TCS S-P5 laser scanning confocal 
microscope.  Images were merged using ImageJ (NIH, Bethesda, MD, USA). 
2.16 Statistical analysis 
All statistical analyses were carried out using Minitab version 13.1.  For data to 
be assessed by parametric statistical tests (ANOVA, followed by Tukey’s post hoc 
pair-wise comparisons tests or Student’s t-test) all data sets were tested for 
normal distribution using the Anderson Darling normality test.  Where data were 
not normally distributed they were transformed by Box-Cox transformation.  
Non-parametric tests were utilised where transformed data did not result in 
normal distribution (Mann-Whitney or Wilcoxon-rank tests).  Statistical 
significance was set at p<0.05.  Data were expressed as mean ± standard error of 
the mean (SEM).   
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Table 2-8 Summary of antibodies and dilutions used for 
immunofluorescence and western blotting experiments 
Antibody Supplier Cat No. Species Dilution 
Primary antibodies     
     
-Erbb4 Santa Cruz sc-283 Rabbit 1:1000 
-Nrg1 Santa Cruz sc-348 Rabbit 1:1000 
-Actin-HRP Santa Cruz sc-1616 Rabbit 1:2000-1:7000 
-GFP Serotec 4745-1051 Sheep 1:1000-1:3000 
-GFAP Autogen Bioclear AB-J158 Mouse 1:400-1:500 
-Akt Cell Signalling #9272 Rabbit 1:1000 
-phospho-Akt Cell Signalling #4058 Rabbit 1:1000 
-Erk Cell Signalling #4696 Mouse 1:2000 
-phospho-Erk Cell Signalling #4377 Rabbit 1:1000 
-N200 Sigma-Aldrich N 0142 Mouse 1:400 
-Parvalbumin Swant PV 235 Mouse 1:5000 
     
Secondary 
antibodies 
    
     
-sheep-HRP Santa Cruz sc-2473 Donkey 1:1000-1:2000 
-mouse-HRP Santa Cruz sc-2306 Donkey 1:1000-1:2000 
- rabbit-HRP Santa Cruz sc-2305 Donkey 1:1000-1:2000 
Alexa Fluor® 488 -
sheep IgG 
Invitrogen 
Molecular 
Probes® 
 
A-11015 
Donkey 1:1000 
Alexa Fluor® 594 -
mouse IgG 
Invitrogen 
Molecular 
Probes® 
A-11005 Goat 1:200 
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3 Validation of the NG108-15 cell line as a tool for 
researching Erbb4 
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3.1 Introduction 
3.1.1 Neuronal cell lines as a tool for investigating CNS systems 
Cell lines can serve as effective models for investigating several aspects of the 
CNS, such as researching pharmacological responses to new therapeutics before 
in vivo testing and exploring mechanisms of receptor mediated signalling.  
Although it is unlikely cell lines encapsulate the entire complex neuronal 
network system of the CNS, they are useful in determining roles of specific 
proteins in different cell types by utilising cell lines of different cellular origins; 
for example C6 and JS1 cells for investigating glial cells or Schwann cells, 
respectively. Moreover, the use of cell lines can help reduce the amount of 
animals required for neuroscience research.   
In addition, neuronal-like cell lines are generally easy to maintain in culture, 
and although optimisation is required, they can be manipulated more simply 
than primary cultured cells.  Much research has been performed in neuronal and 
non-neuronal cell lines to investigate proteins potentially involved in neuronal 
disorders.  However, many studies over-express genes of interest in these cell 
lines without prior determination of whether the gene is endogenously 
expressed.  It is important to characterise which genes/proteins are 
endogenously expressed in neuronal cell lines, as this will allow the study of 
processes that may be involved in disorders of the CNS in an environment where 
the cell has complete control over the expression of all components involved.  
Manipulation of gene expression i.e. by over-expression systems, may thus take 
over the endogenous control the cell has over these components of the process 
being investigated, and may lead to potentially unnatural interactions.   
3.1.2 NG108-15 cell line 
The NG108-15 cell line is a hybrid clonal cell line formed by Sendai virus-induced 
fusion of the mouse neuroblastoma cell clone N18TG-2 and the rat glioma cell 
clone C6 BV-1 (Klee & Nirenberg, 1974).  This cell line has been widely used to 
investigate many aspects of the CNS and is known to express genes/proteins of 
multiple neuronal signalling systems endogenously.  A large proportion of studies 
69 
utilising NG108-15 cells have been to research the renin-angiotensin system 
(Gendron et al., 2003; Kilian et al., 2008) and -opioid receptor signalling 
(Eisinger & Ammer, 2011).  
NG108-15 cells express multiple important neurotransmitter receptors including 
5HT3 receptors (Emerit et al., 1995; Matsushima et al., 2010), NMDA receptors 
(Ohkuma et al., 1994), glutamate receptors (Tanaka et al., 2010) and 
acetylcholine receptors (both muscarinic and nicotinic) (Hamprecht, 1985).  
NG108-15 cells also express the inhibitory neurotransmitter GABA and its 
synthesising enzyme GAD (Searles & Singer, 1988).  Since NG108-15 cells express 
aspects of these neurotransmitter systems, which have also been linked with 
Nrg1-Erbb4 function, it is likely that this signalling pathway is expressed in 
NG108-15 cells but this hypothesis requires confirmation.  
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3.2 Aims 
The aims of this chapter were to validate the neuronal cell line NG108-15, as a 
potential tool for exploring the Nrg1-Erbb4 signalling pathway by investigating 
the mRNA and protein expression of Erbb4 in this cell line, and to determine if 
Erbb4 levels could be altered by siRNA mediated RNA interference and to study 
the consequences of such knockdown.  In addition, the functionality of the Erbb4 
receptors in NG108-15 cells was studied to explore if Nrg1-Erbb4 signalling in this 
cell line was a relevant model of Nrg1-Erbb4 signalling within the CNS.   
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3.3 Results 
3.3.1 Expression of Erbb4 mRNA in NG108-15 cells 
RT-PCR carried out on total RNA isolated from NG108-15 cells (sections 2.8.1 and 
2.9) confirmed that Erbb4 mRNA is expressed in this cell line (Figure 3.1).  
Species-specific PCR primers were utilised (section 2.10.2) as the genome of this 
cell line contains rat and mouse chromosomes and therefore potentially rat 
and/or mouse Erbb4 transcripts.  An amplicon of the predicted molecular weight 
(approximately 300bp) was obtained using a mouse specific forward PCR primer 
(FwdM1, section 2.10.1) in combination with a universal reverse primer (RevRM1, 
section 2.10.1) (Figure 3.1, lane 3) indicating that mouse Erbb4 transcripts are 
expressed in this cell line. However no amplicons were obtained using a rat 
specific forward PCR primer (FwdR1, section 2.10.1) in combination with a 
universal reverse primer (RevRM1, section 2.10.1) (Figure 3.1, lane 5).  These 
data suggest that the Erbb4 transcripts in NG108-15 cells are of mouse origin. 
To confirm that the NG108-15 Erbb4 PCR product obtained with the mouse 
specific primers (Figure 3.1, lane 3) was indeed derived from mouse 
chromosomes in the hybrid cell line, the DNA sequence of this amplicon was 
obtained (sections 2.10.3 and 2.10.4).  Bioinformatic analyses (section 2.10.4) 
showed that there was 100% sequence identity with this amplicon and mouse 
Erbb4 mRNA (Figure 3.2A) and that no matches were found with any other mouse 
or rat transcripts or genomic DNA or sequences from other species, suggesting 
that this Erbb4 PCR product was indeed of mouse origin.  Furthermore, when the 
sequence of the PCR product was aligned with the 288bp rat Erbb4 mRNA 
sequence there were multiple differences between the two sequences, 
confirming that the sequenced amplicon was not of rat origin (Figure 3.2B).  
These data showed that Erbb4 mRNA was expressed in the NG108-15 cell line 
and that it was likely to be solely of mouse origin. However the lack of a rat PCR 
product could be a technical artefact and therefore further PCR analyses were 
carried out.  RT-PCR was performed on total RNA isolated from rat and mouse 
brains (sections 2.10.2) using the rat specific primers (FwdR1 and RevRM1). An 
amplicon of the correct molecular weight (approximately 300bp) was obtained 
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from the rat brain cDNA (Figure 3.3A, lane 4), confirming that the technical 
conditions employed could amplify a rat Erbb4 transcript if it was present in the 
NG108-15 sample. However, no amplicon was obtained from the mouse brain 
cDNA using the rat primers suggesting that the rat primers were indeed specific 
for the rat Erbb4 mRNA (Figure 3.3A, lane 3). The species specificity of the PCR 
primers was confirmed when the mouse specific primers (FwdM1 and RevRM1) 
were used for RT-PCR on total RNA isolated from rat and mouse brains (sections 
2.10.2).  The mouse specific primers used to amplify an Erbb4 product in NG108-
15 cells (Figure 3.1, lane 3) were able to generate an amplicon from mouse brain 
cDNA (Figure 3.3B, lane 3) but not from rat brain cDNA (Figure 3.3B, lane 4). 
Moreover, analysis of the DNA sequence of the PCR product produced from 
amplifying rat brain cDNA with the rat specific primers (FwdR1 and RevRM1) 
showed 100% sequence identity with rat Erbb4 mRNA (Figure 3.4A).  In addition 
there were no 100% identity matches with transcripts or genomic DNA from other 
species with.  Furthermore, when the sequence of the rat brain cDNA PCR 
product was aligned with mouse Erbb4 mRNA sequence there were multiple 
differences in the nucleotide sequence (Figure 3.4B) whereas alignment of the 
PCR product with the expected rat Erbb4 amplicon sequence showed 100% 
sequence identity.  
In addition as the correct molecular weight of the expected amplicon was 
achieved in all reactions, along with the 100% sequence identity of mouse Erbb4 
in NG108-15 PCR products and rat Erbb4 in rat brain PCR products and that the 
resultant sequences of these PCR products showed two exons of Erbb4 confirm 
that the PCR products are very unlikely to be due to a genomic artefact.  In 
summary, these data show that Erbb4 is expressed in the NG108-15 cell line and 
despite these cells being a hybridoma of rat and mouse chromosomes, Erbb4 is 
expressed from mouse chromosomes only.  
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Figure 3.1  Expression of Erbb4 in NG108-15 cells.  Analysis of 30% (v/v) of 
RT-PCR products in a 2.5% (w/v) agarose gel visualised by ethidium bromide 
DNA stain under ultraviolet light. The molecular weight marker (lane 1) is 0.1g 
1Kb+ DNA ladder (Invitrogen).  Lanes 2 and 3 contain products from using mouse 
specific primers (mouse exon 27 forward primer FwdM1 and exon 28 rat/mouse 
universal primer) in water (lane 2) and NG108-15 cell cDNA (lane 3).  Lanes 4 and 
5 contain products from using rat specific primers (rat exon 27 forward primer 
FwdR1 and exon 28 rat/mouse universal primer) in water (lane 4) and NG108-15 
cell cDNA (lane 5). There are no amplicons from reactions using water as the 
template or using rat specific primers. A band of approximately 300bp, consistent 
with the predicted molecular weight, was obtained with mouse specific primers in 
cDNA from the NG108-15 cells. 
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A 
 
B 
 
 
  
 NG Product         1                                                ATC      3 
                                                                    ||| 
 Rat Erbb4          1 AGGCTACATGACTCCCATGCATGACAAGCCAAAACAAGAATATCTGAATC     50 
 
 NG Product         4 CTGTGGAAGAGAACCCTTTTGTGTCCCGAAGGAAGAATGGAGATCTTCAA     53 
                      ||||||||||||||||||||||||||||.||||||||||||||.|||||| 
 Rat Erbb4         51 CTGTGGAAGAGAACCCTTTTGTGTCCCGGAGGAAGAATGGAGACCTTCAA    100 
 
 NG Product        54 GCTTTAGATAATCCGGAGTATCACAGTGCTTCCAGCGGTCCACCCAAGGC    103 
                      ||||||||||||||.|||||||||||.||||||||||||||.|||||||| 
 Rat Erbb4        101 GCTTTAGATAATCCAGAGTATCACAGCGCTTCCAGCGGTCCCCCCAAGGC    150 
 
 NG Product       104 GGAGGATGAATACGTGAATGAGCCTCTATACCTCAACACCTTCGCCAATG    153 
                      .||||||||.||||||||||||||.||.||.||||||||||||.||||.| 
 Rat Erbb4        151 AGAGGATGAGTACGTGAATGAGCCCCTTTATCTCAACACCTTCACCAACG    200 
 
 NG Product       154 CCTTGGGGAGTGCAGAGTACATGAAAAACAGTGTACTGTCTGTGCCAGAG    203 
                      |||||||.|.|||||||||||||||||||||..||||||||||||||||| 
 Rat Erbb4        201 CCTTGGGAAATGCAGAGTACATGAAAAACAGCTTACTGTCTGTGCCAGAG    250 
 
 NG Product       204 AAAGCCAAGAAAGCATTTGACAACCCCGACTACTGGAA                241 
                      ||||||||||||||||||||||||||||||||||||||  
 Rat Erbb4        251 AAAGCCAAGAAAGCATTTGACAACCCCGACTACTGGAA                288 
 
Figure 3.2  Sequence analyses of the NG108-15 cell mouse specific Erbb4 
PCR product.  (A) BLAST analysis (section 2.10.4) of the DNA sequence of the 
Erbb4 amplicon generated with mouse specific PCR primers (section 2.10.1). 
Query = NG108-15 cell PCR product sequence, Sbjct = mouse Erbb4 mRNA 
sequence.  The alignment of the Erbb4 PCR product sequence (Query) with 
mouse Erbb4 mRNA (Sbjct) shows 100% sequence identity, confirming that this 
amplicon is of mouse origin.   Gene name and sequence identity are highlighted 
by red boxes.  (B) Alignment of the DNA sequence of the Erbb4 amplicon (NG 
product) generated with mouse specific PCR primers with rat Erbb4 mRNA 
sequence.  Sequence identity was 93% indicating that this was not a rat transcript. 
The nucleotides that did not match between the two sequences are highlighted in 
red. 
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Figure 3.3 Validation of mouse and rat Erbb4 PCR primers.  Analysis of 10% 
(v/v) of RT-PCR products in a 2.5% (w/v) agarose gel visualised by ethidium 
bromide DNA stain under ultraviolet light. The molecular weight marker (lane 1) is 
0.1g 1Kb+ DNA ladder (Invitrogen). (A) Lanes 2, 3 and 4 contain products from 
using rat specific primers (rat exon 27 forward primer FwdR1 and exon 28 
rat/mouse universal primer) in water (lane 2), mouse brain cDNA (lane 3) and rat 
brain cDNA (lane 4).  (B)  Lanes 2,3 and 4 contain products from using mouse 
specific primers (mouse exon 27 forward primer FwdM1 and exon 28 rat/mouse 
universal primer) in water (lane 2), mouse brain cDNA (lane 3) and rat brain cDNA 
(lane 4). There are no amplicons from reactions using water as the template or 
using rat specific primers with mouse brain cDNA or using mouse specific primers 
with rat specific primers.  A band of approximately 300bp, consistent with the 
predicted molecular weight, was obtained with mouse specific primers in cDNA 
from mouse brain and with rat specific primers in cDNA from rat brain. 
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A 
 
B 
Rat product         GAACCCTTTTGTGTCCCGGAGGAAGAATGGAGACCTTCAAGCTTTAGATAATCCAGAGTA 77 
 
Mouse Erbb4         GAACCCTTTTGTGTCCCGAAGGAAGAATGGAGATCTTCAAGCTTTAGATAATCCGGAGTA 120 
                    ****************** ************** ******************** ***** 
Rat product         TCACAGCGCTTCCAGCGGTCCCCCCAAGGCAGAGGATGAGTACGTGAATGAGCCCCTTTA 137 
 
Mouse Erbb4         TCACAGTGCTTCCAGCGGTCCACCCAAGGCGGAGGATGAATACGTGAATGAGCCTCTATA 180 
                    ****** ************** ******** ******** ************** ** ** 
 
Rat product         TCTCAACACCTTCACCAACGCCTTGGGAAATGCAGAGTACATGAAAAACAGCTTACTGTC 197 
 
Mouse Erbb4         CCTCAACACCTTCGCCAATGCCTTGGGGAGTGCAGAGTACATGAAAAACAGTGTACTGTC 240 
                     ************ **** ******** * *********************  ******* 
 
Rat product         TGTGCCAGAGAAAGCCAAGAAAGCATTTGACAACCCCGACTACTGGAA             245 
 
Mouse Erbb4         TGTGCCAGAGAAAGCCAAGAAAGCATTTGACAACCCCGACTACTGGAA             286 
                    ************************************************   
 
Figure 3.4 Sequence analyses of rat brain PCR product.  (A) BLAST analysis 
(section 2.10.4) of the DNA sequence of the Erbb4 amplicon generated with rat 
specific PCR primers (section 2.10.1).  Query = rat brain PCR product sequence, 
Sbjct = rat Erbb4 mRNA sequence.  The alignment of the rat brain PCR product 
sequence (Query) with rat Erbb4 mRNA (Sbjct) shows 100% sequence identity, 
confirming that this amplicon is of rat origin.   Gene name and sequence identity 
are highlighted by red boxes.  (B) Alignment of the DNA sequence of the Erbb4 
amplicon (rat brain product) generated with rat specific PCR primers with mouse 
Erbb4 mRNA sequence.  Sequence identity was 93% indicating that this was not a 
mouse transcript. The nucleotides that did not match between the two sequences 
are highlighted in red. 
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3.3.2 Expression of Erbb4 isoforms in NG108-15 cells 
The splicing pattern of Erbb4 is complex (Elenius et al., 1997; Elenius et al., 
1999; Tan et al., 2010) and so having confirmed that Erbb4 is expressed in the 
NG108-15 cells, it was necessary to determine which splice variants are 
expressed. Isoform specific primers were designed that would distinguish 
between the JMa and JMb isoforms and also between the CYT1 and CYT2 
isoforms (JMa/b isoforms: exon 14, M/R JMa/b Fwd primer and exon 17, M/R 
JMa/b Rev primer and CYT1/2 isoforms: exon 25, M CYT1/2 Fwd and exon 27, M 
CYT1/2 Rev).   
An amplicon of the predicted molecular weight for the Erbb4 JMa isoform 
(approximately 140bp) was detected in the NG108-15 cells (Figure 3.5A, lane 3) 
but there was no amplicon for the predicted molecular weight of the JMb 
isoform. The presence of a product with an amplicon of 140bp but not 100bp in 
the NG108-15 cell sample indicates that NG108-15 cells express the mouse JMa 
Erbb4 isoform only.  The RT-PCR conditions were tested using total RNA isolated 
from mouse brain, in which Erbb4 seems to be more highly expressed.  
Amplicons were obtained for JMa (140bp) and JMb (100bp) in the mouse brain 
cDNA (Figure 3.5B, lane 3), indicating that if the JMb Isoform is expressed in the 
NG108-15 cells it would have been detected.  
Amplicons of the predicted molecular weight of the Erbb4 CYT1 and CYT2 
isoforms (approximately 100 bp and 150bp, respectively) were detected in the 
NG108-15 cell cDNA (Figure 3.6A, lane 4).  Again, the RT-PCR conditions were 
tested using total RNA isolated from mouse brain, in which Erbb4 seems to be 
more highly expressed.  Amplicons were obtained for both Erbb4 CYT1 and CYT2 
isoforms (Figure 3.6B, lane 3).  The presence of products with amplicons of 
100bp and 150bp in the NG108-15 cell sample indicates that NG108-15 cells 
express the mouse CYT1 and CYT2 Erbb4 isoforms.     
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Figure 3.5 Investigation of Erbb4 JMa/JMb isoform expression in NG108-15 
cells.  Analysis of RT-PCR products in a 2.5% (w/v) agarose gel visualised by 
ethidium bromide DNA stain under ultraviolet light. The molecular weight marker 
(lane 1) is 0.1g 1Kb+ DNA ladder (Invitrogen). (A) Lanes 2, and 3 contain 40% 
(v/v) PCR products from using primers designed to detect JMa/JMb isoforms with 
expected amplicon lengths of 135bp and 103bp, respectively (mouse/rat exon 14 
forward primer M/R JMa/b Fwd and mouse/rat exon 17 reverse primer JMa/b Rev) 
in water (lane 2), and NG108-15 cell cDNA (lane 3).  (B)  Lanes 2, and 3 contain 
20% (v/v) PCR products from using primers designed to detect JMa/JMb isoforms 
with expected amplicon lengths of 135bp and 103bp, respectively (mouse/rat exon 
14 forward primer M/R JMa/b Fwd and mouse/rat exon 17 reverse primer JMa/b 
Rev) in water (lane 2), and mouse brain cDNA (lane 3).  There are no amplicons 
from reactions using water as the template.  A band of approximately 140bp, 
consistent with the predicted molecular weight of JMa, was obtained with JMa/b 
specific primers in cDNA from NG108-15 cell, two bands of approximately 100bp 
and 140bp, consistent with the predicted molecular weight of JMa and JMb, were 
obtained with JMa/b specific primers in cDNA from mouse brain. 
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Figure 3.6 Investigation of CYT1/2 isoform expression in NG108-15 cells.  
Analysis of RT-PCR products in a 2.5% (w/v) agarose gel visualised by ethidium 
bromide DNA stain under ultraviolet light. The molecular weight marker (lane 1) is 
0.1g 1Kb+ DNA ladder (Invitrogen). (A) Lanes 2, and 4 contain 40% (v/v) PCR 
products from using primers designed to detect CYT1/CYT2 isoforms with 
expected amplicon lengths of 149bp and 101bp, respectively (mouse exon 25 
forward primer M CYT1/2 Fwd and mouse exon 27 reverse primer M CYT1/2 Rev) 
in water (lane 2), and NG108-15 cell cDNA (lane 4).  (B)  Lanes 2, and 3 contain 
20% (v/v) PCR products from using primers designed to detect CYT1/CYT2 
isoforms with expected amplicon lengths of 149bp and 101bp, respectively (mouse 
exon 25 forward primer M CYT1/2 Fwd and mouse exon 27 reverse primer M 
CYT1/2 Rev) in water (lane 2), and mouse brain cDNA (lane 3).  There are no 
amplicons from reactions using water as the template.  Bands of approximately 
100bp and 150bp, consistent with the predicted molecular weight of CYT1 and 
CYT2, were obtained with CYT1/2 specific primers in cDNA from NG108-15 cell 
and cDNA from mouse brain. 
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3.3.3 Expression of Erbb4 and Nrg1 protein in NG108-15 cells 
Western blotting was carried out to determine whether the Erbb4 mRNA is 
translated to protein and whether Nrg1 protein is expressed in NG108-15 cells 
(Section 2.13) and also to determine if expression of these proteins is similar to 
other neural tissues.   
Erbb4 immunoreactive bands of approximately 180kDa, 150kDa, and 60kDa were 
observed in the NG108-15 cell sample.  All of these immunoreactive bands were 
also present in rat and mouse brain samples with faint bands at 100kDa also 
present (Figure 3.7).  The 180kDa band corresponds to the predicted full length 
molecular weight of Erbb4, whereas the lower molecular weight bands 
correspond to predicted molecular weights of cleaved and truncated forms of 
Erbb4.  To compare the expression of Erbb4 in neuronal tissue (rat and mouse 
brain) and neuronal-like cells (NG108-15) with a peripheral tissue, 
immunoreactive bands of Erbb4 in rat heart tissue were also examined.  Very 
similar immunoreactive bands were observed in the rat heart lysate than that of 
the NG108-15 cells, rat and mouse brain, but there was no 60kDa 
immunoreactive band in the rat heart sample.  To achieve the 180kDa 
immunoreactive band, predicted to represent full length Erbb4, 45g of NG108-
15 cell lysate was required whereas 15g of the brain and heart tissue was 
enough tissue to give prominent immunoreactive bands.  This is suggestive that 
the expression of Erbb4 in NG108-15 cells is relatively low compared to cardiac 
or neuronal tissue.   
Nrg1 immunoreactive bands of approximately 150kDa, 100kDa, 80kDa, 55kDa, 
53kDa and 48kDa were observed in the NG108-15 cell sample (Figure 3.8).  All 
these immunoreactive bands were also present in the rat and mouse brain 
samples with additional lower molecular weight bands of less than 48kDa also 
present (Figure 3.8).  These bands represent both full length and cleaved forms 
of Nrg1.  The intensities of the immunoreactive bands did differ between 
samples, with the NG108-15 cell sample having a much lower intensity of the 
100kDa immunoreactive band than the brain samples despite the amount of 
NG108-15 cell total protein lysate analysed being much greater than that of the 
brain samples (45g from the NG108-15 cells and 15g from the brain samples).  
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The NG108-15 cells did however appear to have a greater abundance of the 
48kDa immunoreactive band.    
In summary, the western blot analysis of NG108-15 cell total protein lysates 
showed that multiple Erbb4 and Nrg1 protein isoforms, including the full length 
proteins, are expressed in NG108-15 cells. 
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Figure 3.7 Comparison of the expression of Erbb4 protein in NG108-15 cells 
with neuronal and non-neuronal tissue.  Representative western blots of 45g 
NG108-15 cell (lane 1), 15g rat brain (lane 2), 15g mouse brain (lane 3) and 
15g rat heart (lane 4) total protein lysates depicting immunoreactive Erbb4 
protein. 
 
 
Figure 3.8 Comparison of the expression of Nrg1 protein in NG108-15 cells 
with  neuronal tissue  Representative western blots of 45g NG108-15 cell (lane 
1), 15g rat brain (lane 2) and 15g mouse brain (lane 3) total protein lysates 
depicting immunoreactive Nrg1 protein. 
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85 
3.3.4 Optimisation of siRNA mediated Erbb4 knockdown 
Confirmation of the expression of Erbb4 at the mRNA and protein levels 
indicated that this cell line could be used as an in vitro tool for validating Erbb4 
function in a critical signalling pathway for schizophrenia by utilising siRNA 
(section 2.3.1) to knockdown expression and for validating viral vectors for in 
vivo analyses (methods section 2.3.2 and results section 4.3.1).   Successful gene 
expression knockdown requires optimisation of key factors such as concentration 
of the siRNA and the cell transfection reagent. Optimisation experiments were 
conducted in which three concentrations of mouse Erbb4 siRNA (5nM, 10nM and 
20nM) were tested in conjunction with two volumes of transfection reagent 
(3.75l and 7.5l) (section 2.3.1).  Knockdown of Erbb4 mRNA was measured in 
the NG108-15 cells 24 hours post-siRNA application using qRT-PCR (section 2.11).  
Treatment of the cells with all three concentrations of Erbb4 siRNA and both 
volumes of transfection reagent resulted in Erbb4 mRNA knockdown (Figure 
3.9A).  Although there was no overall significant effect of transfection reagent 
volume on Erbb4 expression (F (1, 33) =0.15 p>0.05), cells transfected with the 
Erbb4 siRNA and the higher volume of transfection reagent (7.5l 
Lipofectamine™ RNAiMAX), reduced Erbb4 expression to a greater extent than 
those transfected with the lower volume (3.75l Lipofectamine™ RNAiMAX) when 
compared to cells treated with non-targeting siRNA (Figure3.9A). NG108-15 cells 
had up to 77% knockdown in Erbb4 expression following Erbb4 siRNA treatment.  
All concentrations of Erbb4 siRNA with 7.5l transfection reagent significantly 
reduced Erbb4 expression compared to untreated cells, cells treated with non-
targeting siRNA and cells treated with Gapdh siRNA.  Importantly there was no 
difference in Erbb4 expression between the control treatment groups (untreated 
cells, non-targeting siRNA treated cells and Gapdh siRNA treated cells).  
Measurement of the expression of a house-keeping gene, -2-microglobulin, was 
utilised to determine if the volume of transfection reagent or the Erbb4 siRNA 
had off-target effects.  There was no significant effect of treatment (F (10, 39) 
=0.33 p>0.05) or transfection reagent volume (F (1, 33) =0.01 p>0.05) on -2-
microglobulin expression. (Figure 3.9B) 
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Figure 3.9 Optimisation of the concentration of Erbb4 siRNA and 
transfection reagent volume to produce significant knockdown of Erbb4 in 
NG108-15 cell transfections.  (A) % expression remaining of Erbb4 relative to 
Erbb4 expression in non-targeting siRNA treated NG108-15 cells (B) % expression 
remaining of -2-microglobulin relative to -2-microglobulin expression in non-
targeting siRNA treated NG108-15 cells.  low lipofectamine = 3.75l 
Lipofectamine™ RNAiMAX transfection reagent, high lipofectamine = 7.5l 
Lipofectamine™ RNAiMAX transfection reagent.   qRT-PCR was performed on 
total RNA isolated from Untreated = untreated NG108-15 cells, non-targeting = 
NG108-15 cells transfected with non-targeting siRNA, siGapdh = NG108-15 cells 
transfected with a Gapdh siRNA, siErbb4 = NG108-15 cells transfected with the 
Erbb4 siRNA at a concentration of 5nM, 10nM and 20nM. Data represent mean ± 
SE expressed as a percentage of the Erbb4 or -2-microglobulin expression 
remaining in cells transfected with non-targeting siRNA at equivalent lipofectamine 
volumes.  n=3-6/treatment group.  ### p<0.001 vs. Erbb4 expression in NG108-15 
cells transfected with Gapdh siRNA at equivalent lipofectamine volume, *** 
p<0.001 vs. Erbb4 expression in NG108-15 cells transfected with non-targeting 
siRNA treated samples at equivalent lipofectamine volume, @ p<0.05, @@p<0.01 
vs. Erbb4 expression in untreated NG108-15 cells using two-way ANOVA followed 
by Tukey’s test for multiple comparisons. 
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Concurrently NG108-15 cells were transfected with a siRNA for the house-
keeping gene Gapdh, to act as a positive control for the procedure. Knockdown 
of Gapdh mRNA was measured in the NG108-15 cells 24 hours post-siRNA 
application using qRT-PCR. Gapdh expression was significantly affected by 
treatment (F (5,17)=41.59 p<0.001) with post hoc comparisons revealing cells 
transfected with Gapdh siRNA had significantly less Gapdh expression than all 
other treatment groups (p<0.001) (Figure 3.10).  Gapdh expression was also 
measured to check for off-target effects of the Erbb4 siRNA, in addition to the 
measurement of -2-microglobulin. Importantly Gapdh expression did not 
change under any of the conditions that the cells were transfected with Erbb4 
siRNA (Figure 3.10).   
In summary, transfection of NG108-15 cells with the Erbb4 siRNA produced 
significant knockdown of Erbb4 mRNA but not Gapdh or -2-microglobulin, 
suggesting knockdown specificity. 
These data showed that transfection of NG108-15 cells with 20nM Erbb4 siRNA 
using 7.5l Lipofectamine™ RNAiMAX led to a 77% knockdown of Erbb4 mRNA 
without affecting the expression of Gapdh or -2-microglobulin. Therefore these 
conditions were chosen to investigate if reduced Erbb4 protein levels could be 
achieved and detected.   
Although real time PCR analysis showed that at 24 hours post-Erbb4 siRNA 
treatment there was significant Erbb4 mRNA knockdown, protein levels of Erbb4 
at 24 hours post-Erbb4 siRNA treatment remain comparable to untreated cells 
and non-targeting siRNA treated cells.  Erbb4 protein levels were also not 
knocked down using 20nM Erbb4 siRNA treatment 48 hours, 72 hours or 96 hours 
post-siRNA application (Figure 3.11 top panel).  Gapdh siRNA application 
however resulted in Gapdh protein knockdown 48 hours post-siRNA application 
(Figure 3.11 middle panel).  Unfortunately, Erbb4 expression in NG108-15 cells 
was below the detection levels of the ERBB4 ELISA, therefore Erbb4 levels post-
siRNA treatment could not be quantified using this method. 
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Figure 3.10 Effects on Gapdh expression in NG108-15 cells transfected with 
siRNA.   % expression remaining of Gapdh.   qRT-PCR was performed on total 
RNA isolated from Untreated = untreated NG108-15 cells, non-targeting = NG108-
15 cells transfected with non-targeting siRNA, siGapdh = NG108-15 cells 
transfected with a Gapdh siRNA, siErbb4 = NG108-15 cells transfected with the 
Erbb4 siRNA at a concentration of 5nM, 10nM and 20nM.  Data represent mean ± 
SE expressed as a percentage of the Gapdh expression remaining in cells 
transfected with non-targeting siRNA.  n=3/treatment group.  ### p<0.001 vs. 
Gapdh expression in NG108-15 cells transfected with Erbb4 siRNA at all 
concentrations tested, *** p<0.001 vs. Gapdh expression in NG108-15 cells 
transfected with non-targeting siRNA, @@@ p<0.001 vs. Gapdh expression in 
untreated NG108-15 cells using two-way ANOVA followed by Tukey’s test for 
multiple comparisons. 
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Figure 3.11 Erbb4 protein expression in NG108-15 cells following siRNA 
treatment.  Representative western blots of 45g NG108-15 cell lysates depicting 
immunoreactive protein levels of Erbb4 at 180kDa, Gapdh at 37kDa and Actin at 
42kDa at 24 hours, 48 hours, 72 hours and 96 hours following application of 
siRNA.  Untreated= untreated NG108-15 cells, non-targeting= NG108-15 cells 
transfected with non-targeting siRNA, siGapdh= NG108-15 cell transfected with 
Gapdh siRNA, siErbb4= NG108-15 cells transfected with Erbb4 siRNA.  
Immunoblots are representative results of n=4 at each condition. 
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3.3.5 Effect of siRNA-mediated knockdown of Erbb4 in NG-108-15 
cells on the expression of related genes 
Having obtained Erbb4 knockdown in NG108-15, expression of genes in the Erbb4 
signalling pathway was assessed. Real-time PCR was used to quantify the 
expression of Akt and Grin1.  Akt expression was not significantly affected by 
transfection of the cells with siRNA (F (5, 32) =2.19 p>0.05) (Figure 3.12).  
Conversely, Grin1 expression was significantly affected in cells transfected with 
non-targeting siRNA (F (5, 32) =11.22 p<0.001) (Figure 3.13).  However, there 
were no differences in Grin1 expression in cells transfected with Erbb4 siRNA. 
 
 
 
 
 
 
 
 
 
92 
 
Figure 3.12 Effects on Akt expression in NG108-15 cells transfected with 
siRNA.  % expression remaining of Akt.   qRT-PCR was performed on total RNA 
isolated from Untreated = untreated NG108-15 cells, non-targeting = NG108-15 
cells transfected with non-targeting siRNA, siGapdh = NG108-15 cells transfected 
with a Gapdh siRNA, siErbb4 = NG108-15 cells transfected with the Erbb4 siRNA 
at a concentration of 5nM, 10nM and 20nM.  Data represent mean ± SE 
expressed as a percentage of the Akt expression remaining in cells transfected 
with non-targeting siRNA.  n=3/treatment group.  
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Figure 3.13 Effects on Grin1 expression in NG108-15 cells transfected with 
siRNA.  % expression remaining of Grin1.   qRT-PCR was performed on total 
RNA isolated from Untreated = untreated NG108-15 cells, non-targeting = NG108-
15 cells transfected with non-targeting siRNA, siGapdh = NG108-15 cells 
transfected with a Gapdh siRNA, siErbb4 = NG108-15 cells transfected with the 
Erbb4 siRNA at a concentration of 5nM, 10nM and 20nM.  Data represent mean ± 
SE expressed as a percentage of the Grin1 expression remaining in cells 
transfected with non-targeting siRNA n=3/treatment group. ### p<0.001 vs. Grin1 
expression in NG108-15 cells transfected with Erbb4 siRNA at all concentrations 
tested, *** p<0.001 vs. Grin1 expression in NG108-15 cells transfected with Gapdh 
siRNA, @@@ p<0.001 vs. Grin1 expression in untreated NG108-15 cells using 
two-way ANOVA followed by Tukey’s test for multiple comparisons. 
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3.3.6 Assessment of the functionality of Erbb4 receptors in 
NG108-15 cells 
Having shown that Erbb4 receptors are expressed in NG108-15 cells, it was of 
great interest to assess if the receptors were actually functional.  Therefore, 
Erbb4 phosphorylation following NRG1 application (section 2.2.3) was measured 
as a marker of activity and hence functionality.  Phosphorylated Erbb4 (pERBB4) 
was determined using the phosphoERBB4 ELISA (section 2.14) following the  
application of a range of NRG1 concentrations (10ng/ml-200ng/ml) or vehicle 
treatment (PBS/0.1% (w/v) BSA) for varying amounts of time (10, 30 or 60 
minutes) on NG108-15 cells (Figure 3.14).  NRG1 treatment had a very variable 
effect on NG108-15 cells, which is seen as quite large error bars in each group.  
Although individual Mann-Whitney tests comparing the effects of NRG1 
treatments compared to vehicle treatment at any particular time-point did not 
reveal any significant changes in pERBB4 levels following NRG1 treatment, 
there was a general trend that 10 minute stimulation with NRG1 resulted in 
higher phosphorylation levels than 30 minute or 60 minute stimulation durations.  
When the levels of pERBB4 in NRG1 treated cells relative to vehicle treated 
cells were analysed by Wilcoxon Rank Test, 10 minute NRG1 stimulation at the 
highest concentration (200ng/ml) significantly increased pERBB4 levels (p<0.05) 
(Figure 3.14). 
To assess if the minimal change in pERBB4 expression observed in NG108-15 cells 
was due to a sensitivity problem with the pERBB4 ELISA kit, primary cortical 
cultures were treated with 200ng/ml NRG1 or vehicle for 10 minutes then 
pERBB4 levels assessed by ELISA.  NRG1 stimulation led to a 5 fold increase in 
pERBB4 expression compared to vehicle treated cells (p<0.001) (Figure 3.15). 
95 
 
Figure 3.14  Effect of NRG1 stimulation on pERBB4 levels in NG108-15 
cells.  pERBB4 expression in NG108-15 cells analysed by ELISA following 10, 30 
or 60 minute stimulation with vehicle (PBS/0.1% (w/v) BSA), 10ng/ml, 25ng/ml, 
50ng/ml, 100ng/ml or 200ng/ml NRG1Data represent mean optical density ± SE 
relative to vehicle treated NG108-15 cells.  n=2-5/treatment group.  * p<0.05 
greater than 1 using Wilcoxon Rank Sum Test.  
 
 
Figure 3.15 Effect of NRG1 stimulation on pERBB4 levels in primary cortical 
cells.  pERBB4 expression in primary cortical cells analysed by ELISA following 
10 minute stimulation with vehicle (veh)  (PBS/0.1% (w/v) BSA), or 200ng/ml 
NRG1Data represent mean optical density ± SE relative to vehicle treated 
primary cortical cells.  n=4-5/treatment group.  *** p<0.001 vs. vehicle treated cells 
using unpaired Students t test. 
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To assess if NRG1 stimulation of Erbb4 in NG108-15 cells resulted in activation 
of downstream Nrg1-Erbb4 signalling pathways, levels of phosphorylated Gsk3, 
Akt and Erk2 were measured by western blot analysis (Figure 3.16).  As with 
pERBB4 levels, levels of phosphorylated Gsk3, Akt and Erk2 in NG108-15 cells 
were very variable following NRG1 stimulation.  However, Wilcoxon Rank Sum 
Tests revealed applications of 10ng/ml and 25ng/ml NRG1 on NG108-15 cells 
for 10 minutes, significantly increased pGSK3 levels compared to vehicle 
treated cells (p<0.05) (Figure 3.16).  Phosphorylation of Akt or Erk2 in NG108-15 
cells was not significantly changed at any concentration of NRG1.   
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Figure 3.16 Effect of NRG1 stimulation on the activation of Nrg1-Erbb4 
signalling pathways.  pGSK3, pAkt and pErk expression normalised to Actin 
levels in NG108-15 cells as analysed by western blot following 10 minute 
stimulation with vehicle (PBS/0.1% (w/v) BSA) or 10ng/ml, 25ng/ml, 50ng/ml, 
100ng/ml or 200ng/ml NRG1Data represent mean optical density ± SE relative 
to vehicle treated NG108-15 cells.  n=2-5/treatment group.  * p<0.05 greater than 
1 using Wilcoxon Rank Sum Test. 
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3.4 Discussion 
3.4.1 Expression of Erbb4 in NG108-15 cells 
A pinnacle finding of this study was that Erbb4 mRNA and protein are expressed 
in NG108-15 cells, as shown by RT-PCR and western blotting.  This is the first 
study which has specifically looked at Erbb4 expression in this neuronal cell line 
and is in agreement with a previous study which showed that NG108-15 cells 
expressed the Erbb4 ligand Nrg1 (Pun et al., 1997), which is also confirmed at 
the protein level in this current study.  This suggests that Nrg1-Erbb4 signalling 
is present in NG108-15 cells and that this cell line may serve as a good in vitro 
model for investigating this signalling pathway.    
A previous study by Schulz and colleagues (2005) suggested that Erbb receptors 
are not endogenously expressed by NG108-15 cells.  The conflict in findings 
between this study and that of Schulz et al., (2005) may be due to differences in 
methodology, as an antibody for Erbb1 and a non-specific Erbb inhibitor were 
used by Schulz et al.,.  However, in the present study primers and antibodies 
specific for Erbb4 were used.  In addition, previous studies of Erbb4 expression 
in other cell lines have led to contradictory results.  For example, endogenous 
Erbb4 expression has been shown in HEK293 cells (Yang et al., 2005); whereas 
other studies have concluded there is no endogenous Erbb4 expression in this 
cell line (Deb et al., 2008).  Other neuronal cell lines have been shown to 
express Erbb4 endogenously including the human SK-N-MC neuroblastoma, rat C6 
glioma and human U251 glioma cell lines (Ritch et al., 2003; Fallon et al., 2004).  
Interestingly, many neuronal cell lines express either or both Erbb2 and Erbb3, 
but lack endogenous expression of Erbb4 (Vaskovsky et al., 2000; Frohnert et 
al., 2003; Gambarotta et al., 2004; Fallon et al., 2004; Croslan et al., 2008).  
The specificity of the RT-PCR primers designed for Erbb4 in this study was 
thoroughly checked and bioinformatic testing confirmed no other transcripts 
were detected by these primers.  It is therefore unlikely that they detected any 
of the other Erbb receptor mRNAs. 
From the RT-PCR results seen with “pan” Erbb4 primers and isoform specific 
Erbb4 primers, endogenous Erbb4 expression in NG108-15 cells is low but 
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detectable, when compared to the levels of Erbb4 expression in mouse and rat 
brain.  Other studies of endogenous Erbb4 expression in cell lines have found 
similar low levels, such as in the mouse epithelial cell line YAMC (Frey et al., 
2009).  In addition, many studies of endogenous Erbb4 expression in cell lines 
may wrongly assume lack of expression if the same amount of template RNA or 
cell lysate is used for quantification of multiple Erbb family members, as it has 
been shown that in some cell lines such as L6 skeletal muscle cell line Erbb4 
expression is 50-fold less than that of Erbb3 (Zhu et al., 1995).  The amount of 
NG108-15 cell lysate used in this study is consistent with a previous study in 
which similar amounts of cell lysate as used to visualise Erbb4 immunoreactive 
bands (Fallon et al., 2004).  However it should be noted that faint PCR products 
or western blots may be partly due to technical artefacts, such as a poorly 
designed PCR primer.  However, it is unlikely that the low levels of Erbb4 mRNA 
and protein detected in the present study are due to technical artefacts as qRT-
PCR experiments showed the cycle number at which the level of fluorescence 
overcame threshold levels was much higher in NG108-15 cell samples than that 
of samples from brain tissue (data not shown) emphasising a lower expression in 
the cell line than neuronal tissue.     
As NG108-15 cells are a hybrid cell line derived from mouse and rat cell clones, 
it was of interest to determine the origin of Erbb4, in order to specify which 
sequence should be the target of downstream applications i.e. siRNA target 
sequence and qRT-PCR assay specificity.  As NG108-15 cell cDNA only amplified 
with PCR primers specifically designed to recognise mouse Erbb4, and resulting 
sequencing confirmed NG108-15 PCR products were mouse Erbb4 it can be 
concluded that the endogenous Erbb4 in NG108-15 cells is expressed from the 
mouse genome.  This finding is perhaps not surprising as a previous study found 
NG108-15 cells predominantly consist of mouse chromosomes, with an expected 
ratio of mouse:rat chromosomes of 1.9:1 (Ajiro et al., 1982).  Other studies have 
also found that their genes of interest were endogenously expressed in NG108-15 
cells and originate from the mouse genome (LaFlamme et al., 1998; Gorzalka et 
al., 2005).  On the other hand, other studies investigating NG108-15 cells have 
found genes deriving from the rat genome (LaFlamme et al., 1998).  Moreover, 
NG108-15 cells can express both mouse and rat cDNA transcripts of the same 
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gene (Ajiro et al., 1982; Ho & Zhao, 1996).  It can’t be ruled out therefore that 
other Erbb receptors or Nrg1 in NG108-15 cells derive from the rat genome.  
It should be noted that the NG108-15 cells used here were not differentiated.  
These cells can be differentiated into a more “neuron-like” phenotype using a 
variety of agents, resulting in the appearance of neuron-specific markers, and 
the extensions of neurites (Ma et al., 1998; Nagasawa et al., 2009).  Had more 
time been available it would be of interest to determine how Nrg1/Erbb4 
expression alters during the process of differentiation.   
3.4.2 Isoform specific expression of Erbb4 in NG108-15 cells  
Following the finding that NG108-15 cells express mouse Erbb4 mRNA, further 
exploration using RT-PCR primers designed to specifically recognise selected 
isoforms of Erbb4 showed that NG108-15 cells express JMa, CYT1 and CYT2 
containing isoforms of Erbb4, which are also abundantly expressed in the human 
and rodent prefrontal cortex (Law et al., 2007).  The expression of CYT1 and 
CYT2 isoforms in NG108-15 cells suggests that activation of Erbb4 in NG108-15 
cells could lead to the cascade of Mapk or PI3k signalling.  The expression of the 
JMa but not JMb containing isoforms in NG108-15 cells suggests that all of the 
Erbb4 receptors present in this cell line are susceptible to cleavage by presenilin 
-secretase.  The presence of the expression of JMa and CYT1 containing 
isoforms in the NG108-15 cells is of great interest in terms of the validity of this 
cell line in investigating the role of Erbb4 in schizophrenia, as it is specifically 
the JMa/CYT1 isoform which has been implicated in the pathophysiology of 
schizophrenia (Silberberg et al., 2006; Law et al., 2007).  Unfortunately, it is 
not possible to compare this isoform specific expression of Erbb4 in NG108-15 
cells with other cell lines as the investigation of endogenous Erbb4 isoform 
specific expression has not been carried out.   
Also of great interest is that, like NG108-15 cells, human B lymphoblastoid cells 
which are widely used to study receptor tyrosine kinase signalling and as a model 
of investigating schizophrenia genes, exclusively express the JMa transcripts i.e. 
JMa/CYT1 and JMa/CYT2 (Law et al., in press). 
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3.4.3  Protein expression of Erbb4 and Nrg1 in NG108-15 cells 
Subsequent to finding Erbb4 mRNA expression, protein expression of Erbb4 and 
Nrg1 was investigated in NG108-15 cells.  Furthermore to validate the neuronal-
like properties of the cell line the expression of Nrg1 and Erbb4 in NG108-15 
cells was compared to that of neuronal and non-neuronal tissues.  The 
immunoreactive banding pattern produced from the Nrg1 and Erbb4 antibodies 
was very similar to that of previous studies of human, non-primate and rodent 
that have utilised the same antibody as in this present study (Thompson et al., 
2007; Chong et al., 2008; Feng et al., 2010).  Multiple immunoreactive bands 
were observed in all of these studies and the lower molecular weight bands are 
thought to represent cleavage products.  The observation that there was a very 
strong immunoreactive band at ~60kDa in NG108-15 cells is in keeping with the 
finding that NG108-15 cells express the JMa isoform which is susceptible to 
cleavage by proteases. 
Furthermore, the immunoreactive banding pattern in NG108-15 cells for both 
Nrg1 and Erbb4 are very similar to that observed for the rat and mouse brain 
samples, further validating the NG108-15 cell line as a good in vitro neuronal 
model.  NG108-15 cell, rat and mouse brain samples did have a different 
immunoreactive banding pattern than rat heart which could be explained by 
cardiac tissue lacking expression of JMa isoform of Erbb4 (Elenius et al., 1997a). 
3.4.4 Optimisation of Erbb4 knockdown in NG108-15 cells 
Knockdown of genes utilising siRNA mediated RNA interference has been widely 
used to investigate the function of genes/proteins of interest in many different 
cell lines and also in vivo.  It was therefore of great interest to determine 
whether Erbb4 could be knocked down in NG108-15 cells to validate the use of 
this cell line further to investigate the Nrg1-Erbb4 signalling pathway.  Moreover, 
knockdown of Erbb4 expression utilising this Erbb4 siRNA which has the same 
sequence as that of the rAAV particles validates that this 19 nucleotide sequence 
complementary to Erbb4 is proficient in activating the RNAi pathway and 
generating significant knockdown of Erbb4 expression.  Although Erbb4 mRNA 
expression was low it was still possible to detect up to a 77% knockdown in 
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NG108-15 cells, following optimisation of the concentration of siRNA and 
transfection volume.   
The knockdown of Erbb4 and Gapdh in NG108-15 cells following the application 
of siRNAs targeting the respective genes suggests that the transfection reagent 
used (Lipofectamine™ RNAiMAX) was efficient in transducing NG108-15 cells.  
Lipofectamine based transfection reagent has been previously shown to be very 
effective in transducing NG108-15 cells (Martin-Montanez et al., 2010).  In 
addition, the approach taken to optimise siRNA mediated knockdown was similar 
to previous studies utilising siRNAs to knockdown Erbb4 (Zscheppang et al., 
2007).  Normally multiple target sequences are tested for siRNA studies.  
However, only one was tested in the present study as the target sequence of the 
siRNA was designed to be the same sequence as that of the shRNA used in the 
following viral mediated Erbb4 knockdown studies.  As the knockdown of Erbb4 
appeared not to change level of Gapdh, Akt or -2-microglobulin it is unlikely 
the knockdown of Erbb4 following Erbb4 siRNA is an off target effect. 
As Erbb4 signals through the PI3k signalling cascade which involves Akt, the 
expression of Akt following Erbb4 knockdown was assessed.  There appeared to 
be no knockdown of Akt expression even though Erbb4 in these samples was 
significantly knocked down. This might be explained by the fact that previous 
studies have shown that when Erbb4 signalling is altered it is Akt activity rather 
than Akt expression that is altered (Hahn et al., 2006; Horie et al., 2010).   
Furthermore, the expression of another gene which has also been linked to 
Erbb4 signalling was tested following Erbb4 knockdown.  Both the Erbb4 receptor 
and the NMDA receptor are associated with the PSD95 complex, and therefore 
the signalling of the two receptors has been linked.  For that reason expression 
of the NMDA receptor gene Grin1 was measured.  Unfortunately, Grin1 
expression appeared to be affected by the non-targeting siRNA.  Although the 
sequence of the non-targeting siRNA was unknown, the supplier ensures the 
sequence of this siRNA is does not have sequence identity to any known gene.  
As there appears to be no effect of either Gapdh or Erbb4 siRNAs on Grin1 
expression, partial recognition of the non-targeting siRNA to Grin1 is the most 
likely explanation of this unexpected knockdown.  In all of the previous 
experiments the level of the gene expression in untreated cells was very similar 
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to non-targeting siRNA treated cells; therefore comparison of Erbb4 siRNA 
treated cells to untreated should give an indication of changes in Grin1 
expression following Erbb4 knockdown. Previous studies have shown that 
changes in Erbb4 signalling capabilities result in altered NMDA receptor activity 
rather than NMDA receptor expression (Hahn et al., 2006; Li et al., 2007). 
In addition, although non-targeting siRNA was the most appropriate negative 
control of the treatments used in this study as it encompasses effects of both 
transfection reagent and siRNA, the best negative control to use in such studies 
is an siRNA that contains a scrambled version of the gene of interest.  
Nonetheless, non-targeting siRNAs are widely and successfully used in siRNA 
studies. 
Although there was a significant knockdown of Erbb4 at the mRNA level in 
NG108-15 cells at 24 hours post-siRNA application, there was no quantifiable 
Erbb4 protein knockdown at this time point.  Furthermore, there was lack of 
Erbb4 protein knockdown at 48, 72 and 96 hours post-siRNA application, 
however, since Erbb4 mRNA expression was not assessed at these additional time 
points it cannot be determined if the Erbb4 mRNA knockdown quantified at 24 
hours was still present at the later time points.  The lack of protein knockdown 
may be due to several reasons including further optimisation of concentration 
and time point post-siRNA application needed.  The NG108-15 cells were 
successfully transduced and the quantification of protein valid as Gapdh 
expression was successfully knocked down.  Other studies have been more 
successful in achieving Erbb4 protein knockdown (albeit not in NG108-15 cells) 
(Sharif et al., 2009; Frey et al., 2010; Horie et al., 2010). This divergence of 
results may be due to several technical differences, such as the Erbb4 siRNA 
target sequence, cell type transfected and transfection reagent used.  
Interestingly, one study utilised a double transfection protocol to achieve 
significant Erbb4 protein knockdown, and thus an alternative transfection 
protocol in NG08-15 cells may achieve significant Erbb4 knockdown (Zscheppang 
et al., 2007).  An important point to note is that the half-life of the Erbb4 
receptor in NG108-15 cells is unknown therefore it is very difficult to interpret 
at which time-point to measure Erbb4 expression.  The half-life of Erbb4 has 
been shown to dependent upon ligand stimulation (Yang et al., 2005), therefore 
it is possible that if in NG108-15 cells the expression of Nrg1 is endogenously 
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very high, the half-life of the Erbb4 receptor may be very short and thus difficult 
to measure changes in expression.   
3.4.5 Functionality of Erbb4 receptors in NG108-15 cells 
Although the expression of Erbb4 in NG108-15 cells was not within the range of 
detection by the total ERBB4 ELISA kit, the levels of phosphorylated Erbb4 were 
detectable by the phophoERBB4 ELISA kit.  To determine if Erbb4 receptor 
expressed in NG108-15 cells was functional and thus provides a valid in vitro 
model in which to investigate Nrg1-Erbb4 signalling, the NG108-15 cells were 
stimulated with NRG1 and the activity of Erbb4 and downstream signalling 
partners were measured.  Even though multiple concentrations of NRG1 were 
used (ranging from 10ng/ml to 200ng/ml) and stimulation durations of 15 
minutes, 30 minutes and 60 minutes were analysed, very minimal activation of 
any of the molecules was observed.  PErbb4 levels were significantly higher in 
NG108-15 cells following 10 minute stimulation with 200ng/ml NRG1; however, 
in general the phosphorylation levels of Erbb4 (and the other molecules 
measured) were very variable.  This variability may be due to changes in levels 
of Erbb4 or Nrg1 in different passages of the NG108-15 cells.  Moreover this 
variability was not observed in rat primary cortical cultures which were used as 
a positive control.  Also it was clear from the cortical cultures that the pERBB4 
ELISA was able to detect larger changes in pErbb4 expression than that observed 
in the NG108-15 levels.  Similar concentrations of Nrg1 isoforms have been used 
in previous studies to increase phosphorylation of Erbb4 or other Erbb receptors 
significantly (Hahn et al., 2006; Lok et al., 2009).   
Since NG108-15 cells expressed both CYT1 and CYT2 isoforms of Erbb4, 
stimulation of the cells with NRG1 could possibly lead to the activation of PI3k 
and MAPK signalling cascades.  NRG1 application however only led to minimal 
activation of Gsk3 and had no effect on pAkt or pErk.  pAkt and pErk expression 
has been shown to be increased following Nrg1 or  application in multiple 
studies, utilising multiple cell types (Flores et al., 2000; Li et al., 2001; Chae et 
al., 2005; Hahn et al., 2006; Hellyer et al., 2006; Sei et al., 2007; Keri et al., 
2009).  In addition previous studies utilising NG108-15 cells have shown that 
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activation of Akt and Erk is achievable with other ligands such as opioids (Heiss 
et al., 2009).   
Schulz et al. (2005) found that in NG108-15 cells application of epidermal growth 
factor did not result in activation of Erk, but a reason for the lack of 
phosphorylation may be the low level of Erbb4 expression in the cell line.  
Conversely, another explanation for the low response in NG108-15 cell to NRG1 
is that NG108-15 cells already express NRG1 (Pun et al., 1997) and therefore 
the basal levels of activation and thus phosphorylation of Erbb4 and its 
downstream signalling partners are constitutively high and cannot be further 
increased.   Interestingly, one study has showed that levels of Erbb4 
phosphorylation are dependent upon the ratio of Erbb4 isoforms expressed; with 
JMa/CYT2 isoforms of Erbb4 being highly constitutively phosphorylated (Määttä 
et al., 2006).  Although the ratio of Erbb4 isoforms were not quantified in the 
present study, it was confirmed JMa and CYT2 were expressed, so it is plausible 
phosphorylation of Erbb4 was at its maximum pre-NRG1 application.  
Furthermore, JMa expression was confirmed by RT-PCR and a high expression of 
Erbb4 cleavage products observed by western blot suggesting Erbb4 in NG108-15 
cells may be predominantly in the form of intracellular forms.  Therefore 
NRG1may not be able to bind to the receptor and activate dimerisation and 
thus phosphorylation. 
In addition, the minimal effect of NRG1 on NG108-15 cell activation of Erbb4 
signalling should not be hastily interpreted as lack of functionality of the Erbb4 
receptor in this cell line for the reasons described above, and also because there 
are multiple other ligands of the Erbb4 receptor that have not been investigated 
in this study such as Nrg3 and betacellulin (Zhang et al., 1997).  Finally as noted 
above, it should be noted that these studies have been carried out in 
undifferentiated NG108-15 cells, and therefore the activity or expression of the 
Erbb4 receptor in the cell line may change following differentiation.  Previous 
studies have shown that receptor number increases following NG108-15 cell 
differentiation, such as the muscarinic acetylcholine receptors (Ghahary & 
Cheng, 1989).  
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3.5  Conclusions 
In this chapter data has been presented that validates NG108-15 cells as a 
suitable in vitro model for studying Erbb4.  Confirmation of the expression of 
Erbb4 in NG108-15 cells was carried out using RT-PCR and western blot.  mRNA 
analysis displayed that NG108-15 cells express a low but detectable level of 
Erbb4 that originates from the mouse genome, specifically the JMa/CYT1 and 
JMa/CYT2 isoforms. Furthermore this mRNA expression of Erbb4 in NG108-15 
cells can be knocked down by the use of an optimised Erbb4 siRNA.   
Akin to these findings Erbb4 is expressed at the protein level in NG108-15 cells 
and the resultant receptors can be activated by NRG1 and become 
phosphorylated, activating selected downstream molecules. 
Not only is the finding that NG108-15 cells express Erbb4 endogenously in terms 
of a novel model of investigating Nrg1-Erbb4 signalling, but also because the 
validation of this cell line confirms its potential use for the initial in vitro 
validation of adeno-associated viral particle studies.   
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4.1 Introduction 
4.1.1 Viral mediated gene manipulation 
Manipulation of gene expression in vivo has become an increasingly popular 
method for investigating gene function, to allow a greater knowledge of the 
pathophysiology of diseases and identification of potential therapeutic targets, 
since the production of the first transgenic mouse in 1989. Nonetheless, there 
are several limitations to the use of genetically modified rodents for 
translational research; often gross manipulation of genes is lethal during 
embryonic development, and the gene manipulation is not spatially controlled 
and therefore behavioural phenotypes can arise that are due to manipulation of 
the genes in tissues other than the region of interest.  In addition gene 
manipulation is present during neurodevelopment and thus can lead to 
compensatory changes resulting in altered behavioural and/or pharmacology in 
adulthood that are not representative of the actual gene function in adulthood.  
However, recent technological advances have allowed the production of 
“conditional” transgenics through which the advanced knowledge of systems 
such as Cre-Lox recombinase and cell type specific promoters have led to control 
of gene expression at specific time-points in the animals development and in 
which cells this gene manipulation will occur.  Yet the production of these 
rodents is very expensive and generation of a stable colony of genetically 
manipulated rodents can take years depending on the strain used and gene 
targeted.   
In vivo viral mediated gene manipulation allows superior control of gene 
manipulation to that of transgenic laboratory animals due to strict spatial and 
temporal regulation of over expression or knockdown of genes of interest.  In 
particular in the brain where no cell types are definitively specific to a distinct 
brain region, viral mediated gene manipulation allows spatial control of viral 
injection and thus gene manipulation in specific brain regions.  Furthermore, 
multiple genes can be targeted over several brain regions simultaneously and 
this can be carried out at any time point throughout the rodent’s life-span from 
in utero to adulthood.  Moreover, although this technique requires a skilled 
surgical procedure and the production and optimisation of viral particles can be 
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problematic, genetically manipulated animals can be quickly generated 
(Seshadri et al., 2009).  
Several types of viruses are commonly utilised for viral mediated gene 
manipulation in vivo including adenovirus, lentivirus and adeno associated virus 
(AAV). 
4.1.2 Adeno-associated gene manipulation 
The discovery of the human AAV was fortuitous as it was found as a contaminant 
of an adenovirus preparation (Atchison, 1965).  Since their discovery AAV 
research has established that the viral particles are small, non-enveloped with a 
single stranded DNA (ssDNA) genome.  AAVs are highly suited for use in viral 
mediated gene manipulation as they are not associated with any known disease 
in humans and moreover they cannot replicate independently, but instead rely 
on co-infection with adenovirus or exposure to genotoxic or UV radiation to 
remove the virus from its latent to lytic phase (Meyers et al., 2000).  The wild 
type AAV genome contains rep and cap genes which encode proteins responsible 
for viral replication and encapsulation, respectively.  These genes are flanked by 
inverted terminal repeats (ITR) and in recombinant AAVs (rAAV) used for viral 
mediated gene manipulation these are the only viral genetic component 
remaining, since the rep and cap genes are removed to produce a “gutless 
vector”, thus rendering the rAAVs replication incompetent.  The ssDNA genome 
is instead manipulated to express or knockdown the expression of genes of 
interest.  Often other elements are additionally engineered into the genome, for 
example for ease of identification of transduced cells a reporter gene is also 
commonly co-expressed.  The woodchuck posttranscriptional regulatory element 
(WPRE) is often included in rAAVs as it is thought to enhance mRNA processing 
and increase the efficiency of mRNA translation (Xu et al., 2001; Lipshutz et al., 
2003).  A study showed inclusion of WPRE in the vector increased expression of a 
reporter gene by 6 fold in cortical cultures and by up to 35 fold in the 
hippocampus (Xu et al., 2001). 
RAAVs were first used as a vehicle for gene transfer in 1984 (Hermonat et al., 
1984) and since then have been widely used to investigate gene function due to 
their ability to transduce terminally differentiated cells such as photoreceptor 
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cells, hepatocytes, bronchial epithelial cells and neurons (Kaplitt et al., 1994; 
Conrad et al,. 1996; Flannery et al., 1997; Mingozzi et al., 2002).  Unlike 
lentiviruses which readily integrate into multiple sites in the host genome, wild 
type AAVs have a specific integration site in the human genome on chromosome 
19 termed AAVS1 (Kotin et al., 1990).  However integration is dependent upon 
the rep gene and therefore rAAVs cannot integrate at this site and instead 
evidence suggests that rAAVs generate their second strand DNA episomally.  
There have been studies suggesting integration of AAVs does occur, but it is 
thought that these integrations occur at pre-existing DNA breaks (Miller et al., 
2004) and very infrequently.  Two studies estimated that integration of AAV 
occurred at one integration event per 103-104 vector particles (Russell et al., 
1994; Rutledge et al., 1997). 
RAAV transduction is dependent upon binding of the viral particle to a cell 
surface receptor.  The serotype of AAV defines which cell surface receptor it 
binds to and therefore which cell types the AAV can transduce, explaining the 
altered tropism observed amongst the AAV serotypes.  To date 12 AAV serotypes 
have been identified (Muramatsu et al., 1996; Rutledge et al., 1998; Chiorini et 
al., 1999a; Chiorini et al., 1999b; Xiao et al., 1999; Gao et al., 2002; Gao et al., 
2004; Mori et al., 2004; Schmidt et al., 2008).  AAV9 is thought to bind to the 
laminin receptor, as do AAVs 2, 3 and 8 (Akache et al., 2006).  Many studies are 
taking advantage of the varying tropism of AAV serotypes by producing 
pseudotyped rAAVs which package AAV2 genomes into capsids of other serotypes 
(Grimm et al., 2003).  This approach may be of benefit in reducing antibody 
mediated response to rAAVs, especially in human trials utilising rAAVs for gene 
therapy as approximately 80% of the population have antibodies against AAV2 
(Erles et al., 1999). 
The mechanism of how rAAVs mediate gene manipulation is a multi-step process 
including internalisation of the viral particle into the cell, followed by trafficking 
to the nucleus where the rAAV genome is translated, to over expression of genes 
of interest or hairpin sequences resulting in knockdown of genes of interest.  A 
summary of this process is shown schematically in Figure 4.1.   
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Figure 4.1 Schematic summary of the mechanism of adeno-association viral 
mediated gene manipulation.  1. rAAV binds to specific cells surface receptor. 2. 
rAAV binding and co-receptor activation initiates endocytosis. 3. rAAV is 
internalised via clathrin coated pit. 4. rAAV is transported to the nucleus by 
endosomal trafficking. 5. rAAV undergoes endosomal release. 6. rAAV enters the 
nucleus via the nuclear pore complex. 7. Viral uncoating releases rAAV ssDNA 
genome. 8. Viral ssDNA remains episomally or integrates into the host genome 
(rare). 9. Second strand cDNA synthesis. 10a. mRNA transcription. 11a. Protein 
translation. 10b. shRNA transcription. 11b. Activation of RNAi pathway – protein 
knockdown.  
Image produced from information from Schultz & Chamberlain, 2008; Goncalves, 
2005 and Ding et al., 2005.   
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4.1.3 AAV mediated gene manipulation in the CNS 
RAAVs have been repeatedly shown to be able to transduce brain tissue following 
intravenous injection of the virus (Inagaki et al., 2006; Foust et al., 2009).  
Local injection of rAAV into distinct brain regions has shown successful 
transduction of cells specifically within the rodent striatum (Xue et al., 2009), 
hippocampus (Klein et al., 2007; de Backer et al., 2010), cortex (Nathanson et 
al., 2009) and amygdala (de Backer et al., 2010).  The majority of rAAV studies 
in the CNS have made use of promoters for RNA Polymerase II or III promoters 
(Pol II or Pol III, respectively) however, gene promoters specific for the neuronal 
system such as the neuron-specific enolase (NSE), glial fibrillary acidic protein 
(GFAP) have been shown to have increased efficiency and effectiveness in 
transducing CNS tissue in vitro and in vivo (Xu et al., 2001).   Since the first 
knockdown study using rAAVs in 2003 (Tomar et al., 2003), shRNA expression by 
rAAVs have led to many interesting findings regarding genes implicated in 
disorders of the CNS. 
Many neurodegenerative disorders have been investigated using viral mediated 
gene manipulation and rAAVs have been successfully utilised for investigating 
the functions of genes in these disorders due to their capability of expressing 
transgenes for long periods of time, with reporter genes being observed up to 5 
months after systemic AAV9 delivery (Duque et al., 2009).  Localised knockdown 
of the ataxin gene in the cerebellum of a mouse model of spinocerebellar ataxia 
type 1 (SCA1) resulted in the reversal of motor deficits in these mice (Xia et al., 
2004).  In a study of another polyglutamine expansion disease, Huntington’s 
disease, suppression of the Htt gene in the striatum of R6/1 mice which display 
behavioural phenotypes resembling those of Huntington’s disease resulted in 
delayed onset of these behaviour phenotypes (Rodriguez-Lebron et al., 2005).  
As well as reversing behavioural deficits, studies have made use of rAAVs to 
knockdown genes to induce phenotypes analogous to neurodegenerative 
disorders.  Hommel and colleagues (2003) induced motor deficits and 
biochemical changes related to Parkinson’s disease by reducing expression of the 
Th  gene which encodes the enzyme tyrosine hydroxylase essential for dopamine 
synthesis.   
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4.1.4 Viral mediated gene manipulation to investigate potential 
schizophrenia candidate genes 
As well as investigating genes associated with the pathophysiology of 
neurodegenerative disorders, rAAVs have been successfully employed to 
investigate genes that have biological relevance to aspects of schizophrenia.  
Polymorphisms in the HOMER1 gene have been associated with increased risk for 
schizophrenia (Norton et al., 2003; Spellman et al., 2010) and the biological 
function of HOMER1 in regulating glutamate neurotransmission make this an 
interesting target to investigate its role of being potentially involved in the 
pathophysiology of schizophrenia.  RAAV mediated over-expression of specific 
isoforms of Homer 1 within the PFC of Homer 1 knock-out mice resulted in 
isoform specific reversal of working memory and sensorimotor gating deficits as 
well as reversing glutamate deficits seen in the knock-out mice (Lominac et al., 
2005).  RAAV mediated over-expression of another gene with biological 
relevance to schizophrenia, Snap25 which regulates glutamate-dependent 
excitatory synaptic transmission within the dorsal hippocampus of rats, resulted 
in impaired performance in the water maze and fear conditioning, both of which 
are thought to reflect decreased cognition as seen in schizophrenia (McKee et 
al., 2010).  Camk2a knockdown in the rat hippocampus produced impairments in 
performance of the open field and water maze tasks reflective of the important 
roles Camk2a endogenously plays in spatial learning and maintaining neuronal 
plasticity (Babcock et al., 2005).   
As well as AAVs other virus types have been exploited to investigate genes 
potentially implicated in schizophrenia.  Over the past few years investigations 
into the schizophrenia candidate gene DISC1, using in vivo viral mediated gene 
manipulation, have shed some light into the roles this gene may play within 
specific brain regions and how these may relate to the patholophysiology of 
schizophrenia.  Retroviral-based introduction of shDisc1 into the hippocampus of 
mice has revealed that Disc1 is important in several aspects of cell morphology 
such as soma size and dendritic initiation, as well as maturation and migration of 
newborn neurons in the adult brain (Duan et al., 2007; Faulkner et al., 2008).  A 
more recent study has been the first to use viral mediated investigation of a well 
known schizophrenia candidate gene to investigate behavioural outcomes of the 
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gene manipulation. Mao and colleagues (2009) targeted the knockdown of Disc1 
in the dentate gyrus of adult mice using lentivirus based technology and 
subsequently found that cells from this brain region transduced with lentivirus 
had reduced BrdU incorporation indicative of decreased cell proliferation, an 
effect that was reversed by application of an inhibitor of GSK3.  Moreover the 
authors found that Disc1 knockdown affected selected behaviours that may be 
relevant to schizophrenia, such as alterations in locomotor activity to a novel 
environment and depressive like behaviour in the forced swim test but no effect 
on anxiety related behaviour as measured by performance in the elevated plus 
maze.  Interestingly performance in the affected behavioural tasks was 
normalised back to control level by application of the GSK3 inhibitor, suggesting 
that Disc1 functioning through the GSK3 pathway is important in regulating cell 
proliferation and subsequent behaviours involving the dentate gyrus (Mao et al., 
2009). 
In a very recent study, lentiviral mediated knockdown specifically within the 
mouse cerebellum was carried out to target D-amino acid oxidase (Dao), a glial 
enzyme important in the degradation of D-amino acids.  These amino-acids 
including D-serine, which is a co-activator of NMDA receptor transmission and 
therefore potentially of importance in the NMDA receptor hypofunction 
hypothesis of schizophrenia.  Not only were protein and mRNA levels of Dao 
quantifiably reduced, but expression of several other components of the 
pathway Dao is involved in were altered, including D-serine and Grin2a (NR2A) 
levels specifically within the cerebellum (Burnet et al., 2011).  This study 
emphasised that not only is viral mediated gene manipulation a valid method of 
investigating the functions of a single gene within a distinct brain region, but 
also to investigate downstream effects on dysregulation of discrete pathways 
which are much more likely to have a greater pathophysiological impact than 
dysregulation of a single gene in such a complex disorder as schizophrenia.   
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4.2 Aims 
The aims of the validation study described in this chapter were three-fold:  
1) To test the capability of rAAV particles (eGFP.rAAV, scr.rAAV and 
shErbb4.rAAV) to transduce neuronal-like (NG108-15) and neuronal cells (primary 
cortical cultures), to use eGFP expression as a marker of cell transduction and to 
assess if there was quantifiable knockdown of Erbb4 following transduction.  This 
would validate the functionality of the viral particles before using them in in 
vivo experiments.  
2) To validate the use of rAAV particles (eGFP.rAAV) in vivo by confirming their 
ability to transduce cells within the designated brain region of the rodent mPFC 
at specific time points post-surgery, and to determine which cell types of the 
mPFC are transduced by the rAAVs.  This would confirm that, if genetic 
modification took place following viral injection, it would be within the correct 
region of the brain and that knockdown could occur within these cell types. 
3) To quantify the effects of stereotaxic injection of shErbb4.rAAV in the rodent 
mPFC on mRNA and protein levels of Erbb4 and related signalling partners.  This 
would assess whether injection of shErbb4 into the mPFC could knockdown Erbb4 
levels, and determine if this knockdown had secondary effects on the expression 
of members of the Nrg1-Erbb4 signalling pathways. 
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4.3 Results 
4.3.1 Validation of the functionality of rAAV particles in vitro 
Prior to using the rAAV particles in vivo, assessment was carried out to 
determine firstly if the viral particles were capable of transducing neuronal like 
cells (NG108-15) and secondly if they were capable of expressing their inserted 
transgenes (eGFP) in these cells.  As the number of genome copies and length of 
time required for eGFP expression were unknown a range of titres of the 
eGFP.rAAV particles (section 2.1) were used. EGFP protein expression was 
assessed at multiple time points by epifluorescence with and without the use of 
an eGFP antibody (section 2.15.1).   
This in vitro analysis showed that the eGFP.rAAV particles were indeed capable 
of transducing NG108-15 cells and that the expression of eGFP was visible in a 
time and titre dependent manner (summarised in Table 1).  No eGFP expression 
was visible 1 day after rAAV application with any titre but low levels of eGFP 
expression were visible without the use of an eGFP antibody from 2 days post-
transduction using the highest titre (1011gc/ml).  With the use of an antibody for 
eGFP more eGFP positive cells were visible at lower titres (109gc/ml and 
1010gc/ml) at 2 days post-viral application (Figure 4.2 A1-E1).  At 7 days post-
application, all titres showed eGFP positive cells, with the highest titre of  
eGFP.rAAV particles (1011gc/ml) resulting in very high eGFP expression (Figure 
4.2 A2-E2). 
Table 4-1 Summary of eGFP expression at specific time points following 
transduction of NG108-15 cells with increasing titres of eGFP.rAAV.  
– no eGFP expression, + low eGFP expression, ++ moderate eGFP expression, 
+++ high eGFP expression. 
        gc/ml 
Day 
107 108 109 1010 1011 
1 - - - - - 
2 - - + ++ ++ 
3 + + + ++ ++ 
7 + +      ++  +++ ++ +++ 
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A1                                    B1                                     C1                                    D1                                     E1 
 
 
 
 
A2                                    B2                                     C2                                    D2                                     E2                                  
 
 
 
 
 
 
 
 
 
 
 
Figure 4.2 eGFP expression in NG108-15 cells transduced with eGFP.rAAV.  eGFP expression in NG 108-15 cells transduced with 
eGFP.rAAV at titres of 1x1011 gc/ml (A), 1x1010 gc/ml (B), 1x109 gc/ml (C), 1x108 gc/ml (D), 1x107 gc/ml (E).  Images represent positive 
eGFP immunoreactivity 2 days (1) and 7 days (2) post-viral application.  Scale bars represent 20m. 
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To validate further the use of the viral particles in vitro prior to carrying out in 
vivo injections, the functionality of the viral particles (scr.rAAV and 
shErbb4.rAAV, section 2.1) was assessed further in primary dissociated cortical 
cultures from p1/2 rat pups to investigate a model system closer to in vivo 
conditions (section 2.2.2).  This showed that application of scr.rAAV and 
shErbb4.rAAV particles at 2.5x1010gc/ml resulted in prominent eGFP expression 
and at 7 days post-viral application eGFP could clearly be seen without the use 
of an eGFP antibody.  Both scr.rAAV particles (Figure 4.3A) and shErbb4.rAAV 
particles (Figure 4.3B) were capable of transducing cortical cells and producing 
the expression of eGFP in cell bodies and processes.   
In addition, analysis of the capability of the shErbb4.rAAV particles to 
knockdown the expression of Erbb4 mRNA in primary cortical cells was assessed 
by qRt-PCR (section 2.11).  Again, different titres of viral particles were tested 
to assess this as it was unknown how many viral particles were necessary to 
affect mRNA levels.  qRT-PCR at 4 days post-viral application revealed that 5x109 
gc/ml shErbb4.rAAV particles were sufficient to knockdown the expression of 
Erbb4 significantly (F(2,14)= 8.64 p<0.01) (Figure 4.4A).  Post hoc comparisons 
exposed there was significantly less Erbb4 mRNA in cortical cells following 
shErbb4.rAAV treatment than cells treated with vehicle (p<0.05) or scr.rAAV 
(p<0.01).  Furthermore, treating the cells with slightly more viral particles 
resulted in an even greater Erbb4 knockdown (Figure 4.4B), with 2.5x1010 gc/ml 
shErbb4.rAAV particles knocking down Erbb4 mRNA levels in cortical cells by 42% 
compared to cells treated with the same amount of scr.rAAV particles.  There 
was no significant difference in Erbb4 expression between vehicle treated cells 
and cells transduced with scr.rAAV at either titre of viral particles tested. 
As there was a significant effect of the shErbb4.rAAV viral particles on Erbb4 
expression in primary cortical cells the mRNA expression of Erbb4 ligand Nrg1 
was also assessed.  Interestingly, there was a significant effect of treatment on 
Nrg1 expression (F (2,11)=10.73 p<0.01), with 2.5x1010 gc/ml shErbb4.rAAV 
treatment increasing the expression of Nrg1 in cortical cells compared to vehicle 
treated cells (p<0.01) and 2.5x1010 gc/ml scr.rAAV (p<0.05) 4 days post-
treatment (Figure 4.5). 
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 B 
 
Figure 4.3 eGFP expression in P1/2 rat cortical cells.  eGFP expression in 
dissociated rat cortical cultures visualised by epifluorescence 7days post-
application of 2.5x1010gc/ml scr.rAAV (A) or shErbb4.rAAV (B) viral particles.  
Scale bar represents 20m. 
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Figure 4.4 Effect of rAAV treatment on Erbb4 expression in primary cortical 
cells.  % ErbB4 mRNA expression remaining in primary cortical cells 4 days post-
transduction of vehicle = veh (n=4), scr = scr.rAAV (n=4-5) or shErbb4 = 
shErbb4.rAAV (n=4-6) at titres of 5x109gc/ml (A) or 2.5x1010gc/ml (B) Quantified 
by qRT-PCR using the 2-CT method (section 2.11.2).  Data represent mean ± 
S.E. relative to vehicle treated samples. * p<0.05, ** p<0.01 analysed using one-
way ANOVA followed by Tukey’s post hoc test for multiple comparisons. 
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Figure 4.5 Effect of rAAV treatment on Nrg1 expression in primary cortical 
cells.  % Nrg1 mRNA expression remaining in primary cortical cells 4 days post-
transduction of vehicle = veh (n=4), scr = scr.rAAV (n=4) or shErbb4 = 
shErbb4.rAAV (n=4) at a titre of 2.5x1010gc/ml quantified by qRT-PCR using the 2-
CT method.  Data represent mean ± S.E. relative to vehicle treated samples. * 
p<0.05, ** p<0.01 analysed using one-way ANOVA followed by Tukey’s post hoc 
test for multiple comparisons. 
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4.3.2 Validation of the injection of rAAV particles in vivo 
Following the in vitro validation of the eGFP.rAAV, scr.rAAV and shErbb4.rAAV 
rAAV particles, the location of the injections to confirm targeting of the rodent 
mPFC, along with the number of viral particles, and the length of time post-
surgery necessary for eGFP expression were assessed.   First the injection site to 
be used for targeting Erbb4 knockdown specifically to the mPFC was confirmed 
using injections of cresyl violet dye into the brain at co-ordinates according to 
Paxinos & Watson (2007).  Injection of 2l of cresyl violet dye at a 20° angle 
4mm into the brain at 3.2mm anterior and 2mm lateral to Bregma resulted in 
localised dye remaining within the region of the prelimbic area of the mPFC 
(Figure 4.6A, left hemisphere), whereas insertion of the needle without injection 
resulted in very localised tissue damage at the cortex surface at the entrance 
site of the injection (see 2.4.2) (Figure 4.6A, right hemisphere).  The region 
where cresyl violet dye was observed was equivalent to the prelimbic (PrL) area 
(Figure 4.6B).   
After validating the injection site, injections of 2l of eGFP.rAAV at 1x1011gc/ml 
or 1x1012gc/ml or vehicle were carried out and eGFP expression was analysed at 
1 week, 3 weeks and 8 weeks post-surgery to confirm a) how many viral particles 
(titre) were required to cause eGFP expression, b) what length of time was 
required for eGFP expression and c) how much spread of eGFP positive cells 
were observed at these time points.  Injections of vehicle at all time points 
resulted in a visible needle tract with very little tissue damage (as indicated by 
yellow auto-fluorescing cells localised to the needle tract) and no eGFP 
expression (Figure 4.7A).  At one week post-surgery injection of both titres of 
eGFP.rAAV produced localised eGFP expression in cells close to the needle tract, 
this level of eGFP expression was comparable to that observed at 8 weeks post-
surgery.  Peak expression of eGFP was observed at 3 weeks post-surgery with 
injection of 1x1011gc/ml eGFP.rAAV resulting in slightly more eGFP positive cells 
than seen with the higher titre at 1 week post-surgery.  1x1012gc/ml eGFP.rAAV 
injection produced a spread of eGFP positive cells of approximately 0.65mm 
from the needle tract both in the medial-lateral plane (Figure 4.7B). At this time 
point eGFP positive cells were routinely observed over a series of 25-30 20m 
coronal sections indicating an approximate rostro-caudal spread of 0.6mm. 
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Figure 4.6  Validation of prL injection site in the rat brain.  Representative 
brain section cut at the level of the PrL showing the effects of 2l injection of cresyl 
violet dye into the left hemisphere compared to insertion of a Hamilton syringe 
without injection into the right hemisphere (A).  The co-ordinates to the site of 
injection as indicated by the red line at a 20° angle into the mPFC 3.2mm anterior 
to bregma (B) (Image taken from Paxinos & Watson, 2007). 
 
 
 
 
 
124 
A                                                            B 
     
Figure 4.7 In vivo expression of eGFP following eGFP.rAAV injection.  
Representative 20m coronal brain sections showing eGFP expression 5 weeks 
post-injection of 2l vehicle (A) or 2l 1x1012gc/ml eGFP.rAAV (B) into the mPFC.  
Immunofluorescent staining was carried out to detect eGFP expression (section 
2.15.2). The cortical edge of the brain sections are bordered by a dashed white 
line.  Scale bar represents 200m. 
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4.3.3 Identification of cell types transduced by rAAV particles in 
vivo 
To identify which cell types were transduced, sections from hemispheres 
injected with 1x1012gc/ml eGFP.rAAV 3 weeks post-surgery were  analysed with 
antibodies for eGFP, Gfap (glial fibrillary acidic protein), N200 (Neurofilament 
200) and Pvalb (parvalbumin) (section 2.15.2).  eGFP positive cells were again 
prominent at this time point with this titre of virus (Figures 4.8, 4.9 and 4.10 top 
left panels). Glial cells were identified by immunoreactivity with the Gfap 
antibody and a proportion of the eGFP expressing cells were also reactive for 
Gfap (Figure 4.8, right panel).  Pyramidal cells were identified using the N200 
antibody and a fraction of the eGFP expressing cells were also reactive for N200 
(Figure 4.9, right panel).  Finally eGFP expressing cells were also seen in a 
subgroup of Pvalb containing interneurons (Figure 4.10, right panel). 
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Figure 4.8  Co-localisation of eGFP and Gfap in eGFP.rAAV transduced cells.  
Immunohistological staining of brain sections cut at the level of the mPFC 3 weeks 
post-injection of 2l 1x1012gc/ml eGFP.rAAV.  Immunofluorescence shows cortical 
cells positive for either eGFP (green, top left panel) or Gfap (red, bottom left 
panel), merging of the two images shows co-localisation of eGFP and Gfap in 
some cortical glial cells (yellow, right panel).  Arrows indicate eGFP+Gfap positive 
cells.  Scale bar represents 20m. 
 
 
Figure 4.9 Co-localisation of eGFP and N200 in eGFP.rAAV transduced cells. 
Immunohistological staining of brain sections cut at the level of the mPFC 3 weeks 
post-injection of 2l 1x1012gc/ml eGFP.rAAV.  Immunofluorescence shows cortical 
dendritic processes of pyramidal cells positive for either eGFP (green, top left 
panel) or N200 (red, bottom left panel), merging of the two images shows co-
localisation of eGFP and N200 in some dendritic processes (yellow, right panel).  
Arrows indicate eGFP+N200 positive processes.  Scale bar represents 20m. 
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Figure 4.10 Co-localisation of eGFP and Pvalb in eGFP.rAAV transduced 
cells.  Immunohistological staining of brain sections cut at the level of the mPFC 3 
weeks post-injection of 2l 1x1012gc/ml eGFP.rAAV.  Immunofluorescence shows 
cortical cells positive for either eGFP (green, top left panel) or Pvalb (red, bottom 
left panel), merging of the two images shows co-localisation of eGFP and Pvalb in 
some cortical cells (yellow, right panel).  Arrows indicate eGFP+Pvalb positive 
cells.  Scale bar represents 20m. 
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4.3.4 Quantification of mRNA expression following rAAV injection 
in the mPFC 
To ensure that any changes in mRNA expression following viral injection were 
not due to degradation of RNA, RNA quality was assessed using the Agilent 
Bioanalyser 2100 (section 2.8.3).  Analysis of total RNA isolated from one PFC 
hemisphere of each rat 5 weeks post-stereotaxic surgery (vehicle, scr.RAAV and 
shErbb4.rAAV) showed that the RNA quality did not differ between surgical 
groups and therefore any subsequent changes in mRNA expression were unlikely 
to be due to RNA degradation.  The average RIN values of vehicle, scr.RAAV and 
shErbb4.rAAV treated rats were 8.65 ± 0.59, 8.4 ± 0.46 and 8.78 ± 0.29, 
respectively.   
At 5 weeks post-injection of 2l of 1x1012 gc/ml shErbb4.rAAV there was no 
significant effect on Erbb4 mRNA expression in the PFC compared to the other 
surgical groups, with no effect of surgical group (F (2,22)=0.38 p>0.05) (Figure 
4.11A), although there appeared to be a trend towards decreased Erbb4 mRNA 
levels after shErbb4.rAAV injection.  In concordance with this result there was 
also no effect of surgical group on Nrg1 mRNA expression in these samples at this 
time point (F (2, 22) =0.72 p>0.05) (Figure 4.11B).  However, when the ratio of 
ligand mRNA to receptor mRNA was quantified there was a significant effect of 
surgical group (F (2, 22) =11.13 p<0.001) with post hoc comparisons revealing 
rats treated with shErbb4.rAAV had significantly higher Nrg1/Erbb4 mRNA ratio 
than scr.rAAV treated rats (p<0.01) and vehicle treated rats (p<0.001) (Figure 
4.12). 
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Figure 4.11 Effect of in vivo viral-mediated targeting of Erbb4 on Erbb4 and 
Nrg1 mRNA expression.  % Erbb4 (A) and Nrg1 (B) mRNA expression remaining 
in one hemisphere of the mPFC dissected from rats 5 weeks post 2l injection of 
vehicle = veh (n=7), 1x1012gc/ml scr.rAAV = scr (n=8) or 1x1012gc/ml 
shErbb4.rAAV = shErbb4 (n=8) quantified by qRT-PCR using the 2-CT method.  
Data represent mean ± S.E. relative to vehicle treated samples.  
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Figure 4.12 Effect of in vivo viral-mediated targeting of Erbb4 on the ratio of 
Nrg1/Erbb4 mRNA expression.  The ratio of Nrg1 mRNA to Erbb4 mRNA 
expression in one hemisphere of the mPFC dissected from rats 5 weeks post 2l 
injection of vehicle = veh (n=7), 1x1012gc/ml scr.rAAV = scr (n=8) or 1x1012gc/ml 
shErbb4.rAAV = shErbb4 (n=8) quantified by qRT-PCR using the 2-CT method.  
Data represent mean ± S.E. relative to vehicle treated samples.  ** p<0.01, *** 
p<0.001 analysed using one-way ANOVA followed by Tukey’s post hoc test for 
multiple comparisons. 
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4.3.5 Quantification of protein expression following rAAV 
injection in the mPFC 
Erbb4 protein quantification using an ELISA (section 2.14) showed that surgical 
group had a significant effect on Erbb4 protein levels (F(2,22)=11.2 p<0.001) 
with rats injected with 2l of 1x1012 gc/ml shErbb4.rAAV having significantly 
reduced Erbb4 protein expression in the PFC compared to vehicle (p<0.001) and 
scr.rAAV injected rats (p<0.01) (Figure 4.13A).  However, the expression of 
phosphorylated Erbb4 was not significantly affected by surgical group (F (2, 
2)0.98 p>0.05) (Figure 4.13B), although there was a non-significant decrease in 
pErbb4 levels in shErbb4.rAAV treated samples.  Furthermore the ratio of 
phosphorylated Erbb4 to total Erbb4 was also not significantly affected by 
surgical group (F (2, 22) =0.01 p>0.05) (Figure 4.13C).   
To assess if injection of viral particles caused glial infiltration within the PFC, 
levels of Gfap were quantified by western blotting in each sample at 5 weeks 
post-surgery (section 2.13).  There was no significant effect of surgical group on 
Gfap expression (F (2, 21) =0.55 p>0.05).  Although both viral groups did appear 
to have slightly heightened Gfap expression, this was not significantly higher 
than vehicle treated rats and most importantly not different between viral 
groups (Figure 4.14).  To ensure there was eGFP expression in all protein lysates 
isolated from viral treated PFC tissue 5 weeks post-surgery (as this was not a 
time point assessed in the previous validation study (section 4.3.2), eGFP protein 
levels were assessed by western blot analysis (section 2.13).  All scr.rAAV and 
shErbb4.rAAV treated samples showed eGFP expression, although levels were 
somewhat variable.  Importantly no eGFP was visible in vehicle treated samples 
(Figure 4.15).   
The weight of the rats post-stereotaxic surgery was monitored to assess for 
adverse effects of surgery or viral infection. There was no difference in the 
weight of rats in different surgical groups (F (2, 68) = 2.80 p>0.05) (Figure 4.16A) 
or 5-CSRTT (F (2, 98) = 2.5 p>0.05) (Figure 4.16B)).  
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Figure 4.13 Effect of in vivo viral-mediated targeting of Erbb4 on Erbb4 and 
pErbb4 protein expression.  % Erbb4 (A), phosphorylated Erbb4 (pErbb4) (B) 
and the ratio of pErbb4 to total Erbb4 (C) protein expression remaining in one 
hemisphere of the mPFC dissected from rats 5 weeks post 2l injection of vehicle 
= veh (n=7), 1x1012gc/ml scr.rAAV = scr (n=8) or 1x1012gc/ml shErbb4.rAAV = 
shErbb4 (n=8) quantified by Erbb4 or phosphoErbb4 ELISA.  Data represent mean 
± S.E. relative to vehicle treated samples. ** p<0.01, *** p<0.001 analysed using 
one-way ANOVA followed by Tukey’s post hoc test for multiple comparisons. 
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Figure 4.14 Effect of in vivo viral-mediated targeting of Erbb4 on Gfap 
protein expression. Representative immunoblots of Gfap (top panel) and Actin 
(lower panel) in lysates prepared from one hemisphere of the mPFC dissected 
from rats 5 weeks post-2l injection of vehicle = veh, 1x1012gc/ml scr.rAAV = scr 
or 1x1012gc/ml shErbb4.rAAV = shErbb4 (A).  Quantification of Gfap protein 
expression in lysates prepared from one hemisphere of the mPFC dissected from 
rats 5 weeks post-2l injection of vehicle = veh (n=7), 1x1012gc/ml scr.rAAV = scr 
(n=8) or 1x1012gc/ml shErbb4.rAAV = shErbb4 (n=8) normalised to the expression 
of Actin (B).  Data represent mean ± S.E. relative to vehicle treated samples.  
 
 
Figure 4.15 in vivo eGFP protein expression 5 weeks post-stereotaxic 
surgery. Representative immunoblots of eGFP in lysates prepared from one 
hemisphere of the mPFC dissected from rats 5 weeks post-2l injection of 
vehicle= veh, 1x1012gc/ml scr.rAAV = scr or 1x1012gc/ml shErbb4.rAAV = 
shErbb4. 
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Figure 4.16  Effect of stereotaxic surgery on weight.  Weight gain as measured 
by % of pre-surgery weight of rats in prepulse inhibition and locomotor activity 
study (A) or 5-CSRTT study (B) at 1, 3 and 5 weeks post-injection of 2l injection 
of vehicle = veh (n=7-11), 1x1012gc/ml scr.rAAV  = scrambled (n=8-12) or 
1x1012gc/ml shErbb4.rAAV = shErbb4 (n=8-11). 
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4.3.6 Effects of rAAV injection in the mPFC on protein levels of 
the Nrg1-Erbb4 signalling pathway 
As there were significant reductions in Erbb4 protein levels 5 weeks post-surgery 
in the PFC of rats treated with shErbb4.rAAV particles, activity levels of the two 
downstream signalling pathways of Erbb4 were assessed.  The activity of the Erk 
signalling pathway as measured by the ratio of pErk expression to total Erk (tErk) 
expression was not significantly affected by surgical group (F(2,21)=0.39 p>0.05) 
(Figure 4.17).  In comparison, the activity of the Akt signalling pathway as 
measured by the ratio of pAkt expression to total Akt (tAkt) expression was 
significantly affected by surgical group (F(2,20)=3.82 p<0.05).  Post hoc 
comparisons revealed shErbb4.rAAV treated rats had significantly less pAkt/tAkt 
than vehicle treated rats (p<0.05) and to some extent scr.rAAV treated rats 
(although not to a significant level) (Figure 4.18). 
In agreement with mRNA results in vitro and to a certain degree in vivo, surgical 
group had a significant effect on Nrg1 protein expression (F (2,22)=8.82 p<0.01) 
with shErbb4.rAAV treatment resulting in approximately a 70% increase full 
length Nrg1 (100 kDa) expression compared to the scr.rAAV  group (p<0.05) and 
vehicle group (p<0.01) (Figure 4.19).  There were no effects on the expression of 
Nrg1 cleavage products (data not shown).  Pearson’s correlation analysis 
revealed a significant negative correlation between Erbb4 and Nrg1 protein 
levels remaining 5 weeks after surgery (p<0.05) (Figure 4.20). 
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Figure 4.17 Effect of in vivo viral-mediated targeting of Erbb4 on Erk 
signalling.  Representative immunoblots of tErk2 (top panel), pErk2 (middle 
panel) and Actin (lower panel) in lysates prepared from one hemisphere of the 
mPFC dissected from rats 5 weeks post-2l injection of vehicle = veh, 1x1012gc/ml 
scr.rAAV = scr or 1x1012gc/ml shErbb4.rAAV = shErbb4 (A).  Quantification of the 
ratio of pErk2 to tErk2 protein expression in lysates prepared from one hemisphere 
of the mPFC dissected from rats 5 weeks post-2l injection of vehicle = veh (n=7), 
1x1012gc/ml scr.rAAV = scr (n=8) or 1x1012gc/ml shErbb4.rAAV = shErbb4 (n=8) 
normalised to the expression of Actin (B).  Data represent mean ± S.E. relative to 
vehicle treated samples. 
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Figure 4.18 Effect of in vivo viral-mediated targeting of Erbb4 on Akt 
signalling.  Representative immunoblots of tAkt (top panel), pAkt (middle panel) 
and Actin (lower panel) in lysates prepared from one hemisphere of the mPFC 
dissected from rats 5 weeks post-2l injection of vehicle = veh, 1x1012gc/ml 
scr.rAAV = scr or 1x1012gc/ml shErbb4.rAAV = shErbb4 (A).  Quantification of the 
ratio of pAkt to tAkt protein expression in lysates prepared from one hemisphere of 
the mPFC dissected from rats 5 weeks post-2l injection of vehicle = veh (n=7), 
1x1012gc/ml scr.rAAV = scr (n=8) or 1x1012gc/ml shErbb4.rAAV = shErbb4 (n=8) 
normalised to the expression of Actin (B).  Data represent mean ± S.E. relative to 
vehicle treated samples. * p<0.05 analysed using one-way ANOVA followed by 
Tukey’s post hoc test for multiple comparisons.  
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Figure 4.19 Effect of in vivo viral-mediated targeting of Erbb4 on Nrg1 
protein expression. Representative immunoblots of Nrg1 (top panel) and Actin 
(lower panel) in lysates prepared from one hemisphere of the mPFC dissected 
from rats 5 weeks post-2l injection of vehicle = veh, 1x1012gc/ml scr.rAAV = scr 
or 1x1012gc/ml shErbb4.rAAV = shErbb4 (A).  Quantification of Nrg1 protein 
expression in lysates prepared from one hemisphere of the mPFC dissected from 
rats 5 weeks post-2l injection of vehicle = veh (n=7), 1x1012gc/ml scr.rAAV = scr 
(n=8) or 1x1012gc/ml shErbb4.rAAV = shErbb4 (n=8) normalised to the expression 
of Actin (B).  Data represent mean ± S.E. relative to vehicle treated samples. * 
p<0.05, ** p<0.01 analysed using one-way ANOVA followed by Tukey’s post hoc 
test for multiple comparisons. 
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Figure 4.20  Correlation analysis of Erbb4 and Nrg1 protein levels.  
Correlation between Erbb4 protein expression and full length Nrg1 (100 kDa) 
protein expression in PFC lysates prepared from one hemisphere of the mPFC 
dissected from rats 5 weeks post-2l injection of vehicle = veh, 1x1012gc/ml (n=7), 
scr.rAAV = scr (n=8) or 1x1012gc/ml shErbb4.rAAV = shErbb4 (n=7).  Solid line 
represents the equation of best fit.  Pearson’s correlation co-efficient (R) and p 
value indicate significant negative correlation between Erbb4 and Nrg1 protein 
expression. 
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4.4 Discussion 
4.4.1 Validation of rAAV functionality in vitro 
Validation of the functionality of the rAAV particles was essential in this study as 
the particles themselves were a gift from an outside source, and evidence of 
their functionality in vitro or in vivo was not readily available.  The aim of this 
in vitro validation study was not to calculate a titre for in vivo work. This 
preliminary analysis however, demonstrated that the viral particles were 
capable of transducing neuronal-like (NG108-15) and neuronal cells (primary 
cortical cultures) and that they drove the expression of eGFP, indicative of likely 
co-expression of the short-hairpin sequences in the other viral particles used in 
this study (scr.rAAV and shErbb4.rAAV).  Additionally the in vitro validation 
study was successful in confirming that the hairpin sequence of the 
shErbb4.rAAV particles could elicit the knockdown of Erbb4 expression in 
primary cortical cultures, to a significant level compared to treatment with 
scr.rAAV particles.  This effect seems to be specific to the hairpin sequence as 
importantly even at the highest titre of viral particles used, there was no 
significant difference in Erbb4 expression between vehicle treatment and 
scr.rAAV treatment, suggesting that the viral particles themselves were not 
overtly toxic.  This validation study established the confidence required to 
progress to utilising these viral particles in vivo. 
4.4.2 Validation of rAAV particles in vivo 
The eGFP.rAAV viral particles were validated in vivo using 2 different titres and 
at 3 time points to assess viral tropism and expression of the eGFP transgene.  
The titres of viral particles used in this in vivo validation study were in line with 
multiple in vivo studies using rAAV particles within the CNS of rodents (Xia et 
al., 2004; Babcock et al., 2005; Ulusoy et al., 2009) and importantly were below 
the threshold of those shown to be too toxic within the CNS (Ulusoy et al., 
2009).  As expected the higher number of viral particles resulted in the 
transduction of more cells in the area surrounding the needle tract.  The 
presence of eGFP expressing cells at 1 week following surgery is in accordance 
with a study which showed eGFP expression within the brain from 4 days 
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onwards following rAAV treatment (Reimsnider et al., 2007).  In the present 
study peak eGFP expression was observed at 3 weeks post-surgery.  Akin to this a 
study by Reimsnider et al., (2007) confirmed that peak eGFP expression 
following rAAV injection into the striatum was by 4 weeks.  As eGFP 
immunofluorescence analysis was not performed at 4 or 5 weeks post-surgery, it 
is unclear whether eGFP expression increased from week 3 to week 5.  
Interestingly, behavioural phenotypes emerged at 5 weeks post-surgery which 
may suggest that peak eGFP expression and thus hairpin expression will have 
already occurred by 5 weeks post-surgery.  Although in the present study eGFP 
expression appeared to have diminished by 8 weeks post-surgery many studies 
have shown strong eGFP expression under the control of the same or similar 
promoters as this study at time points beyond 8 weeks (Kaplitt et al., 1994; Xu 
et al., 2001; Xue et al., 2010).  This may reflect region specific differences in 
factors which limit the expression of rAAV transgenes such as impaired 
intracellular trafficking (Ding et al., 2005), uncoating of the viral capsid (Hauck 
et al., 2004) or second strand DNA synthesis as single stranded rAAV genomes are 
only very transiently expressed in target cells before degradation (Hauck et al., 
2004).  Since at 8 weeks post-surgery eGFP levels had returned to a similar level 
of that of 1 week post surgery, this would suggest that target cells surrounding 
the needle tract were transduced by multiple rAAV particles resulting in longer 
term eGFP expression than cells further from the needle tract that were 
presumably transduced by fewer rAAV particles owing to the more transient 
eGFP expression in cells out with the needle tract.   
Peak spread of eGFP expression at 3 weeks post-surgery was approximately 
0.65mm2.  This level of transduction is very similar to that of previous studies 
(Hommel et al., 2003; Reimsnider et al., 2007; Burnet et al., 2011) and although 
this level of transduction has been sufficient in this study to produce both 
downstream behavioural and molecular alterations, it is of interest that previous 
studies have successfully reported behavioural and biochemical changes 
following injections of viral particles at multiple brain sites simultaneously 
(Winstanley et al., 2009).  Moreover, it has been shown that co-administration of 
viral particles along with agents that aid vasodilation such as mannitol increase 
spread of AAV transduction (Mastakov et al., 2001). 
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Co-localisation of eGFP expression with multiple cell type markers revealed that 
within the mPFC rAAV serotype 9 is capable of transducing neurons and glia.  
Systemic injection of rAAV 9 has previously been reported to result in neuronal 
(Inagaki et al., 2006) and neuronal and glial transduction (Foust et al., 2009).  
However, intra-striatal injection of rAAV 9 was only efficient in transducing 
neurons but not glia (Xue et al., 2010).  This is in keeping with multiple reports 
of rAAVs having preference over neuronal than glial transduction (Cearly & 
Wolfe, 2006; Lawlor et al., 2009).  Although quantification was not carried out 
in the present study it was evident that the ratio of co-localised eGFP/Gfap 
expressing cells to un-colocalised Gfap expressing cells was very low.  However, 
the presence of glial transduction within the mPFC in the present study 
compared to the lack of this observation in previous studies could be due to the 
suggestion that the tropism of rAAVs may vary dramatically between brain 
regions due to the expression of the specific serotypes and cell surface receptors 
or co-receptors with the distinct brain region, and also regional differences in 
the regulation of Gfap expression (Xu et al., 2001).  eGFP co-localisation in 
selected parvalbumin-expressing cells suggests the rAAVs were capable of 
transducing parvalbumin-positive GABAergic interneurons; this is in agreement 
with a previous study which found AAV 1/2 were capable of transducing both 
cortical inhibitory and excitatory interneurons (Nathanson et al., 2009).   
It is not surprising that the rAAVs used in this study transduced multiple cell 
types since the laminin receptor (thought to be the cell surface receptor for 
rAAV 9) is widely expressed throughout the CNS and is expressed in glial cells 
and neuronal cells including parvalbumin-containing interneurons (Baloui et al., 
2004).  The wide tropism of eGFP expression observed in this study is indicative 
that the shRNA sequence of scr.rAAV and shErbb4.rAAV particles will also be 
expressed in these multiple cells types, and although it would be interesting to 
investigate the effects of knockdown of Erbb4 in specific cell types it is unlikely 
that the pathophysiology of schizophrenia is due to gene changes in gene 
expression in one individual cell type.  In addition, in the rodent brain Erbb4 is 
expressed in glial cells (Gereck et al., 2001), parvalbumin-containing intereurons 
(Yau et al., 2003; Vullhorst et al., 2009; Neddens & Buonanno, 2010) and also 
pyramidal cells (Gereck et al., 2001; Mechawar et al., 2007).  However, this has 
recently been under debate (Vullhorst et al., 2009; Neddens & Buonanno, 2010).  
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One very recent study has successfully utilised viral mediated technology to 
selectively target cortical inhibitory interneurons expressing Erbb4 in the mouse 
brain, but no functional measurements of behaviour or signalling were 
performed (Choi et al., 2010). 
4.4.3 Erbb4 mRNA and protein knockdown in vivo 
Knockdown of Erbb4 mRNA after injection of shErbb4.rAAV was not observed in 
the PFC at 5 weeks post-surgery, despite there being a significant decrease in 
the expression of Erbb4 protein. There are a number of reasons for why this is 
likely including that that the mRNA levels of Erbb4 within shErbb4.rAAV 
transduced cells were successfully knocked down at 5 weeks post-surgery but 
this effect was diluted out by the large amount of tissue not transduced in the 
dissected PFC tissue analysed.  MRNA and protein knockdown via viral mediated 
shRNA expression have been previously shown to occur at different time points 
post-viral injection (Burnet et al., 2011).  In the present study protein 
knockdown of Erbb4 within the PFC was on average 18%, suggesting that the 
transduced cells within the transduced region of the mPFC had a very low level 
of Erbb4 expression remaining.  Although significant, the overall level of 
knockdown was subtle, suggesting that non-transduced cells within the dissected 
PFC tissue may have diluted out the Erbb4 knockdown levels.  Some studies have 
shown greater knockdown levels using similar titres as in the present study 
however, it should be noted that many studies use techniques that quantify 
more defined areas than a gross tissue dissection, such as fluorescence-activated 
cell sorting (FACS) to analyse only GFP positive cells or laser capture dissection 
to dissect out only the precise area transduced by the virus (Hommel et al., 
2003; Mao et al., 2009; McKee et al., 2010). 
4.4.4 The effect of Erbb4 knockdown on Nrg1-Erbb4 signalling 
Erbb4 knockdown led to increased Nrg1 mRNA levels in vitro and protein levels 
in vivo suggesting that the increase in the ligand expression compensates for the 
reduction in receptor number following shErbb4.rAAV treatment.  This may 
explain why even though there is a significant knockdown in total Erbb4 the 
activity of the receptor as assessed by the ratio of pErbb4/tErbb4 is not 
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changed, presumably caused by the remaining Erbb4 receptors being over-
stimulated by the increased Nrg1.  Moreover, this is strengthened by Pearson’s 
correlation analysis revealing that the compensatory increase in Nrg1 is even 
more evident with the decreasing levels of Erbb4.  Interestingly, although there 
have been numerous transgenic mouse lines produced with mutations in Nrg1 or 
Erbb4, none of these studies have analysed whether there is a secondary effect 
on Erbb4 or Nrg1 levels, respectively.  Similarly, many studies have measured 
Erbb4 and Nrg1 levels in the brains of patients with schizophrenia.  However, 
these studies rarely measure both the ligand and receptor instead solely showing 
a change in levels of Nrg1 or Erbb4 (Hashimoto et al., 2004; Law et al., 2006; 
Law et al., 2007; Silberberg et al., 2007).  One study correlated the level of 
both proteins in the PFC of patients with schizophrenia and found that increased 
NRG1 was correlated with increased ERBB4 levels (Chong et al., 2008).  Although 
these results are in opposition with what is seen in the present study, it should 
be noted that Chong and colleagues found a positive correlation with a cleaved 
form of NRG1 whereas here full length Nrg1 is changed and there was no effect 
of Erbb4 knockdown on any Nrg1 cleavage products.  This suggests that Erbb4 
knockdown in the mPFC did not affect the enzymatic cleavage of Nrg1.  In a 
recent study, knock-out of the gene bace which transcribes an enzyme important 
in the cleavage of Nrg1 resulted in decreased Nrg1 but no changes in the 
expression levels of Erbb4 (Savonenko et al., 2008). 
As there was no significant change in the activity of the Erbb4 receptor following 
Erbb4 knockdown it was not expected that there would be changes in the 
activity of either of the signalling pathways initiated by Erbb4.  In line with this 
hypothesis there was no effect of Erbb4 knockdown on Erk signalling.  However, 
shErbb4.rAAV treatment appeared to reduce Akt signalling.  Fascinatingly, in the 
PFC of brains from patients with schizophrenia the decrease in Erbb4 expression 
is limited to the CYT1 isoform, which signals through the Akt pathway (Law et 
al., 2007).  Moreover, Nrg1 induced changes in Akt activity in schizophrenia have 
been replicated in several studies, where although Nrg1 consistently increases 
activity of Akt in schizophrenia this increase in activity is attenuated (Sei et al., 
2007; Keri et al., 2009) whereas Erk activity appears to be unaltered (Sei et al., 
2007).   Studies looking at basal activity of Akt are less consistent with both 
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decreases (Emamian et al., 2004) and no changes (Ide et al., 2006; Sei et al., 
2010) in Akt activity being identified.   
Whether the change in Akt activity is a direct effect of Erbb4 knockdown or an 
effect of the secondary change in Nrg1 levels is unclear, and although the 
changes in levels of Erbb4 activity and Akt activity are not significantly different 
between the scr.rAAV and shErbb4.rAAV treatment groups, it is known that 
subtle changes in activity as measured by phosphorylation are less robust than 
changes in total protein levels.  Phosphorylation states are rapid and reversible 
modifications that are dependent on cell type (Emamian et al., 2004).  
Reductions in Akt activity have been associated with dopamine receptor D2 
(Drd2) over-activity (Beaulieu et al., 2004; Beaulieu et al., 2007).  Akt activity 
has also been associated with GABAergic (Wang et al., 2003; Oishi et al., 2009) 
and glutamatergic neurotransmission (Chalecka-Franaszek & Chuang, 1999).  The 
finding that Akt activity is altered following Erbb4 knockdown is of great interest 
as it is consistent with the growing opinion that Akt is a key mediator of Nrg1-
Erbb4 signalling within the prefrontal cortex, dysregulation of which may 
potentially lead to symptoms that appear to be dependant upon regulated 
function of this brain region.   
4.4.5 Potential off target effects and toxicity of rAAV injection 
GFAP expression is an indicator of astrocytic activation (gliosis) prior to visible 
anatomical neural tissue damage (O’Callaghan, 1988). There was no significant 
increase in Gfap levels in viral treated samples (scr.rAAV or shErbb4.rAAV) 
indicating that the virus itself had no overt adverse effects on the tissue 
surrounding the injection site.  Moreover, since there is no difference in Gfap 
levels between the viral treatment groups the shErbb4 sequence and thus Erbb4 
knockdown did not cause gliosis.  These findings are in agreement with injection 
of similar titres of rAAV than that used in the present study did not increase 
levels of gliosis (Klein et al., 2007).  The weights of the rats in either of the 
studies did not change after injection of rAAV, indicating there were no gross 
effects on the rat’s post-operative health which would lead to reduced eating 
and loss of body weight.  Finally, there were several measures where there was 
no change between treatment groups on Erbb4 and Nrg1 mRNA levels, as well as 
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the levels of housekeeping gene r18s and Erk protein levels, suggestive that 
Erbb4 knockdown and the rAVV particles themselves did not have broad off-
target effects. This finding is in concordance with a study that found only rAAVs 
used at titres above 3.7 x 1012gc/ml had some toxicity and off target effects 
(Ulusoy et al., 2009). 
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4.5 Conclusions 
The data in this chapter present a host of data validating the knockdown of 
schizophrenia candidate Erbb4.   
I have shown in this chapter that following in vitro validation of rAAV particles 
expressing a hairpin sequence to rat Erbb4 in NG108-15 cells and dissociated 
cortical cultures, it was possible to achieve a quantifiable knockdown of Erbb4 
protein expression in the rat PFC at 5 weeks post-surgery.  This knockdown of 
Erbb4 could be in pyramidal neurons, parvalbumin neurons and glial cells of the 
prefrontal cortex, as all of these cells types were capable of transduction by the 
rAAV particles. 
There was no quantifiable Erbb4 mRNA knockdown within the PFC at the time 
point assessed, however the ratio of Nrg1 to Erbb4 mRNA was significantly 
increased, which was in accordance with the finding that Nrg1 protein 
expression increased in response to Erbb4 knockdown.  Furthermore, the activity 
of the Akt signalling pathway was significantly reduced by Erbb4 knockdown, 
whereas the Erk signalling pathway was unaffected. 
Overall this chapter provides supporting evidence that viral-mediated 
knockdown in vivo is achievable, and validates the view that any behavioural 
changes due to shErbb4.rAAV injection will be due to subtle but significant 
knockdown of Erbb4 within the PFC.   
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5 Viral-mediated Erbb4 knockdown produces 
differential effects on schizophrenia-related 
behaviours 
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5.1 Introduction 
Schizophrenia is characterised by several behaviour phenotypes, many of which 
have been induced in rodent models of schizophrenia by pharmacological agents, 
environmental insults and also by genetic insults (section 1.7).  Rodent models 
with manipulations of the schizophrenia candidate genes Nrg1 and Erbb4 show a 
diverse range of schizophrenia-related behavioural phenotypes (section 1.9.4); 
however it is unclear if these phenotypes are due to the function of Nrg1-Erbb4 
signalling in distinct brain regions.  It is therefore of great interest to determine 
region specific functionality of these molecules in mediating schizophrenia-
related behaviours in order to potentially dissect the roles of these candidate 
genes in schizophrenia.   
5.1.1 Prepulse inhibition of the startle response 
Prepulse inhibition of the startle response is a cross-species phenomenon 
whereby a non-startling “prepulse” stimulus suppresses the magnitude of the 
startle reflex to a startling stimulus.  This test is widely used to measure 
sensorimotor gating and deficits in the performance of this task have been 
observed in patients with schizophrenia and also their unaffected relatives (Braff 
et al., 2001).  Decreased PPI is also apparent in multiple other neurological 
disorders such as Huntington’s disease, obsessive compulsive disorder (OCD), 
Tourette Syndrome and some forms of Bipolar disorder (Swerdlow et al., 1995; 
Castellanos et al., 1996; Hoenig et al., 2005; Gogos et al., 2009). 
5.1.2 Modalities of cognition assessed by PPI 
PPI deficits in schizophrenia representing sensorimotor gating dysfunction are 
thought to correspond to the inability of patients to filter out unimportant 
external stimuli leading to loss of focus and disorganised behaviour.  Although 
the exact functional consequence of deficits in PPI in schizophrenia is unknown 
PPI has been termed as a promising endophenotype for schizophrenia by the 
CNTRICS program as a measure of “gain control” (Green et al., 2009).  Whether 
PPI deficits in schizophrenia are related to cognitive dysfunction is debatable, 
with some studies showing a positive correlation of PPI performance with 
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performance in the CANTAB battery in healthy controls (Bitsios et al., 2006) and 
Global Assessment  of Function and Independent Living Scales in patients 
(Swerdlow et al., 2006) .  However, there appears to be no association of poor 
PPI with poor performance in tasks such as WCST in schizophrenia (Swerdlow et 
al., 2006). Therefore PPI deficits may be important in being an early signal to 
consequential deficits in cognition.  However, there is much more research 
needed to identify how deficits in PPI in schizophrenia patients manifest into 
cognitive deficits, and indeed which modality of cognition PPI deficits represent. 
5.1.3 Neuronal circuitry and neurotransmitters involved in PPI 
Studies in rats have helped elucidate the brain circuitry involved in the 
maintenance of PPI; this complex circuitry involves connections between the 
limbic cortex, ventral striatum, ventral pallidum and the pontine tegmentum, 
termed the CSPP circuit (Swerdlow & Geyer, 1999).  Lesioning or direct infusion 
of multiple substances directly into regions of the limbic cortex, including the 
mPFC, hippocampus and amygdala result in PPI disruption (Swerdlow, 2001).   
Pharmacological studies have highlighted some of the neurotransmitter systems 
that disrupt PPI which in turn may elucidate the aberrant neurotransmission 
occurring in schizophrenia resulting in dysfunctional PPI performance in patients.  
PPI is thought to be heavily dependant upon regulated dopaminergic signalling, 
as over-stimulation of the dopamine system by direct or indirect dopamine 
agonists such as amphetamine disrupts PPI in rodents (Mansbach 1998, Larrauri 
et al., 2010).  Moreover rats with genetic disruption of the dopamine transporter 
gene show deficits in PPI, namely due to the constant hyperdopaminergic state 
in the synaptic cleft via lack of dopamine clearance (Ralph et al., 2001; Barr et 
al., 2004).   
Blockade of glutamatergic neurotransmission also results in PPI deficits in 
rodents with previous work from our laboratory showing that acute and sub-
chronic PCP administration result in robust PPI deficits (Egerton et al., 2008). In 
addition, mice with a reduction in the expression of the NMDA receptor subunit, 
NR1, show PPI deficits (Duncan et al., 2004).  Other neurotransmitter systems 
also appear to play an important role in regulating PPI, with nicotine injection in 
rats resulting in increased PPI (Levin et al., 2005; Curzon 1994).  It is therefore 
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clear that PPI is a behaviour regulated by a distinct but complex circuitry 
involving multiple neurotransmitter systems. 
5.1.4 Locomotor activity in response to a novel environment 
Although positive symptoms such as hallucinations and delusions cannot be 
readily assessed in rodents other positive symptoms such as psychomotor 
agitation, which is apparent in patients with schizophrenia, can be characterised 
by increased locomotor activity in response to a novel environment (Arguello & 
Gogos, 2006).  The open field task is an ideal way to measure locomotor activity 
utilising the inbuilt characteristic of rodents to be naturally explorative but also 
cautious to a novel environment. Locomotor activity is widely used to study 
behavioural phenotypes similar to positive symptoms in schizophrenia as it is 
relatively easy and inexpensive to perform. 
Locomotor activity is a dopamine dependent process and in some studies 
increased locomotor activity to a novel environment can be reversed or 
dampened by antipsychotic treatment (which generally have high affinity for D2 
receptors)(Stefansson et al., 2002).  Moreover, mice that lack D2 receptors 
perform at approximately half the locomotor activity of control mice (Kelly et 
al., 2008). 
5.1.5 Sensitivity to amphetamine 
In addition to assessing locomotor activity to a novel environment, many studies 
have employed the additional challenge of the psychostimulant amphetamine on 
locomotor activity.  This has been employed as it is known that amphetamine 
has psychosis- like effects in non-schizophrenic individuals (Carlsson & Lindqvist, 
1963) and also exacerbates positive symptoms in patients with schizophrenia.  
Moreover, amphetamine challenge in patients with schizophrenia results in a 
much greater amphetamine-induced dopamine release than that seen in healthy 
controls (Laruelle et al., 1996; Breier et al., 1997; Abi-Dargham et al., 1998; 
Laruelle et al., 1999) and therefore, changes in response to amphetamine in 
rodents may indicate a schizophrenia-like dopaminergic imbalance due to 
pharmacological challenge or gene manipulation.  Amphetamine acts primarily 
by increasing dopamine levels at the synaptic cleft (Seiden et al., 1993). 
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However, amphetamine not only increases dopamine levels but also levels of 
monoamines such as noradrenaline and serotonin (Kuczenski & Segal, 1997).   
Amphetamine challenge in rodents has also been commonly used to test the 
intactness of the cortico-striatal loop which is essential in mediating the effects 
of amphetamine (Burns et al., 1993). Therefore a heightened response to 
amphetamine in response to a pharmacological agent or genetic modification 
may indicate a disturbance in dopaminergic signalling resulting from a 
dysfunction in the cortico-striatal loop circuitry.   
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5.2 Aims 
The aims of this study were to test the hypothesis that viral mediated 
knockdown of Erbb4 within the mPFC in rats produces schizophrenia-related 
behaviour in rats.  This was achieved by examining Erbb4 knockdown on 
sensorimotor gating (PPI) and hyperactivity to a novel environment (open field), 
thus determining if Erbb4 within this specific brain region was important in 
mediating or regulating these behaviours.  In addition, the effect of an 
amphetamine challenge on locomotor activity was investigated with the aim to 
determine if altering Erbb4 expression within the mPFC affected dopaminergic 
transmission and the integrity of the cortico-striatal loop.   
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5.3 Results 
5.3.1 Effect of viral-mediated gene manipulation on pre-pulse 
inhibition 
To assess if Erbb4 within the prefrontal cortex of the adult brain is important in 
regulation of sensorimotor gating rats underwent stereotaxic surgery receiving 
bilateral injections of either vehicle (veh)n=7, rAAV encoding a scrambled 
hairpin sequence (scr) n=8 or rAAV encoding a hairpin sequence complementarily  
to rat Erbb4 (shErbb4) n=8 (section 2.4.2). One, three and five weeks post-
surgery sensorimotor gating was assessed via measuring prepulse inhibition of 
the startle response (section 2.6.3).   
Startle response to 120dB startle alone pulses (i.e. those not preceded by pre-
pulse stimuli) was not affected by surgical group (F (2, 68) =1.19 p>0.05) (Figure 
5.1).  Startle response levels did not significantly change over the three time 
points assessed post-surgery, with no significant effect of week on startle 
response (F(2,68)=1.64 p>0.05) and moreover there were no significant 
differences in startle levels between surgical groups at individual time points 
(surgical group x week interaction F(4, 68)=1 p>0.05).   
Mean % PPI (mean % PPI of 4, 8 and 16dB prepulse amplitudes) was significantly 
affected by surgical group (F (2, 68) =9.10 p<0.001), with post hoc analysis 
revealing that scrambled hairpin virus (scr.rAAV) treated rats (p<0.01) and 
shErbb4 virus (shErbb4.rAAV) treated rats (p<0.001) had a significantly lower 
mean %PPI than vehicle treated rats.  This effect was a general observation over 
all time points with no significant interaction between surgical group and week 
being found (F (4, 68) =1.1 p>0.05).  Interestingly, there was a significant effect 
of week on mean % PPI (F (2, 68) =11.46 p<0.001) with mean % PPI being 
significantly higher at week 5 than at weeks 1 (p<0.001) and 3 (p<0.05) (Figure 
5.2).   
To probe the results observed with mean % PPI further, the effects of viral 
manipulation on % PPI were analysed by individual prepulse amplitudes.  The 
most striking finding was that prepulse amplitude had a very significant effect 
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on % PPI (F (2,206) =213.05 p<0.001), with % PPI increasing with increasing 
prepulse amplitude level.  % PPI at a prepulse amplitude of 16dB was 
significantly higher than at amplitudes of 8dB (p<0.001) and 4dB (p<0.001) and 
prepulse amplitude of 8dB resulting in higher % PPI than 4dB (p<0.001).  The 
analysis of % PPI by individual prepulse amplitude yielded very similar findings to 
those of mean % PPI.  Again surgical group had a significant effect on % PPI (F (2, 
206) =13.07 p<0.001) with both viral groups showing reduced %PPI than vehicle 
treated rats.  In agreement with mean % PPI, week also had a significant effect 
on % PPI (F (2,206)=15.61 p<0.001) with % PPI being higher at week 5 than at 
weeks 1 and 3, however this effect was observed over all prepulse amplitudes 
with no prepulse amplitude x week interaction being found (F (4,206)=0.41 
p>0.05). 
Unlike the findings of mean % PPI, % PPI analysed by individual prepulse 
amplitudes showed there was a significant interaction between surgical group 
and week (F (4, 206) =2.57 p<0.05) owing to shErbb4.rAAV treated rats having a 
significantly lower % PPI than vehicle treated rats at 1 week post-surgery 
(p<0.05) and scr.rAAV treated rats having significantly lower % PPI than vehicle 
treated rats at 3 weeks post-surgery (p<0.001).  These observations were general 
findings over all prepulse amplitudes as there was no significant interaction 
between surgical group x prepulse amplitude x week (F (8, 206) =0.95 p>0.05) 
(Figure 5.3).   
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Figure 5.1 Effect of viral mediated gene manipulation on startle response.  
The startle response to 120dB startle only trials at 1, 3 and 5 weeks following 
bilateral injections of vehicle (veh) (n=7), scr.rAAV (scr) (n=8) or shErbb4.rAAV 
(shErbb4) (n=8) into the mPFC.  There was no effect of surgical group on startle 
response.  Data represents mean startle response (measured in arbitrary units 
(a.u.)) ± SE. 
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Figure 5.2 Effect of viral mediated gene manipulation on mean % PPI.  % PPI  
(mean of %PPI at prepulse amplitudes of 4dB, 8dB and 16dB) was measured at 1, 
3 and 5 weeks following bilateral injections of vehicle (veh) (n=7), scr.rAAV (scr) 
(n=8) or shErbb4.rAAV (shErbb4) (n=8) into the mPFC. Data represents mean ± 
SE.  Data were analysed using two-way repeated measures ANOVA followed by 
Tukey’s test for multiple comparisons.  Mean %PPI was overall significantly lower 
in scr.rAAV (p<0.01) and shErbb4.rAAV (p<0.001) treated rats compared to 
vehicle treated rats.     
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Figure 5.3 Effect of viral-mediated gene manipulation on % PPI at prepulse 
amplitudes of 4dB, 8dB or 16dB.  % PPI was assessed at prepulse amplitudes 
of 4, 8 and 16dB at 1, 3 and 5 weeks following bilateral injections of vehicle (veh) 
(n=7), scr.rAAV (scr) (n=8) or shErbb4.rAAV (shErbb4) (n=8) into the mPFC.   
Data represents mean ± SE.  Data were analysed using two-way repeated 
measures ANOVA followed by Tukey’s test for multiple comparisons.  %PPI was 
overall significantly lower in scr.rAAV (p<0.001) and shErbb4.rAAV (p<0.001) 
treated rats compared to vehicle treated rats   
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5.3.2 Effect of viral mediated gene manipulation on locomotor 
activity 
In the same rats that were being assessed for sensorimotor gating deficits, 
locomotor activity in response to amphetamine was also measured to assess if 
Erbb4 within the prefrontal cortex of the adult brain is important in regulation 
of cortico-striatal dopamine regulation. 23 rats that had received intra-mPFC 
injections of vehicle (veh) n=7, rAAV encoding a scrambled hairpin sequence 
(scr) n=8 or rAAV encoding a hairpin sequence directed against rat Erbb4 
(shErbb4) n=8 (section 2.4.2) were assessed in the open field one, three and five 
weeks post-surgery (section 2.5).  In the open field assessments rats were 
monitored for a 30 minute habituation period (2.5.2), and injected with vehicle 
(0.9% w/v saline) or 1mg/ml amphetamine before being monitored for a test 
period of 60 minutes (section 2.6).    
Analysis of locomotor activity during the 30 minute habituation phase to the 
open field showed that there was no significant difference in the distance 
travelled during this habituation period on the first or second exposure to the 
open field apparatus at each week that the locomotor activity was assessed (F 
(1, 827) =1.75 p>0.05).  Therefore any further effects seen during the 
habituation period are not due to differences by day.  There was an overall 
significant effect of surgical group on distance travelled during the habituation 
phase (F (2, 827)=7.08 p=0.001) with post hoc analysis showing vehicle treated 
rats travelled less distance than scrambled hairpin virus treated rats (p<0.01) 
and shErbb4 virus treated rats (p<0.01).  However these significant differences 
between surgical groups were not observed at any individual week assessed 
(surgical group x week interaction F (4, 827) =1.13 p>0.05) 
The rats in general travelled a significantly longer distance at week 5 than at 
weeks 1 (p<0.01) or 3 (p<0.001) explaining the significant effect of week on 
distance travelled during the habituation phase (F (2,827) =7.08 p<0.001).  There 
was also a significant effect of time on distance travelled during the habituation 
phase (F (5, 827)=280.91 p<0.001) with distance travelled dropping over time.   
Each time bin was significantly different from the previous time bin until 20 
minutes into the habituation phase where final three time bins were not 
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statistically significant from each other.  This drop in distance travelled over 
time during the habituation phase was observed over all surgical groups at all 
weeks owing to no significant surgical group x week x time interaction (F (20, 
827)=0.38 p>0.05) (Figures 5.4A-C).   
5.3.3 Effect of viral mediated gene manipulation on sensitivity to 
amphetamine 
Concurrent with the results of the locomotor activity habituation phase, there 
was a significant effect of surgical group on distance travelled during the test 
phase (F (2, 1655) =6.02 p<0.01).  Again, this was due to scr.rAAV treated rats 
(p<0.05) and shErbb4.rAAV treated rats (p<0.01) travelling longer distances than 
vehicle treated rats.  Distance travelled was significantly affected by the drug 
administered (F (1, 1655) =323.6 p<0.001) with 1mg/kg amphetamine causing 
hyperlocomotor activity in all surgical groups in all weeks assessed.  Importantly, 
distance travelled was not affected by the cross-over design implemented in the 
experiment as the day amphetamine was administered (day 1 or 2 at each week) 
did not have a significant effect on distance travelled in the test phase ((F (1, 
1655)=0.25 p>0.05). 
Importantly at 5 weeks post-surgery rats with Erbb4 knockdown within the mPFC 
travelled significantly longer distance under the influence of amphetamine than 
vehicle (p<0.05) or scr.rAAV treated rats (p<0.001).  This led to a significant 
group x week x drug interaction ((F (4, 1655)=5.3 p<0.001) on distance travelled 
in the test phase.  Post hoc comparisons revealed that although there was an 
effect at 5 weeks post-surgery, there was no significant difference in the effect 
of amphetamine challenge between surgical groups at weeks 1 or 3 post-surgery. 
 Some similarities between the results of the habituation phase and test phase 
were apparent with saline administered scr.rAAV treated rat travelling longer 
distances than saline administered vehicle treated rats at weeks 3 and 5 post-
surgery. 
Time had a significant effect on distance travelled in the test phase ((F (11, 
1655)=7.22 p<0.001) where it was observed that at 30 minutes after saline 
injection the rats in all  surgical groups were travelling only very short distances.  
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Amphetamine treated rats’ peak distance travelled was observed at 15 minutes 
post-injection. 
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Figure 5.4 Effects of viral mediated gene manipulation on amphetamine 
induced hyperlocomotor activity.  Locomotor activity was assessed 1 (A), 3(B) 
and 5(C) weeks post-bilateral injections of vehicle (veh) (n=7), scr.rAAV (scr) (n=8) 
or shErbb4.rAAV (shErbb4) (n=8) into the mPFC of rats. Activity was measured 
during a 30 minute habituation phase (habituation, left panel of graphs) and a 1 
hour testing phase (test) immediately following s.c. injection of 0.9% saline (saline, 
lower data sets on graph) or 1mg/kg amphetamine (amph, upper data sets on 
graphs).  Data represents distance travelled in 5 minute time bins ±SE mean 
analysed using three-way repeated measures ANOVA followed by Tukey’s test for 
multiple comparisons.  ANOVA analysis showed an overall significant effect of 
drug administration on locomotor activity with amphetamine significantly increasing 
distance travelled compared to saline (p<0.001).  Post hoc comparisons showed 
shErbb4.rAAV treated rats had a significantly heightened locomotor response to 
amphetamine at 5 weeks post-surgery compared to vehicle (p<0.05=@) and 
scr.rAAV (p<0.001=***) treated rats.  Saline injected vehicle treated rats travelled 
significantly shorter distances than saline injected scr.rAAV treated rats at 3 weeks 
(##=p<0.01) and 5 weeks (#=p<0.05) post-surgery and saline injected 
shErbb4.rAAV treated rats 3 weeks post-surgery ($=p<0.05). 
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5.4 Discussion 
5.4.1 Erbb4 knockdown does not disrupt PPI 
The lack of changes in the amplitude of startle response between surgical groups 
may suggest that there is no difference in the levels of anxiety following viral 
injection or Erbb4 knockdown, as increases in the startle levels per se have been 
previously associated with increased anxiety (Deakin et al., 2009).  The finding 
that there is no difference in % PPI between the rAAV.scr and rAAV.shErbb4 
treatments groups suggests that decreasing Erbb4 specifically in the mPFC does 
not affect sensorimotor gating. This is in agreement with a previous study using 
heterozygous null Erbb4 transgenic mice (Stefansson et al., 2002).  However, 
several studies have also shown deficits in PPI following CNS specific knock-out 
of Erbb2/4 (Barros et al., 2009) or knock-out of Erbb4 in parvalbumin-positive 
interneurons (Wen et al., 2010).  Variation in the PPI results obtained from 
transgenic Erbb4 mice may reflect differences in which isoforms are affected by 
the gene manipulation and in addition which background strains of mice are used 
for backcrossing.   
This is highlighted when reviewing the literature of Nrg1 mutant mice and PPI 
performance.  The effect on PPI appears to be dependant upon which isoform of 
Nrg1 is mutated: deficits in PPI have been reported in transmembrane domain 
knock-out mice (Stefansson et al., 2002) and type III Nrg1 knock-out mice, but 
no changes in PPI in epidermal growth factor containing isoforms (Ehrlichman et 
al., 2009).    Moreover, Nrg1 type I over-expression also results in deficits in PPI 
(Deakin et al., 2009), conflicting with results of this study, as an increase of 
Nrg1 in the mPFC, secondary to Erbb4 knockdown results in no change in PPI.  As 
well as differences in which isoforms are being manipulated, these studies are 
manipulating the expression of Erbb4/Nrg1 signalling in multiple brain regions.  
Therefore, it is plausible that manipulation of Nrg1-Erbb4 signalling 
simultaneously in multiple brain regions disrupts PPI, as PPI depends on cortical, 
limbic and striatal systems (Swerdlow et al., 2001).  
Additionally, it is also possible that the level of Erbb4 expression changes in this 
study were too subtle to cause a gross effect on PPI.  However, a recent study 
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using antisense oligodeoxynucleotides to knockdown the expression of mortalin 
within the mPFC showed that even though there was only a trend towards 
knockdown of mortalin protein within the PFC there was still a significant deficit 
in PPI in mortalin knockdown rats (Gabriele et al., 2010).  Interestingly, recent 
studies utilising viral-mediated gene manipulation to knock down the expression 
of Disc1 in the prefrontal cortex of mice in utero led to PPI deficits at postnatal 
day 56 (Niwa et al., 2010) suggesting Disc1 expression in the PFC is essential for 
intact sensorimotor gating.  A subsequent study has showed that Disc1 
expression is regulated by Nrg-Erbb signalling but it is not dependent on Erbb4 or 
the Erbb4-specific ligand, Nrg3 (Seshadri et al., 2010), further emphasising that 
Erbb4 may not be important in sensorimotor gating.   
Another pertinent point is that all of the studies of the effect of Nrg1 and Erbb4 
on PPI have been carried out in mice, whereas this present study has utilised 
rats.  Although the neuroanatomical systems that underpin PPI are similar in 
mice and rats, there is some evidence that PPI differs between rat and mice 
with 5-HT-1A agonists (Gogos et al., 2008) and D2 receptor agonists (Mohr et al., 
2007) having differing roles between the species.  In further support of the lack 
of effect on PPI in the present study, a recent study reported that although 
polymorphisms in the 5HT2R and COMT genes elicited changes in PPI 
performance, a polymorphism in NRG1 had no effect on PPI levels (Quednow et 
al., 2009).  However, another study did show an effect of NRG1 genotype on PPI 
performance (Hong et al., 2008), albeit this study was investigating a different 
SNP.  This strengthens the idea that the isoform or exon targeted for gene 
manipulation may have a strong impact in the behavioural outcome. 
Although there was no difference in %PPI between both the viral treatment 
groups, the viral groups did have overall a reduced %PPI compared to vehicle 
treated rats.  This suggests that the viral particles themselves had a slight effect 
on PPI, in keeping with the findings that rats treated with viral particles were 
different from vehicle treated rats in terms of locomotor activity (see sections 
5.3.2 and 5.3.3) and response speeds in the 5-CSRTT (section 6.3).  These “off-
target” effects of the viral particles themselves are difficult to explain as the 
majority of other studies using viral particles in conjunction with behavioural 
analysis do not include comparison of data from viral-manipulated rats with 
vehicle treated rats and so therefore these off target effects may actually be 
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routinely occurring.  As the main focus of the present study was to investigate 
the role of Erbb4 on behaviour the effects between viral treatment groups (or 
lack of effect) is the key observation. 
As a final point it is also significant to highlight that the lack of effects seen in 
this study on PPI performance is unlikely due to experimental limitations as the 
values obtained were very similar to that of another study in rats in our 
laboratory where %PPI was altered by a pharmacological challenge (Egerton et 
al., 2008).  Also in concordance with this study %PPI increases with repetition of 
the task, suggesting sensitisation/habituation of the rats to the anxiolytic nature 
of the task.  Moreover, the quality of the experimental set-up is confirmed by 
%PPI values increasing with the increasing amplitude of the pre-pulse.  
Furthermore, this also validates that the hearing of the rats was not impaired by 
the atraumatic earbars that were in place during stereotaxic surgery.   
5.4.2 Erbb4 knockdown has no effect on general locomotor 
activity 
As with PPI, knockdown of Erbb4 specifically within the mPFC did not result in a 
change in response to a novel environment.  Thus there were no differences 
between scrambled hairpin virus treated rats and rats treated with shErbb4 
virus.  All groups of rats appeared to habituate to the novel environment of the 
open field apparatus and this appeared to take around 20 minutes.  The increase 
in distance travelled during the habituation period at week 5 compared to weeks 
1 and 3 may be due to the rats becoming desensitised to the novelty of the open 
field arenas, and therefore less anxious to their surrounding environment, 
resulting in the rats moving more freely around the arena.   
The hypolocomotor state of the vehicle treated group of rats compared to the 
virus treated groups reflects the increase in response speeds observed in the 5-
CSRTT in the virus treated rats (section 6.3).  In general, tissue damage caused 
by injection of the virus would be hypothesised to cause a motor retardation 
rather than an increase in motor activity.  As seen in the PPI task, where 
differences were observed between vehicle and virus treated rats there may be 
some minor off-target effect of the rAAV in general.  Yet again, this may be a 
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common occurrence not revealed in previous studies utilising rAAV by the 
exclusion of “non-virus” behavioural control group.  For example many studies 
have used viral-mediated gene manipulation to target genes involved in 
Parkinson’s disease, with gene manipulation causing a blatant motor deficit 
(measured by lever pressing or open field) however the effect of viral injection 
alone on these measures is not assessed (Hommel et al., 2003).  Moreover, this 
hyperlocomotor effect by viral injection in the present study is not significant at 
individual time points and so is clearly not a gross deficit while the vehicle 
treated rats are still travelling an average of 7.4 meters in the 30 minute 
habituation phase.  Interestingly, Xue and collegues (2009) found an altered 
response to amphetamine in mice injected with rAAV expressing GFP compared 
to saline treated rats.  The authors suggest this was an effect of the viral 
particles themselves, and propose that the GFP expressed from the rAAV may 
have built up within the transduced cells, and led to neurotoxicity (Xue et al., 
2009).   
As with PPI there have been many studies of basal locomotor activity in Erbb4 
and Nrg1 transgenic mouse lines, and akin to the PPI data many of the studies of 
locomotor activity in these mice are contradictory.  Studies of Erbb4 transgenic 
mice have showed locomotor phenotypes of hyperactivity (Stefansson et al., 
2002; Wen et al., 2010), hypoactivity (Golub et al., 2004) and in concordance 
with the present study locomotor activity akin to wildtype controls (Barros et 
al., 2009).  Neuregulin knock-out mice also show a varied response to novelty 
induced locomotor activity with multiple studies showing a hyperactive response 
compared to wildtypes (Gerlai et al., 2000; Stefansson et al., 2002; Karl et al., 
2007; O’Tuathaigh et al., 2007).  However some studies have also shown a motor 
response in Nrg1 knockouts that is not different from wildtypes (Rimer et al., 
2005; Chen et al., 2008; Ehrlichman et al., 2009). Over expression of type I Nrg1 
appears to result in a slight hypolocomotor activity phenotype which is more 
evident in female transgenic mice (Deakin et al., 2009). 
Divergence of the results in this study compared to previous studies again may 
be due to the region specific focus of the manipulation of gene expression in this 
study compared to global gene manipulation, due to the isoforms or ratio of 
heterodimers affected by the gene manipulation. 
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5.4.3 Erbb4 knockdown induces hypersensitivity to amphetamine 
Firstly, the hyperlocomotor behaviour observed in the viral treated rats during 
the habituation phase was carried through to the testing phase to some extent in 
saline injected rats.  This effect was apparent at multiple time points (unlike 
the response to amphetamine which was present only at 5 weeks post-surgery) 
suggesting that this motor effect was not due to gene manipulation.  Moreover 
this general virus vs. vehicle hyperactivity was not observed when the rats were 
injected with amphetamine, this may highlight again that the potential “off 
target” effect of rAAV injection on motor activity is not a gross motor effect as 
under the influence of amphetamine the rats’ motor systems are greatly 
challenged and motor deficits should thus be more apparent under amphetamine 
challenge than with saline. 
The effect of amphetamine increasing locomotor activity was in complete 
agreement with previous studies and pharmacological evidence of amphetamine 
increasing dopamine levels in the synaptic cleft highlighting the soundness of the 
experimental set-up and behavioural analysis.  There was a clear distinction in 
the locomotor response to amphetamine between the shErbb4.rAAV treated rats 
and vehicle and scr.rAAV treated rats at 5 weeks post-surgery, although there 
were no changes in the response to amphetamine between surgical groups at 1 
or 3 weeks post-surgery.  Thus, at 5 weeks post-viral injection there was 
confirmed Erbb4 knockdown and also effects on multiple sites of the Nrg1-Erbb4 
signalling pathway (section 4.3.5), as well as the manifestation of heightened 
locomotor response to amphetamine.  The behavioural response at this time 
point also correlates with the eGFP expression analysis where peak viral 
expression appeared to be somewhere between 3 and 8 weeks post-surgery.  It is 
unclear whether peak knockdown of Erbb4 was also at 5 weeks post-surgery as 
the expression profiling was only carried out at one time point.  However, it is 
also conceivable that the behavioural response occurred following peak Erbb4 
knockdown as it is likely behavioural changes are due to changes in multiple 
aspects of neuronal circuitry which, in all probability, would not be an 
instantaneous occurrence.   
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Hypersensitivity to amphetamine solely in shErbb4.rAAV treated rats suggests 
that Nrg1-Erbb4 signalling within the mPFC is important in regulating the 
cortico-striatal loop functionality and modulating dopaminergic 
neurotransmission.  To my knowledge only one previous study has utilised 
amphetamine challenge in Erbb4 manipulated animals and the results are 
strikingly similar to the present study.  Roy et al. (2007) showed that mice 
expressing a dominant negative form of Erbb4 in oligodendrocytes to eliminate 
Erbb4 function in white matter had a potentiated locomotor response to 
amphetamine.  Furthermore, this study also showed that these mice had 
increased D1-like receptor binding and dopamine transporter levels in multiple 
brain regions including the cortex and have increased evoked dopamine release 
(Roy et al., 2007).  Taking the results of this previous study into consideration 
may suggest that knockdown of Erbb4 in the mPFC may result in similar 
dopaminergic changes.   
In addition, there is evidence to suggest that Nrg1 function is important in 
dopamine regulation specifically in the mPFC, as Nrg1 administration directly 
into this brain region results in a dopaminergic overflow in the mPFC of mice 
(Kato et al., 2010).  Increased Nrg1 expression and decreased Erbb4 expression 
in the mPFC of the rats in this study following shErbb4.rAAV injection may 
therefore have an increased release of dopamine within their mPFC which would 
lead to an increased sensitivity to the locomotor effects of amphetamine, but 
this increased response to amphetamine may also be due to changes in 
dopamine re-uptake, changes in dopamine receptor number, altered dopamine 
transporter function/expression or reduced metabolism of amphetamine itself. 
Although the main region thought to elicit the hyperdopaminergic effect of 
hypersensitivity to amphetamine challenge is the striatum, it has been noted 
that the hyperdopaminergic state of this brain region is most likely caused by 
over activation of glutamatergic tracts of the PFC and hippocampus connecting 
to the mesolimbic pathway (Grace, 1991).  It is therefore plausible that 
manipulation of neurotransmission specifically in the mPFC would be capable of 
affecting the cortico-striatal circuitry resulting in the observed behavioural 
changes. 
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Interestingly, manipulation of genes related to Nrg1-Erbb4 signalling results in 
altered response to amphetamine.  For example, mice with knock-out of genes 
encoding enzymes known to cleave Nrg1 and/or Erbb4 (and therefore aid their 
signalling capabilities) show heightened response to amphetamine (Dejaegere et 
al., 2008).  It is worthy to note, that manipulation of other schizophrenia 
candidate genes results in altered response to amphetamine with viral mediated 
knockdown of Disc1 within the mPFC resulting in hypersensitivity to the 
hyperlocomotor effects of amphetamine.  It has been shown that amphetamine 
challenge dephosphorylates Akt, via increased dopamine signalling through D2 
receptors, enabling Gsk3b activity which is in part responsible for the 
development of the hyperlomotor response (Beaulieu et al., 2004; Beaulieu et 
al., 2005).  Therefore, if as a result of Erbb4 knockdown Akt signalling in the 
mPFC is somewhat already reduced (section 4.3.5) a challenge of amphetamine 
would have an even greater effect on these rats due to further reduced Akt 
activity.  The data of the present study are therefore consistent with Erbb4 
knockdown potentiating the ability of amphetamine to reduce Akt signalling in 
the prefrontal cortex, and this resulting in hyperlocomotion. 
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5.5 Conclusions 
The data in this chapter present multiple interesting findings regarding the role 
Nrg1-Erbb4 signalling in schizophrenia-related behaviours including PPI and 
locomotor activity in response to a novel environment and an amphetamine 
challenge. 
Lack of response of the manipulation of Nrg1-Erbb4 signalling in the mPFC on PPI 
and novelty-induced hyperactivity strengthens the hypothesis that Erbb4 
signalling in the specific brain region of the mPFC does not play a key role in 
these rather general behaviours and instead may be important in modulating 
more cognitive based behaviours.  Although multiple previous studies have 
shown effects of Nrg1-Erbb4 manipulations on PPI and novelty induced 
hyperactivity, the results of this present study further emphasise the need to 
investigate gene functions in specific brain regions and the validity of using viral 
mediated gene manipulation to accomplish this.   
Overall, a key finding of this study was that Erbb4 knockdown specifically within 
the mPFC results in hypersensitivity to amphetamine.  This suggests that, Nrg1-
Erbb4 signalling is important in regulating dopaminergic neurotransmission in the 
cortico-striatal loop.   
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6 Effect of Erbb4 knockdown on performance in 5-
CSRTT 
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6.1 Introduction  
Deficits in prefrontal cortex function are thought to be highly contributory to the 
cognitive deficits of schizophrenia; however the physiological origins of these 
deficits are still unknown.  Initiatives to identify potential therapeutic targets of 
the poorly treated cognitive deficits in schizophrenia are ongoing.  To progress 
pre-clinical translational animal models of cognitive deficits of schizophrenia, 
the cognitive domains that encompass this symptom group have been identified 
and suitable rodent behavioural paradigms recommended (Young et al., 2009).  
Of these the 5-choice serial reaction time task (5-CSRTT) has high validity for 
assessing cognitive modalities dependent on regulated prefrontal cortical 
function.  Other rodent behavioural tasks are known to measure PFC-dependent 
behaviour and have been previously used to assess the effect of mutations in 
schizophrenia candidate genes, such as the attentional set-shifting task to 
measure COMT function (Tunbridge et al., 2004).  However, the 5-CSRTT was the 
most appropriate task to use in the present study due to the large number of 
animals used.  We therefore required a behavioural task that is high throughput 
and automated, such as the 5-CSRTT.  The attentional set-shifting task requires 
manual monitoring of the rats behaviour, resulting in a maximum of 4 rats being 
able to be tested per day. 
Several potential risk genes for schizophrenia have been identified, with the 
NRG1-ERBB4 genes strong candidates.  Their location within the prefrontal 
cortex and expression in neuronal subtypes that regulate neurotransmission 
within this brain region make them attractive molecules to study in terms of 
cognition (sections 1.1.2 and 1.1.4).  However previous animal models of these 
genes have failed to assess prefrontal cortex dependent cognitive behaviours. 
6.1.1 Aspects of cognition assessed by 5-CSRTT 
The 5-CSRTT was originally developed to investigate attentional deficit 
hyperactivity disorder (ADHD) as an assessment of sustained attention in rodents 
(Carli et al., 1983).  This basic form of the 5-CSRTT parallels that of the 
continuous performance task (CPT) which is routinely used in the clinic to assess 
attentional deficits in humans with ADHD or schizophrenia (Rosvold et al., 1956).  
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Although originally developed to quantify sustained attention, the 5-CSRTT 
simultaneously assesses multiple attributes of cognition including: sustained, 
divided and selective attention, impulse control, cognitive flexibility, motivation 
and processing speed (Robbins et al., 2002).  It is well known that many of these 
aspects of cognition measured by the 5-CSRTT are dysfunctional in 
schizophrenia, adding to the validity this task has in serving as a good pre-
clinical assessment of schizophrenia-related cognitions following 
pharmacological, neural or genetic manipulations.  As with the CPT task, the 5-
CSRTT can be modified by altering inter-trial interval or stimulus duration to 
further challenge the sensory and attentional demand on the rodents.   
 
6.1.2 Neural systems involved in 5-CSRTT performance 
The neuroanatomical involvement of brain regions in 5-CSRTT performance has 
been thoroughly assessed (in rats) by lesion studies.  The frontal cortical systems 
are of critical importance to 5-CSRTT performance with excitotoxic lesions of 
the mPFC producing significant deficits in performance of the task including 
increases in perseverative responses and response latencies simultaneous with a 
reduction in accuracy (Muir et al., 1996).  In addition, studies quantifying 
neuronal activity support the importance of cortical areas on 5-CSRTT 
performance, with increased [14C]deoxyglucose uptake correlating with 
increased accuracy in regions of the forebrain (Barbelivien et al., 2001).  
Furthermore, discrete areas of the prefrontal cortex have been shown to have 
distinct roles in 5-CSRTT performance, with lesions of the dorsal mPFC producing 
decreases in accuracy (Passetti et al., 2002; Chudasama et al., 2003), whereas 
lesions of more ventral regions of the mPFC, such as the prelimbic and 
orbitofrontal regions, result in increased perseverative responses (Chudasama & 
Muir, 2001; Passetti et al., 2002).  Concurrent with findings in human CPT 
performance (Cohen et al., 1998), the hippocampus does not appear to have a 
major role in 5-CSRTT performance as bilateral lesions have little effect on 
performance (Kirkby & Higgins, 1998).  The medial striatum however, is thought 
to play a very important role in 5-CSRTT performance with the same disruptions 
in performance observed in rats with bilateral lesions of either mPFC or striatum 
as in rats with a unilateral lesion of the mPFC in one hemisphere and a lesion of 
the medial striatum in the contra-lateral hemisphere (Christakou et al., 2001).  
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Together these data suggest that an intact cortico-striatal system is necessary 
for task performance.   
 
6.1.3 Neurotransmitter systems involved in 5-CSRTT performance 
Pharmacological studies have allowed some elucidation of which 
neurotransmitter systems are involved in aspects of 5-CSRTT performance.  
Studies using the 5-CSRTT have shown involvement of several monoaminergic 
neurotransmitter systems.  The regulation of the dopaminergic system is of great 
importance to 5-CSRTT performance, as dopamine depletion by 6-OHDA lesions 
of the mPFC result in decreased accuracy when the task parameters are 
manipulated to challenge the rats further (Robbins et al., 1998).  Moreover, D1 
receptor activation in the PFC of rats increased accuracy only in rats performing 
sub-optimally (Granon et al., 2000).  As well as the dopaminergic system, the 
noradrenergic system is also vital in 5-CSRTT performance: the noradrenaline re-
uptake inhibitor, atomoxetine, reduces premature responses in the 5-CSRTT in 
rats (Navarra et al., 2008; Robinson et al., 2008) paralleling the improvement in 
attention and impulsivity seen with noradrenaline re-uptake inhibitors in clinical 
studies in patients with ADHD (Chamberlain et al., 2007).  However clinical 
studies in patients with schizophrenia show little effect of atomoxetine on 
cognition (Kelly et al., 2009) or add-on therapies with other noradrenaline re-
uptake inhibitors (Poyurovsky et al., 2010).  However, as atomoxetine stimulates 
the overflow of both dopamine and noradrenaline in PFC it is unclear whether 
the procognitive effects are due to increases in dopamine or noradrenaline 
(Bymaster et al., 2002). 
 
Other drugs which are non-selective for their monoaminergic site of action also 
have effects on 5-CSRTT performance.  For example methylphenidate is a non-
selective dopamine/noradrenaline re-uptake inhibitor which has been previously 
shown to increase accuracy in the 5-CSRTT along with increasing premature 
responding (Paine et al., 2007). Conversely, d-amphetamine, although it induces 
release of monoamines, has an inhibitory effect on 5-CSRTT performance, 
increasing premature and perseverative responses (Cole & Robbins, 1987; 
Paterson et al., 2011).  The multiple action site of this drug including, 
dopamine, 5-HT and noradrenaline make its actions hard to interpret.  The 
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COMT inhibitor tolcapone, which has previously been shown to enhance 
performance in set-shifting thought to be by increased PFC dopamine levels 
(Tunbridge et al., 2004) has no effect in 5-CSRTT performance (Paterson et al., 
2011).   
 
Serotonergic systems also play a central role in 5-CSRTT and are thought to 
mediate key effects on premature responding (Robbins et al., 2002).  However, 
the importance of the PFC in mediating these effects is under enquiry as direct 
infusions of 5-HT receptor antagonists into the infra-limbic or pre-limbic cortex 
had no effect on impulsivity in 5-CSRTT, but infusion of a 5-HT2A antagonist into 
the nucleus accumbens reduced impulsivity (Robinson, et al., 2008).  This may 
explain why newer atypical antipsychotic treatments, which generally have 
affinity for 5-HT receptors as well as dopamine receptors, have had 
disappointing results in alleviating cognitive deficits in schizophrenia.   
 
In line with the opinion that the high rate of smokers among schizophrenia 
patients is for self-medicating purposes, nicotine administration to rats has been 
shown to increase performance in the 5-CSRTT (Young et al., 2004; Pattij et al., 
2007; Semenova et al., 2007).  However, many of these studies have shown that 
the subtle effect of nicotine on accuracy is only detectable after chronic/sub-
chronic nicotine in sub-optimally performing rats or mice in 5-CSRTT paradigms 
where the task parameters were manipulated.  
 
It is important to take into consideration the gross amount of interplay between 
these neurotransmitter types and also interplay between the brain regions that 
appear to be affected by these pharmacological agents.  It is most likely that it 
is a strict control between the levels of all these neurotransmitters that lead to 
optimal performance in the 5-CSRTT.  
 
6.1.4 The effects of genetic manipulation on 5-CSRTT 
performance 
The majority of studies utilising the 5-CSRTT have been to characterise the 
involvement of neuronal networks in attentional functions or to serve as a 
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translational pre-clinical test for drug functions.  However, there have been 
some studies utilising the task to measure cognitive effects of gene manipulation 
allowing further dissection of the function of the gene product. For example 
homozygous knock-out of the serotonin transporter gene Sert in rats results in 
decreased premature responses (Homberg et al., 2007).  These findings support 
the findings of studies showing systemic application of 5-HT antagonists or 5-HT 
re-uptake inhibitors reduce premature responses (Robinson et al., 2008).   
 
To date there have been very limited studies employing the 5-CSRTT to 
investigate the roles of genes related to the cognitive deficits in schizophrenia.  
This is probably due to genetic manipulations being mainly carried out in mice, 
and although the 5-CSRTT is suitable for mice (albeit slightly modified from the 
rat version, Humby et al., 2005) the majority of groups routinely using 5-CSRTT 
assess rats only.  However, with the recent commercialisation of genetically 
modified rats, this lack of studies will undoubtedly change within the near 
future.  Interestingly, with respect to schizophrenia, transgenic mice lacking the 
-7 nicotinic acetylcholine receptor show deficits in the 5-CSRTT task (Young et 
al., 2004; Hoyle et al., 2006; Young et al., 2007).  Furthermore, there has been 
a huge amount of interest in recent years in -7 nicotinic acetylcholine receptor 
agonists as cognitive enhancers.  For example, the drug DMXBA has shown some 
promising procognitive effects in the 5-CSRTT.  However, when the drug was 
taken forward to clinical trials there have been problems with side-effects and 
desensitisation (see review by Thomsen et al., 2010).    
 
To my knowledge there have been no studies of 5-CSRTT performance in mice 
with genetic modifications of the most popular schizophrenia candidate genes 
such as Disc1, Nrg1 and Comt.  This is most likely due to the necessity of specific 
equipment to perform the task and also because the training and testing 
schedule is somewhat long compared to other behavioural tests. 
 
Given the localisation of Nrg1 and Erbb4 in the prefrontal cortex, previous 
studies showing regulation of several neurotransmitter systems that are involved 
in optimal 5-CSRTT performance and evidence from schizophrenia patients 
identifying variants in these genes lead to impaired cognitive ability, it is 
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reasonable to propose that knockdown of Erbb4 in the rat prefrontal cortex will 
elicit measurable changes in cognition as assessed by the 5-CSRTT.  
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6.2 Aims 
The aim of this study was to test the hypothesis that viral mediated gene 
manipulation of Erbb4, specifically within the mPFC, would affect performance 
in the 5-CSRTT in adult rats, thereby determining if Erbb4 within this distinct 
brain region is important in cognitive functions known to be dysfunctional in 
schizophrenia.  In addition, the effect of manipulating test parameters was 
investigated with the aim to explore if any changes in 5-CSRTT performance 
following Erbb4 knockdown were present in conditions of increased inhibitory or 
cognitive load.   
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6.3 Results 
6.3.1 Baseline performance of rats in three variations of the 5-
Choice Serial Reaction Time Task   
Prior to surgery, the rats were habituated to the 5-CSRTT (section 2.7.2), then 
trained in the task under basic parameters until the rats perform at a criterion 
of at least 80% accuracy with less than 20% omissions at a stimulus duration and 
inter-trial interval of 0.6 seconds and 5 seconds, respectively (section 2.7.3).  
The baseline performance of the rats in three variations of the 5-CSRTT was 
assessed (n=35; one rat failed to meet criteria above training level 9 and so was 
discarded from the study). The performance of the rats was investigated in the 
basic task, the vITI task and the vSD task where attentional load is increased 
(section 2.7.4).  Baseline performance in the 5-CSRTT was performed prior to 
surgery to ensure that when the rats were split into surgical groups, each group 
was performing to an equal level, therefore any post-surgical effects would be 
due to the agent injected during surgery.  In addition, baseline testing was 
performed to confirm that manipulating the task parameters of the 5-CSRTT 
resulted in an alteration in the rats behaviour, reflective of the challenge in 
cognition. 
 
Percentage accuracy in the basic task remained at a stable level of performance 
from the previous training level at 79.5% ±3.6%. As predicted, percentage 
accuracy was overall significantly affected by manipulating task parameters (F 
(2,104) =20.33, p<0.001). Tukey’s post hoc analysis revealed that percentage 
accuracy was significantly reduced in the vITI task (p<0.05) and the vSD task 
(p<0.001) compared to the basic task (Figure 6.1A).  Further analysis of these 
tasks showed that individual inter-trial interval duration was not responsible for 
the drop in percentage accuracy in the vITI task (F (3,139)=0.99, p>0.05, Figure 
6.1B)  Conversely, the duration of stimulus was very significantly associated with 
a decrease in percentage accuracy observed in the vSD task (F (3,139)=42.25, 
p<0.001), with post hoc analysis showing that this reduction in percentage 
accuracy was mainly attributable to stimulus durations of 0.1 and 0.2 seconds 
(Figure 6.1C). 
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In addition to percentage accuracy, percentage omissions and the number of 
premature responses were significantly affected by altering task type ((F (2, 
104) =25.22, p<0.001) and (F (2, 104) =391.44, p<0.001) respectively) (Figures 
6.2A and 6.3A).  Percentage omissions was essentially doubled in the vITI task 
compared to the basic task and vSD task types (p<0.001) where the level of 
omissions was very low at around 7%. More in depth analysis by individual Mann-
Whitney tests of each ITI of the vITI manipulation confirmed this significant 
increase in omissions was a result of increasing inter-trial interval to 10 seconds 
or more (Figure 6.2B).  The number of premature responses was also 
significantly increased with increasing inter-trial duration (Figure 6.3B). 
 
Despite task type initiating  predicted changes in other parameters measured in 
the 5-choice serial reaction time task, task type had no effect on latency to 
correct response  (F (2,104)=0.07, p>0.05) or latency to collect reward (F 
(2,104)=2.65, p>0.05)  (Figures 6.4A and 6.4B).   
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Figure 6.1 Effects of manipulation of stimulus duration and inter-trial interval 
duration upon percentage accuracy in the 5-CSRTT.  Figure A illustrates the 
effects of task type on percentage accuracy in rats prior to surgery.  vITI and vSD 
data represents cumulative percentage accuracy values of all ITI and SD 
durations.  Varying ITI or stimulus duration decreased percentage accuracy.   
Figure B illustrates the effect of increasing inter-trial interval duration from 5 
seconds to 7, 10 and 12 seconds on percentage accuracy.  Increasing ITI duration 
did not alter percentage accuracy.  Figure C illustrates the effect of decreasing 
stimulus duration from 0.5 seconds to 0.4, 0.2 and 0.1 seconds on percentage 
accuracy.  As predicted, decreasing stimulus duration below 0.4 seconds 
decreased percentage accuracy.  Data represent mean ± SE (n=35) analysed 
using one-way ANOVA followed by Tukey’s post hoc test for multiple comparisons.  
*p<0.05, ***p<0.001 between task types indicated.  # p<0.001 vs. 0.1s SD, 
@p<0.001 vs. 0.2s SD.  ITI= inter-trial interval, SD= stimulus duration 
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Figure 6.2 Effects of manipulation of stimulus duration and inter-trial interval 
duration upon percentage omissions in the 5-CSRTT.  Figure A illustrates the 
effects of task type on percentage omissions in rats prior to surgery, as predicted 
varying ITI duration increased percentage omissions.  Figure B illustrates the 
effect of increasing inter-trial interval duration from 5 seconds to 7, 10 and 12 
seconds on percentage omissions, increasing ITI duration above 7seconds 
increased percentage omissions.  Data represent mean ± SE (n=35).  *** p<0.001 
vs. Basic or vSD task types analysed using one-way ANOVA followed by Tukey’s 
post hoc test for multiple comparisons. * p<0.05 vs. 5s ITI **p<0.01 vs. 7s ITI 
analysed using Mann-Whitney non-parametric U tests.  vITI=variable inter-trial 
interval, vSD=variable stimulus duration. 
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Figure 6.3 Effects of manipulation of stimulus duration and inter-trial interval 
duration upon the number of premature responses in the 5-CSRTT.  Figure A 
illustrates the effects of task type on premature responding in rats prior to surgery.  
As predicted varying ITI duration increased premature responding.  Figure B 
illustrates the effect of increasing inter-trial interval duration from 5 seconds to 7, 
10 and 12 seconds on the number of premature responses.  The number of 
premature responses increased with longer ITI durations.  Data represent mean ± 
SE (n=35).  *** p<0.001 vs. Basic or vSD task types analysed using one-way 
ANOVA followed by Tukey’s post hoc test for multiple comparisons.  $ p<0.001 vs. 
5s ITI, ^ p<0.001 vs. 7s ITI, # p<0.001 vs. 10s ITI, @ p<0.001 vs. 12s ITI using 
Mann-Whitney non-parametric U tests.  vITI=variable inter-trial interval, 
vSD=variable stimulus duration 
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Figure 6.4 Effects of manipulation of stimulus duration and inter-trial interval 
duration upon latencies in the 5-CSRTT.  Figure A illustrates the effects of task 
type on latency to correct response in rats prior to surgery.  Varying ITI or SD did 
not affect the latency to correct response.  Figure B illustrates the effects of task 
type on latency to collect reward following correct response in rats prior to surgery.  
Varying ITI or SD did not affect the latency to collect reward.  Data represent mean 
± SE (n=35). 
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6.3.2 Post-surgical testing in the basic 5-CSRTT performance   
Based on baseline performance in the basic, vITI and vSD task the rats were split 
into three equally performing groups (section 2.7.4).  Stereotaxic surgery was 
then carried out on the rats, with bilateral injections of either vehicle, rAAV 
encoding a scrambled hairpin sequence (scr.rAAV) or rAAV encoding a short 
hairpin sequence corresponding to rat Erbb4 into the rat mPFC (section2.4.2). 
One, three and five weeks post-surgery the rats’ performance in the basic 5-
CSRTT was assessed (section 2.7.5).  Five variables were analysed: percentage 
accuracy, percentage omissions, the number of premature responses, latency to 
collect reward and latency to make a correct response.  Two rats died during 
surgery reducing group sizes to vehicle n=10, scr.rAAV n=12, shErbb4.rAAV n=11.   
 
In the basic task the main effect of Erbb4 knockdown was apparent at 5 weeks 
post-surgery where rats with Erbb4 knockdown within the PFC performed at a 
higher percentage accuracy that scr.rAAV treated rats (p<0.05)(Figure 6.5).  
Importantly, percentage accuracy was equal between surgical groups at baseline 
level (pre-surgery) (F (2, 32) =0.03, p>0.05) (Figure 6.5A) permitting the 
interpretation that any changes in this parameter after surgery were due to the 
type of agent injected.  Surgical group had a significant effect on percentage 
accuracy overall (F (2, 131) =4.26), p<0.05).  Following a two-way ANOVA the 
post hoc Tukey’s analysis indicated a significant difference in the performance 
of scr.rAAV treated rats and shErbb4.rAAV treated rats (p=0.01).   
 
There was also a significant effect of week on percentage accuracy (F (3,131) 
=3.21, p<0.05) with percentage accuracy dropping slightly at 1 week post-
surgery compared to the baseline performance (p=0.066) and being significantly 
higher at week 5 compared to week 1 (p<0.05).   
 
Subsequent to this analysis the percentage accuracy relative to the rats’ 
baseline performance was carried out to analyse whether the change in 
percentage accuracy post-surgery was significantly different between surgical 
groups.  Similar to the previous analysis, surgical group had a significant effect 
on relative percentage accuracy (F (2, 98) =9.23), p<0.001) this time with the 
performance of rats that had received virus expressing shErbb4 being 
significantly different from scrambled hairpin virus treated rats (p<0.001) and 
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also vehicle treated rats (p<0.01)  Furthermore, post hoc comparisons 
strengthened the previous finding at 5 weeks post-surgery with rats with Erbb4 
knockdown within the PFC performing the basic task with higher accuracy than 
scrambled virus treated rats (p=0.0025) (Figure 6.6). 
 
As with percentage accuracy, in the basic task percentage omissions, number of 
premature responses, latency to reward and latency to correct response were 
also equal between groups at baseline (Figures 6.7A, 6.8A, 6.9A and 6.10A).  
Compared to baseline, percentage omissions were significantly increased in all 
surgical groups at one week post-surgery (p<0.001).  This level of omissions 
returned back to baseline level, with omissions at weeks 3 and 5 not being 
significantly different from baseline but significantly lower than at week 1.  This 
pattern is reflected by a significant effect of week on percentage omissions (F 
(3, 131) =10.58, p<0.001).  In addition, surgical group had a significant effect on 
percentage omissions (F (2, 131) =8.96, p<0.001) with rats treated with scr.rAAV 
performing significantly more omissions over all weeks than vehicle treated rats 
(p<0.01) and rats with Erbb4 knockdown (p<0.001).  These significant differences 
between surgical groups are reflected by a significant interaction between 
surgical group and week at 3 weeks where scr.rAAV treated rats performed 
significantly more omissions that shErbb4.rAAV treated rats.  At 5 weeks this 
effect was no longer apparent but scr.rAAV treated rats performed significantly 
more omissions than vehicle treated rats at this time point.   
 
Akin to percentage omissions and percentage accuracy, surgical group did have a 
significant effect on the number of premature responses (F (2, 131) =3.52, 
p<0.05) with shErbb4 virus treated rats performing a significantly different 
amount of premature responses over all weeks than vehicle treated rats 
(p<0.05).  Again there was also a significant effect of week on this parameter (F 
(3, 131) =3.90, p=0.01) with week three approaching significance compared to 
week one (p=0.059).  This effect was a consequence of vehicle treated rats 
performing significantly fewer premature responses than scrambled hairpin 
virus-treated rats at week 3 (p<0.05) (Figure 6.8).   
 
Latency to reward was significantly affected by surgical group (F (2, 131) =3.58, 
p<0.05), with rats with Erbb4 knockdown retrieving rewards faster than vehicle 
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treated rats.  This effect was a general observation with no significant effect of 
week (F (3. 131) =2.27, p>0.05) or surgical group x week interactions (Figure 
6.9).  Analysis of latency to correct response showed some results paralleling 
these of latency to reward, with there being no significant effect of week (F (2, 
131) =1.18, p>0.05) or surgical group x week interactions.  There was however a 
significant effect of surgical group on this parameter ((F (2, 131) =7.81, p<0.001) 
with scr.rAAV treated rats being slower to make a correct response than the 
vehicle treated rats (p<0.001) (Figure 6.10). 
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Figure 6.5 Effect of viral mediated gene manipulation on percentage 
accuracy in basic 5-CSRTT.  Rats were split into three surgical groups based on 
baseline percentage accuracy performance (A) then received bilateral injections of 
vehicle (veh) (n=10), scr.rAAV (scr) (n=12) or shErbb4.rAAV (shErbb4) (n=11) into 
the mPFC.  Percentage accuracy was assessed in these rats at 1, 3 and 5 weeks 
post-surgery (B-D).  Data represent mean ± SE (n=10-12).  * p<0.05 analysed 
using two-way repeated measures ANOVA followed by Tukey’s post hoc test for 
multiple comparisons.  Two-way ANOVA showed main effects of surgical group on 
percentage accuracy (p<0.05) with shErbb4.rAAV treated rats performing over all 
significantly higher percentage accuracy than scr.rAAV treated rats (p<0.01).  A 
main effect of week was also found (p<0.05) with percentage accuracy being 
significantly lower at 1 week post-surgery than 5 weeks post-surgery (p<0.05).  
Post hoc analysis revealed that at 5 weeks post-surgery shErbb4.rAAV treated 
rats performed more accurately than scr.rAAV treated rats (p<0.05). 
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Figure 6.6 Effect of viral mediated gene manipulation on percentage 
accuracy relative to performance at baseline in basic 5-CSRTT.  percentage 
accuracy was determined relative to baseline performance at 1, 3 and 5 weeks 
following bilateral injections of vehicle (veh) (n=10), scr.rAAV (scr) (n=12) or 
shErbb4.rAAV (shErbb4) (n=11) into the mPFC.  ** p<0.01 between surgical 
groups analysed using two-way repeated measures ANOVA followed by Tukey’s 
post hoc test for multiple comparisons. Two-way repeated measures ANOVA 
found main effect  of surgical group on percentage accuracy with  shErbb4.rAAV 
treated rats performing more accurately than scr.rAAV (p<0.001) and vehicle 
treated rats (p<0.01).  Post hoc comparisons revealed at 5 weeks post-surgery 
shErbb4.rAAV treated rats performed with increased percentage accuracy than 
scr.rAAV treated rats (p<0.01). 
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Figure 6.7 Effect of viral mediated gene manipulation on percentage 
omissions in basic 5-CSRTT.  Rats were split into three surgical groups based 
on baseline percentage omissions (A) then received bilateral injections of vehicle 
(veh) (n=10), scr.rAAV (scr) (n=12) or shErbb4.rAAV (shErbb4) (n=11) into the 
mPFC.  Percentage omissions were assessed in these rats at 1, 3 and 5 weeks 
post-surgery (B-D).  Data represent mean ± SE (n=10-12).  * p<0.05, ***p<0.001 
analysed using two-way repeated measures ANOVA followed by Tukey’s post hoc 
test for multiple comparisons.  Two-way ANOVA showed an over all effect of 
surgical group on percentage omissions with rats treated with scr.rAAV performing 
significantly more omissions than vehicle (p<0.01) or shErbb4.rAAV (p<0.001) 
treated rats.  There was also an over all effect of week on percentage omissions 
with significantly higher omissions performed at 1 week post-surgery compared to 
all other time points.  Post hoc comparisons revealed scr.rAAV treated rats 
performed significantly more omissions than shErbb4.rAAV treated rats at 3 weeks 
post-surgery (p<0.001), and vehicle treated rats at 5 weeks post-surgery (p<0.05). 
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Figure 6.8 Effect of viral-mediated gene manipulation on the number of 
premature responses in the basic 5-CSRTT.  Rats were split into three surgical 
groups based on baseline premature responding (A) then received bilateral 
injections of vehicle (veh) (n=10), scr.rAAV (scr) (n=12) or shErbb4.rAAV 
(shErbb4) (n=11) into the mPFC.  The number of premature responses was 
assessed in these rats at 1, 3 and 5 weeks post-surgery (B-D).  Data represent 
mean ± SE (n=10-12).  * p<0.05, analysed using two-way repeated measures 
ANOVA followed by Tukey’s post hoc test for multiple comparisons.  Two-way 
ANOVA showed an over all effect of surgical group on premature responding with 
shErbb4.rAAV treated rats performing significantly more premature responses 
than vehicle treated rats overall (p<0.05).  Post hoc comparisons revealed that 
scr.rAAV treated rats performed more premature responses than vehicle treated 
rats at 3 weeks post-surgery (p<0.05). 
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Figure 6.9 Effect of viral-mediated gene manipulation on latency to collect 
reward in the basic 5-CSRTT.  Rats were split into three surgical groups based 
on baseline reward latency (A) then received bilateral injections of vehicle (veh) 
(n=10), scr.rAAV (scr) (n=12) or shErbb4.rAAV (shErbb4) (n=11) into the mPFC.  
Latency to reward was assessed in these rats at 1, 3 and 5 weeks post-surgery 
(B-D).  Data represent mean ± SE (n=10-12).  Data were analysed using two-way 
repeated measures ANOVA followed by Tukey’s post hoc test for multiple 
comparisons.  Two-way ANOVA showed an over all effect of surgical group on 
reward latency with shErbb4.rAAV treated rats having significantly lower latencies 
to collect reward than vehicle treated rats (p<0.05). 
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Figure 6.10 Effect of viral-mediated gene manipulation on latency to correct 
response in the basic 5-CSRTT.  Rats were split into three surgical groups 
based on baseline response latency (A) then received bilateral injections of vehicle 
(veh) (n=10), scr.rAAV (scr) (n=12) or shErbb4.rAAV (shErbb4) (n=11) into the 
mPFC.  Latency to correct response was assessed in these rats at 1, 3 and 5 
weeks post-surgery (B-D).  Data represent mean ± SE (n=10-12).  Data were 
analysed using two-way repeated measures ANOVA followed by Tukey’s post hoc 
test multiple comparisons.  Two-way ANOVA showed a significant effect of 
surgical group on latency to response with scr.rAAV treated rats having an overall 
significantly higher latency to make a correct response than vehicle treated rats 
(p<0.001).   
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6.3.3  Effect of Erbb4 knockdown on performance in vITI task 
To assess if viral-mediated gene knockdown of Erbb4 within the mPFC affected 
the performance of rats in a manipulated form of the 5-CSRTT, where the inter-
trial interval is made variable, rats who had undergone stereotaxic injection of 
vehicle, scr.rAAV or shErbb4.rAAV (2.4.2) were tested in the vITI version of the 
5-CSRTT 1, 3 and 5 weeks post-surgery (2.7.5). 
 
Rats in all three surgical groups performed at equal percentage accuracy in the 
vITI task at baseline (F (2, 32) =0.05, p>0.05) (Figure 6.11A) and this level of 
accuracy did not change significantly between groups at any time point post-
surgery with no significant effect of surgical group (F (2, 131) =0.43, p>0.05) or 
week (F (3,131) =0.51, p>0.05) on percentage accuracy (Figure 6.11 B-D).  
Similarly, there was no effect of surgical group (F (3, 131) =2.66, p>0.05) or 
week (F (3, 131) =0.16, p>0.05) on percentage omissions in the vITI task (Figure 
6.12).  Number of premature responses in the vITI task was not affected by 
surgical group (F (2, 131)=1.33, p>0.05), however, there was a highly significant 
effect of week on premature responding (F (3, 131)=5.39,p<0.01) with post hoc 
comparisons indicating this effect was a result of significantly less premature 
responses being performed at 3 weeks (p<0.01) and 5 weeks (p<0.01) post-
surgery compared to the number of premature responses made prior to surgery 
(Figure 6.13).   
 
Comparable to the basic task, mean latency to reward was significantly affected 
by surgical group in the vITI task (F (2,131) =14.63, p<0.001) again with 
shErbb4.rAAV treated rats being overall significantly quicker to collect reward 
following a correct response than vehicle treated rats (p<0.001) (Figure 6.14).  
In addition, in the vITI task scr.rAAV treated rats also had a significantly lower 
mean latency to reward than vehicle treated rats (p<0.001).  These effects were 
a general observation with no significant interaction between surgical group and 
week being identified.  Furthermore, there was no significant effect of week on 
mean latency to reward (F (3, 131) =0.75,>0.05) (Figure 6.14).  Mean latency to 
correct response was not significantly affected by surgical group (F (2,131) 
=0.19, p>0.05) or week (F (3,131) =0.71, 0>0.05) in the vITI task (Figure 6.15).   
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Figure 6.11 Effect of viral-mediated gene manipulation on percentage 
accuracy in the vITI task.  Rats were split into three surgical groups based on 
baseline percentage accuracy (A) then received bilateral injections of vehicle (veh) 
(n=10), scr.rAAV (scr) (n=12) or shErbb4.rAAV (shErbb4) (n=11) into the mPFC.  
Percentage accuracy was assessed in these rats at 1, 3 and 5 weeks post-surgery 
(B-D).  Data represent mean ± SE of the total percentage accuracy from trials with 
inter-trial intervals of 5, 7, 10 and 12 seconds (n=10-12).  Two-way ANOVA 
showed there was no effect of surgical group or week on percentage accuracy. 
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Figure 6.12 Effect of viral-mediated gene manipulation on percentage 
omissions in the vITI task.  Rats were split into three surgical groups based on 
baseline percentage omissions (A) then received bilateral injections of vehicle 
(veh) (n=10), scr.rAAV (scr) (n=12) or shErbb4.rAAV (shErbb4) (n=11) into the 
mPFC.  Percentage omissions were assessed in these rats at 1, 3 and 5 weeks 
post-surgery (B-D).  Data represent mean ± SE of the total percentage omissions 
from trials with inter-trial intervals of 5, 7, 10 and 12 seconds (n=10-12).  Two-way 
ANOVA showed there was no significant effect of surgical type or week on 
percentage omissions. 
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Figure 6.13 Effect of viral-mediated gene manipulation on the number of 
premature responses in the vITI task.  Rats were split into three surgical groups 
based on baseline premature responding (A) then received bilateral injections of 
vehicle (veh) (n=10), scr.rAAV (scr) (n=12) or shErbb4.rAAV (shErbb4) (n=11) into 
the mPFC. The number of premature responses were assessed in these rats at 1, 
3 and 5 weeks post-surgery (B-D).  Data represent mean ± SE of the total number 
of premature responses from trials with inter-trial intervals of 5, 7, 10 and 12 
seconds (n=10-12).  Two-way ANOVA showed the number of premature 
responses was not affected by surgical group, however, there was an overall 
effect of week on this parameter with more premature responses being made over 
all surgical groups at baseline compared to 3 (p<0.01) and 5 (p<0.01) weeks post-
surgery 
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Figure 6.14 Effect of viral-mediated gene manipulation on latency to reward 
in the vITI task.  Rats were split into three surgical groups based on baseline 
latency to reward (A) then received bilateral injections of vehicle (veh) (n=10), 
scr.rAAV (scr) (n=12) or shErbb4.rAAV (shErbb4) (n=11) into the mPFC. Mean 
reward latency was assessed in these rats at 1, 3 and 5 weeks post-surgery (B-D).  
Data represent mean ± SE of the total mean reward latency from trials with inter-
trial intervals of 5, 7, 10 and 12 seconds (n=10-12).  Data were analysed using 
two-way repeated measures ANOVA followed by Tukey’s post hoc test for multiple 
comparisons.  Two-way ANOVA showed an overall effect of surgical group on 
latency to reward with vehicle treated rats having an overall significantly higher 
latency to collect reward than scr.rAAV (p<0.001) and shErbb4.rAAV treated rats 
(p<0.001). 
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Figure 6.15 Effect of viral-mediated gene manipulation on latency to correct 
response in the vITI task.  Rats were split into three surgical groups based on 
baseline response latency (A) then received bilateral injections of vehicle (veh) 
(n=10), scr.rAAV (scr) (n=12) or shErbb4.rAAV (shErbb4) (n=11) into the mPFC.  
Mean latency to correct response was assessed in these rats at 1, 3 and 5 weeks 
post-surgery (B-D).  Data represent mean ± SE of the total mean response latency 
from trials with inter-trial intervals of 5, 7, 10 and 12 seconds (n=10-12).  Two-way 
ANOVA showed there was no effect of surgical group or week on latency to 
correct response. 
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6.3.4 Effect of Erbb4 knockdown on performance in the vSD task 
To assess if viral-mediated gene knockdown of Erbb4 within the mPFC affected 
the performance of rats in a manipulated form of the 5-CSRTT, where the 
stimulus duration is made variable, rats who had undergone stereotaxic injection 
of vehicle, scr.rAAV or shErbb4.rAAV (2.4.2) were tested in the vSD version of 
the 5-CSRTT 1, 3 and 5 weeks post-surgery (2.7.5). 
 
At baseline each group of rats were performing at an approximately equal level 
of 67% accuracy in the vSD task (Figure 6.16A).  Two-way repeated measures 
ANOVA revealed there was no significant effect of surgical group (F (2, 131) = 
0.71, p>0.05) or week (F (3, 131) = 1.95, p>0.05) on percentage accuracy in the 
vSD task.  Convergent with baseline data, this level of percentage accuracy 
achieved in the vSD task was mainly due to poor performance at stimulus 
durations of 0.1 and 0.2 seconds at all time points where three way repeated 
measures ANOVA showed that although there was no significant effect of 
treatment or week on percentage accuracy, stimulus duration was highly 
significant (F (3,527) = 200.89, p<0.001).  
 
There was an overall significant effect of surgical group on percentage omissions 
(F (2,131) = 5.63, p<0.01) in the vSD task with vehicle treated rats performing 
significantly differently from scrambled hairpin virus treated rats (p<0.01).  
There were no significant week by surgical group interaction however, there was 
a significant effect of week on percentage omissions (F (3, 131) = 5.19, p<0.01).  
Post hoc comparisons revealed this was due to more percentage omissions 
occurring in week three than at baseline (p<0.001) (Figure 6.17).    
 
Similar to premature responding in the vITI task, the number of premature 
responses was significantly lower at week 3 (p<0.01) and week 5 (p<0.01) 
compared to baseline levels in the vSD task.  This contributed to “week” having 
a statistically significant effect on the number of premature responses (F (3,131) 
=5.99, p<0.001).  Surgical group had no effect on the number of premature 
responses performed (Figure 6.18) in the vSD task.  Surgical group did however 
have an effect on mean latency to reward (F (2,131)=5.86, p<0.01) with post hoc 
analysis identifying that, identically to the results of the vITI task, vehicle 
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treated rats were significantly slower to collect rewards after making a correct 
response compared to scr.rAAV (p<0.05) and shErbb4.rAAV (p<0.01) treated rats.  
There were no significant surgical group by week interactions and week itself did 
not have a significant effect on mean latency to reward in the vSD task (F 
(3,131) =1.09, p>0.05) (Figure 6.19).   
 
Unfortunately, despite best efforts of equally splitting the rats into three 
groups, at baseline mean latency to correct response was not equal between 
surgical groups prior to surgery (F (2, 32) = 4.60, p<0.05) (Figure 6.20).  
Therefore, further analysis of this data was performed as mean latency to 
reward expressed as relative to baseline performance.  Interestingly, very 
similar results to latency to reward were found with a significant effect of 
surgical group (F (2, 98) = 6.92, p<0.01).  Subsequent post hoc comparisons 
showed that, as with reward latency, vehicle treated rats correctly responded at 
a significantly slower speed than rats that received scrambled virus (p<0.01) and 
rats that received virus expressing shErbb4 (p<0.01).  In addition no effect of 
week on this parameter was found (F (2, 98) =0.02, p>0.05) (Figure 6.21). 
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Figure 6.16 Effect of viral-mediated gene manipulation on percentage 
accuracy in the vSD task.  Rats were split into three surgical groups based on 
baseline percentage accuracy (A) then received bilateral injections of vehicle (veh) 
(n=10), scr.rAAV (scr) (n=12) or shErbb4.rAAV (shErbb4) (n=11) into the mPFC.  
Percentage accuracy was assessed in these rats at 1, 3 and 5 weeks post-surgery 
(B-D).  Data represent mean ± SE of the total percentage accuracy from trials with 
stimulus durations of 0.1, 0.2, 0.4 and 0.5 seconds (n=10-12).  Two-way ANOVA 
showed percentage accuracy was not affected by surgical group or week in the 
vSD task. 
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Figure 6.17 Effect of viral-mediated gene manipulation on percentage 
omissions in the vSD task.  Rats were split into three surgical groups based on 
baseline percentage omissions (A) then received bilateral injections of vehicle 
(veh) (n=10), scr.rAAV (scr) (n=12) or shErbb4.rAAV (shErbb4) (n=11) into the 
mPFC.  Percentage omissions were assessed in these rats at 1, 3 and 5 weeks 
post-surgery (B-D).  Data represent mean ± SE of the total percentage omissions 
from trials with stimulus durations of 0.1, 0.2, 0.4 and 0.5 seconds.  Data were 
analysed using two-way repeated measures ANOVA followed by Tukey’s post hoc 
test for multiple comparisons.  Two-way ANOVA showed a significant overall effect 
of surgical group on percentage omissions in the vSD task with scr.rAAV treated 
rats performing more omissions than vehicle treated rats (p<0.01).  There was also 
an over all effect of week on percentage omissions with significantly more 
omissions being made over all surgical groups at 3 weeks post-surgery compared 
to baseline (p<0.001). 
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Figure 6.18 Effect of viral-mediated gene manipulation on the number of 
premature response in the vSD task.  Rats were split into three surgical groups 
based on baseline premature responding (A) then received bilateral injections of 
vehicle (veh) (n=10), scr.rAAV (scr) (n=12) or shErbb4.rAAV (shErbb4) (n=11) into 
the mPFC.  The number of premature responses were assessed in these rats at 1, 
3 and 5 weeks post-surgery (B-D).  Data represent mean ± SE of the total number 
of premature responses from trials with stimulus durations of 0.1, 0.2, 0.4 and 0.5 
seconds.  Two-way ANOVA showed premature responding was not affected by 
surgical group, however there was a significant effect of week on premature 
responses with less premature responses being made at 3 (p<0.01) and 5 
(p<0.01) weeks post-surgery compared to baseline. 
217 
 
 
218 
Figure 6.19 Effect of viral-mediated gene manipulation on mean latency to 
reward in the vSD task.  Rats were split into three surgical groups based on 
baseline reward latency (A) then received bilateral injections of vehicle (veh) 
(n=10), scr.rAAV (scr) (n=12) or shErbb4.rAAV (shErbb4) (n=11) into the mPFC.  
Mean reward latency was assessed in these rats at 1, 3 and 5 weeks post-surgery 
(B-D).  Data represent mean ± SE of the total mean latency to response from trials 
with stimulus durations of 0.1, 0.2, 0.4 and 0.5 seconds.  Data were analysed 
using two-way repeated measures ANOVA followed by Tukey’s post hoc test for 
multiple comparisons.  Two-way ANOVA showd an overall effect of surgical group 
on reward latency in the vSD task with vehicle treated rats having significantly 
higher latencies to collect reward than scr.rAAV (p<0.05) and shErbb4.rAAV 
(p<0.01) treated rats. 
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Figure 6.20 Baseline mean latency to correct response in the vITI task.  
Baseline mean latency to correct response in rats prior to surgical procedure of 
bilateral injections of vehicle (veh) (n=10), scr.rAAV (scr) (n=12) or shErbb4.rAAV 
(shErbb4) (n=11).  Data represent mean ± SE of the total mean latency to 
response from trials with stimulus durations of 0.1, 0.2, 0.4 and 0.5 seconds.  
Scr.rAAV and shErbb4 treated rats had significantly higher latency to correct 
response than vehicle treated rats at baseline.  * p<0.05, analysed using one-way 
ANOVA followed by Tukey’s post hoc test for multiple comparisons. 
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Figure 6.21 Effect of viral-mediated gene manipulation on mean latency to 
correct response in the vSD task relative to baseline mean latency to reward 
performance.  Rats were split into three surgical groups then received bilateral 
injections of vehicle (veh) (n=10), scr.rAAV (scr) (n=12) or shErbb4.rAAV 
(shErbb4) (n=11) into the mPFC.  Mean response latency was assessed in these 
rats at 1, 3 and 5 weeks post-surgery.  Data represent mean ± SE of the total 
mean latency to response relative to baseline from trials with stimulus durations of 
0.1, 0.2, 0.4 and 0.5 seconds, analysed using two-way repeated measures 
ANOVA followed by Tukey’s post hoc test for multiple comparisons.  Two-way 
ANOVA showed a significant effect of surgical group on respinse latency with 
scr.rAAV (p<0.01) and shErbb4.rAAV (p<0.01) treated rats having significantly 
lower latencies to correct response compared to vehicle treated rats. 
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6.4 Discussion 
6.4.1 Manipulation of 5-CSRTT parameters alters behaviour 
The present results show that altering the parameters of stimulus duration and 
inter-trial interval duration had the profound predicted effects on many 
measurements of the 5-CSRTT.  This further highlights the validity of the task in 
a pre-clinical model of cognition as it known that when parameters of the CPT in 
humans are altered the performance is significantly affected (Elvevåg et al., 
2000). 
 
Manipulation of stimulus duration 
Percentage accuracy was decreased by an average of 12% in the vSD task 
compared to the basic task, and this was undoubtedly due to changes in the 
stimulus duration; this is in agreement with Bari et al., (2008). Moreover the 
trend seen for decreasing percentage accuracy with stimulus duration has been 
previously reported (Hille et al., 2008) and supports the notion that reducing the 
stimulus duration further challenges the rats’ cognitive ability by increasing the 
need for sustained attention.  As this change in percentage accuracy was the 
only change in the rats’ behaviour following reduction of the stimulus duration, 
the vSD task appears to be a good model system for assessing the specific effect 
of genetic manipulations/pharmacological agents on percentage accuracy. 
 
Manipulation of inter –trial interval 
The number of premature responses were hugely affected by increasing ITI 
duration, in agreement with Bari et al., (2008), and this increase was highly 
correlated with increased ITI duration.  This has been previously reported 
(Navarra et al., 2008; Paterson et al., 2011) and is a clear indication of 
increased impulsivity.  Percentage accuracy was also significantly reduced when 
the inter-trial interval was made variable.  However, this decrease in accuracy 
was a relatively small decrease with an average of 4.6% decrease, in comparison 
to the change in accuracy observed in the vSD task.  Furthermore, the fact that 
percentage accuracy was not significantly associated with increased ITI duration 
suggests that the drop in percentage accuracy was not due to the rats having to 
wait longer between trials, but more than likely was due to the novelty of the 
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task, as this was the first time the rats were exposed to the vITI paradigm.  
Moreover, it is important to note that in the vITI task the amount of “time outs” 
being given to the rats is significantly increased due to increased number of 
premature responses and omissions being performed, and therefore the amount 
of time remaining in the 30 minute task time is decreased.  Therefore it is 
possible that the drop in percentage accuracy observed in the vITI task may be 
an overrepresentation, as fewer corrects and incorrects may be performed and 
thus small changes in percentage accuracy may be calculated as bigger changes 
than if 90 corrects and incorrects were performed as in the basic task.   
 
In comparison to the vSD task, the vITI task appeared to give a more broad 
manipulation to the rats’ behaviours.  As increasing ITI duration also increased 
percentage omissions, especially at ITIs of 10 seconds or more, indicating that in 
all probability the rats, when waiting this extended amount of time for the light 
to appear, had resorted to nose poking in the food magazine to initiate another 
trial, and missed the stimulus when it did appear   
 
Again, the results seen when ITI or SD is manipulated are in agreement with the 
results stated by Bari et al., (2008) in that neither response latency or reward 
latency were affected. 
 
Overall, these results suggest that the 5-CSRTT is flexible, and can be 
manipulated to tease apart specific modalities of cognition and will thus allow 
easier identification of agents which affect specific parameters of the task i.e. 
to test a drug that reduces impulsivity in the vITI task where premature 
responses is the main parameter being controlled.  Moreover, the changes in 
behaviour of the rats in the vSD and vITI task in comparison to the basic task 
imply that in the basic task the rats may have learned to rely on automatic 
processes whereas in the variable tasks the rats have continually to sustain 
attention and adapt their responses.   
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6.4.2 Effects of Erbb4 knockdown on 5-CSRTT performance 
Surgery/training-related deficits 
The general finding that several of the parameters of the 5-CSRTT changed over 
the testing period was not unexpected.  One week following surgery it was 
observed that in the basic task percentage accuracy dropped and percentage 
omissions increased suggesting that there was an overall deficit in task 
performance at this time point.  This deficit was observed over all surgical 
groups and thus was not an effect of the agent injected per se but was most 
likely a general effect of stereotaxic surgery in combination with the fact that 
the rats had not received training for one week.  Moreover the deficits in 
percentage accuracy and percentage omissions were short lived and 
performance returned to at least baseline levels by week 3, supporting the 
previous findings that there was very little tissue damage at the site of injection 
(section 4.3.2) and in addition that viral injection did not have an undesired 
global effect (supported by the findings that body weight and levels of glial 
infiltration did not alter following viral injections) (sections 4.3.5). 
 
The other trend of week having an effect on 5-CSRTT performance was evident 
in the vITI and vSD tasks where the number of premature responses was lower at 
weeks 3 and 5 compared to baseline performance.  This finding is in concordance 
with previous literature suggesting that rats become quickly adapted to 
manipulated forms of the 5-CSRTT (Bari et al., 2008).  Although percentage 
accuracy appeared to be the most affected parameter by altering the stimulus 
duration, there was no evidence that the rats adapted to this parameter in the 
same way as they did with premature responding.  This may suggest that 
impulsivity is a more adaptable process than that of sustained attention. 
 
Specific effects of Erbb4 gene manipulation on task performance 
The increase in percentage accuracy in the basic task detected at 5 weeks post-
surgery in rats that received shErbb4.rAAV is a very interesting result, as this 
corresponds to the previous finding that Erbb4 protein levels were confirmed to 
be decreased in the PFC at this specific time point (section 4.3.5).  In addition, 
the time point post-surgery at which this increase in percentage accuracy 
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became evident in shErbb4.rAAV treated rats (5 weeks) was the same time point 
post-surgery that the change in locomotor response to amphetamine manifested 
in shErbb4.rAAV treated rats in the locomotor activity task (section 5.3.3).  
Again this emphasises the suggestion that whatever effects Erbb4 knockdown is 
having on behaviour, it is taking 5 weeks to become apparent; this may be 
because this is when the optimal amount of hairpin is being expressed and thus 
when maximal gene knockdown is occurring, or it may be due to it taking 5 
weeks for Erbb4 knockdown to affect the prefrontal circuitry and manifest as 
behaviour changes.  
 
The finding of an increase in cognitive ability following Erbb4 knockdown, 
although subtle, is in accordance with previous literature in schizophrenia 
patients where the levels of ERBB4 within the dorsolateral prefrontal cortex are 
significantly increased, and expression is directly associated with a haplotype 
consisting of three intronic SNPs in linkage disequilibrium near exon 3 (Silberberg 
et al., 2006; Law et al., 2007; Chong et al., 2008).  It is therefore feasible to 
consider that decreasing Erbb4 expression within the PFC (thought to be a 
homolog of some aspects of the human DLPFC (Uylings et al., 2003; Seamans et 
al., 2008) would result in increased cognitive ability.  Interestingly one of the 
SNP’s from the risk haplotype, rs839523, has also been associated with poorer 
performance in the oddball task (in terms of reaction time) in healthy individuals 
homozygous for the risk allele (Konrad et al., 2009).  In addition a very recent 
study showed an epistatic interaction of SNPs in NRG1, ERBB4 and AKT1 resulting 
in reduced pre-frontal cortical engagement during the n-back task (Nicodemus et 
al., 2010).   
 
At 5 weeks post-surgery the protein expression of Nrg1 is also altered.  However, 
this is in the opposite direction to Erbb4, with increased expression being found 
(chapter 5).  These behavioural effects on percentage accuracy could therefore 
also be due to a change in the expression of Nrg1.  However, the studies showing 
differential expression of NRG1 in schizophrenia are somewhat unclear with type 
I NRG1 shown to be increased in DLPFC of patients (Hashimoto et al., 2004; Law 
et al., 2006; Chong et al., 2008).  However, studies have also shown decreased 
NRG1 expression at mRNA level (Barakat et al., 2010) and protein level in the 
prefrontal cortex in schizophrenia (Bertram et al., 2007).  Furthermore, studies 
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have also showed no change in NRG1 expression (Boer et al., 2009).  Despite this 
ambiguity in expression studies, NRG1 appears to be important in cognition.  A 
variant in the NRG1 gene which has shown association with increased risk to 
schizophrenia also shows association with decreased activity of the mPFC, and 
decreased premorbid IQ as assessed by the national adult reading test (Hall et 
al., 2006). 
 
Although there is no evidence of this cognitive enhancement effect of PFC Erbb4 
knockdown at 5 weeks post-surgery in the vSD task, this may be due to a “ceiling 
effect” in that the rats cannot perform at a higher level of percentage accuracy 
in the vSD task than they achieved pre-surgery and thus no pro-cognitive effect 
could emerge.  What is more, the cognitive enhancing effects seen by Erbb4 
knockdown on percentage accuracy, although subtle, are similar to levels of 
cognitive enhancement previously shown in the 5-CSRTT by nicotine (Hahn et 
al., 2002; Semenova et al., 2007).  Another explanation for not detecting 
changes in the vSD task is that the rats were not performing at a high enough 
level in the basic task before the task was manipulated as suggested by 
Semenova and colleagues.   They state that for Sprague-Dawley rats performing 
at a baseline accuracy in the basic 5-CSRTT of 79.79±1.74% “there was concern 
that in the modified task, SD rats’ low baseline performance would preclude 
meaningful evaluation of the effects of manipulations”.  Wistar rats performing 
at a baseline level of 87% accuracy in the basic task were, however, thought to 
be suitable for evaluation in the vSD task, where an effect of nicotine on 
accuracy was observed.   
 
Nrg1/Erbb4 signalling affects multiple neurotransmitter systems that are known 
to play an important role in the performance of the 5-CSRTT and in cognition in 
general.  For example Nrg1-Erbb4 signalling is important in maintaining 
glutamatergic neurotransmission, with Nrg1 mutant mice showing reduced NMDA 
receptor phosphorylation (Bjarnadottir et al., 2007) and fewer functional NMDA 
receptors in the forebrain (Stefansson et al., 2002). In addition, in a study by 
Hahn and colleagues in 2006, it was found that in brain tissue from patients that 
had schizophrenia the level of activity of Nrg1-Erbb4 signalling was enhanced 
and that this enhancement led to NMDA receptor hypofunction.  Moreover, Nrg1 
and Erbb4 mutants appear to have some behavioural similarities to NMDA 
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receptor hypomorphs (Mohn et al., 1999).  This evidence is suggestive that 
disruption of Nrg1-Erbb4 signalling affects NMDA receptor functionality, 
interestingly; the NMDA antagonist phencyclidine has a marked effect in 
disrupting 5-CSRTT performance (Amitai et al., 2008; Thomson et al., 2010) with 
acute NMDA blockade leading to deficits in premature responding and accuracy, 
and repeated treatment affecting speed of processing.   
 
Nrg1-Erbb4 signalling is also important in regulating dopaminergic 
neurotransmission, with a mouse line expressing a dominant negative form of 
Erbb4 in oligodendrocytes having significantly more dopamine transporter and 
D1-like receptor binding in the cortex, striatum and nucleus accumbens (Roy et 
al., 2007).  More recently a study showing peripheral Nrg1 injections in mice 
results in Erbb4 receptor activation and elevated dopamine levels (Kato et al., 
2010).   Furthermore injection of Nrg1 into the dorsal substantia nigra stimulates 
striatal dopamine overflow (Yurek et al., 2004).  Therefore, in the current study 
it is possible that the knockdown of Erbb4 in the mPFC affected prefrontal 
dopamine levels and as a result increased percentage accuracy as seen with 
dopaminergic compounds (6.1.3).    
 
Type I Nrg1 (initially termed ARIA: acetylcholine receptor inducing activity) was 
initially identified as a factor which was capable of accumulating AChRs at the 
neuromuscular junction (Usdin & Fischbach, 1986) and later in hippocampal 
interneurons (Liu et al., 2001). Several recent studies have implicated Nrg1 
signalling in 7-nicotinic acetylcholine receptor (-7nAChR) transmission with 
Nrg1 affecting -7nAChR surface expression (Chang & Fischbach, 2006; Hancock 
et al., 2008) and fast inward currents (Chang & Fischbach, 2006).  Additionally, 
cultures from Nrg1 type III heterozygous knock-out mice revealed these mice 
have reduced functional -7nAChR expression (Zhong et al., 2008).  As described 
in section 6.1.4, -7nAChR knock-out mice have reduced accuracy in the 5-
CSRTT whereas -7nAChR agonists have shown some promise as pro-cognitive 
agents in the 5-CSRTT.  The manipulation of the Nrg1-Erbb4 signalling pathway 
leading to pro-cognitive effects, as seen in this study, could consequently be a 
result of elevated -7nAChR expression or activity.   
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It is difficult to compare the results of this behavioural task with those studies 
previously carried out in transgenic Erbb4 and Nrg1 mice for several reasons.  
The primary comparative concern is that none of the previous studies have used 
5-CSRTT to assess the effect of mutations in Erbb4 or Nrg1 on behaviour; instead 
many of the cognitive assessments in these previous studies have relied heavily 
on tests that are hippocampus based.  Previous studies have shown that 
performance in spatial and reference working memory tasks (such as the radial 
arm maze and the Morris water maze) is impaired by knock-out of Erbb4 in the 
CNS (Golub et al., 2004; Wen et al., 2010).  Transgenic Nrg1 mice also show 
deficits in tasks such as fear conditioning, novel object recognition, continuous 
T-maze alternation task and latent inhibition (Rimer et al., 2005; Chen et al., 
2008; Ehrlichman et al., 2009; Duffy et al., 2010).  However, some studies also 
show no effect of Nrg1 manipulation on spatial learning and memory tasks 
(Gerlai et al., 2000; O’Tuathaigh et al., 2007; Duffy et al., 2010).  Care must be 
taken to interpret the wealth of studies utilising transgenic Nrg1 mice as they 
vary in which isoform of Nrg1 is being manipulated.   
 
Interestingly, Nrg1 type I over-expression results in some of the same 
behavioural observations from Nrg1 knock-out mice (Deakin et al., 2009).  This 
finding highlights the inverted U shaped hypothesis whereby either increased or 
decreased levels of Nrg1-Erbb4 signalling from the optimal levels result in 
deficits in synaptic plasticity (Role & Talmage, 2007).  This may also hold true 
for behavioural dysfunction where in schizophrenia the directionality of change 
in expression of Nrg1/Erbb4 is not key for pathophysiology: what is important is 
that the signalling has shifted from the “norm”.   
 
Secondly, it is essential to take into account that the manipulation of Erbb4 in 
this study is region specific whereas previous in vivo studies of Erbb4 have opted 
for a more global depletion of the gene.  One limitation to analysing results (in 
particular behavioural phenotypes) from transgenic mice is that the effects 
observed may be complicated by the interaction between abnormalities in 
multiple brain regions (Chen et al., 1998).   Furthermore, the evidence for 
altered Erbb4 expression in schizophrenia appears to be limited to the prefrontal 
cortex, as no change was quantified in the hippocampus (Law et al., 2006).  
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Therefore, behavioural changes following Erbb4 manipulation specifically in the 
mPFC may be more representative of schizophrenia.   
 
Small but significant changes in omissions and premature responses were 
observed in the present study; however many changes that were observed were 
not stable over time. The amount of premature responses and omissions 
performed in the 30 minute task period is very low, with on average in the basic 
task only 10 omissions and 12 premature responses being performed in the test 
period.  Therefore, a change between surgical groups in premature responses 
and omissions is more likely to produce significant results as a few additional 
premature responses or omissions will result in a big difference.  Moreover, 
there was no significant effect of surgical group on premature responses or 
omissions in the vITI task, despite these parameters being highlighted by 
extending the inter-trial interval.  This task has been widely used to measure 
subtle changes in impulsivity and visuo-spatial attention, and has been 
successful in identifying changes in these parameters not clearly evident in the 
basic task (Paterson et al., 2011). 
 
Changes in latencies suggest that the vehicle treated rats were slower to collect 
rewards than rats with Erbb4 knockdown in all three task types and also slower 
than scr.rAAV treated rats in both the vITI and vSD tasks.  Changes in latency to 
reward are generally thought to reflect changes in motivation (Robbins et al., 
2002).  However, as both viral-treated groups were quicker to collect rewards 
following correct response this would suggest the viral particles themselves 
other than the gene manipulation were affecting motivation.  There also 
appeared to be a slight effect of viral treatment on latency to make a correct 
response with viral treated rats responding quicker than the vehicle treated rats 
in the vSD task.  This may suggest there was a slight effect on the motor system 
of vehicle treated rats.  These changes in response times in viral-treated rats 
compared to vehicle treated rats are similar to the observations seen in the 
open field task where the vehicle treated rats travelled the least distance under 
vehicle treatment compared to the viral treatment groups (see chapter 5). 
However, the results with latency to response were less consistent than those of 
the latency to reward as there was no effect of viral treatment on latency to 
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response in the vITI task and in the basic task the scrambled hairpin treated rats 
were slower than those that received vehicle.  It is important to note that the 
speed that these highly trained rats are performing at is very fast, with the 
speed of the vehicle treated rats in the basic task of 569ms ±16ms, vITI task of 
613ms±34ms and vSD task of 605ms±46ms.  These latencies are very similar to 
that of Bari et al., (2008) who suggest male Hooded Lister rats should perform at 
a response latency of 571ms±41ms, 554ms±31ms, 598ms±41ms in the 
aforementioned tasks, respectively.  Furthermore, it should be noted that the 
differences between the latencies performed by the surgical groups (either to 
reward or correct response) are very small with the biggest difference between 
groups being for reward latency a 100ms difference on average between 
shErbb4.rAAV treated rats and veh treated rats in the vSD task, and for latency 
to response a 97 ms difference on average between scr.rAAV treated rats and 
veh treated rats in the vSD task. 
6.5 Conclusions 
The data in this chapter present some interesting findings with respect to a) the 
utilisation of the 5-CSRTT in measuring cognitive changes following gene 
manipulation, b) the role of Erbb4 in the mPFC in terms of cognition. 
The findings of the change in rats’ performance in the 5-CSRTT when stimulus 
duration is shortened or inter-trial interval is extended are in complete 
agreement with the expected results previously reported (Bari et al., 2008) with 
percentage accuracy decreasing in the vSD task and the number of premature 
responses increasing and slight effects on percentage accuracy and percentage 
omissions in the vITI task compared to that of the basic task set-up.  These 
findings not only support that set-up in habituation, training and testing of the 
5-CSRTT in our laboratory are accurate, but also support that the task is 
versatile and can be manipulated to suit the experimental requirements.   
With respect to viral mediated gene manipulation, this study emphasises that 
this technique is viable in investigating schizophrenia genes and will allow 
further knowledge of what part these genes, which are generally very poorly 
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understood in terms of their potential pathophysiological roles, may play in 
cognition in specific brain regions at specific stages of life.    
The main finding of this chapter was that viral-mediated Erbb4 knockdown in the 
mPFC resulted in an increase in percentage accuracy at 5 weeks post-surgery 
without having a great impact on any of the other parameters assessed in the 
task.  This would suggest that Erbb4 knockdown or Nrg1 over-expression within 
the mPFC is pro-cognitive and that the pre-frontal dependant cognitive deficits 
observed in schizophrenia may be partly due to an imbalance in this signalling 
pathway in this brain region.  Although no specific neurotransmitter system was 
analysed in depth following Erbb4 knockdown, it is most likely that this pro-
cognitive effect is a result of changes in glutamatergic, cholinergic and 
dopaminergic neurotransmission as Nrg1-Erbb4 are known to have important 
roles in all these systems (and most likely others too).  As the effect is subtle, 
and is not emphasised by decreasing SD, these data support the general 
consensus that schizophrenia is not a single gene or network disorder but one 
that is a result of insults in multiple genes which can impact upon multiple 
networks.   
The results of this study emphasise that further research should be invested in 
investigating the Nrg1-Erbb4 signalling pathway specifically in the mPFC in terms 
of cognition in order potentially to identify possible therapeutic drug targets to 
treat the cognitive deficits in schizophrenia or other disorders where Nrg1-Erbb4 
signalling may be dysfunctional.     
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The overall aims of this PhD study were to identify the roles of the schizophrenia 
candidate gene Erbb4 in neuregulin signal pathway transduction, and 
schizophrenia-related behaviours dependent on prefrontal cortex functioning.  I 
demonstrated that adeno-associated viral mediated knockdown of Erbb4 within 
the prefrontal cortex of rats resulted in changes in selected behaviours including 
measures of cognition, along with alterations in expression and activity of 
several components of the Nrg1-Erbb4 signalling cascade.  These data allow a 
greater knowledge of how dysfunctional NRG1-ERBB4 signalling in schizophrenia 
may be potentially linked to the cognitive deficits observed in the disorder, and 
may prospectively lead to therapeutic targets for the treatments of these poorly 
managed symptoms.   
7.1 Nrg1-Erbb4 signalling in NG108-15 cells 
In initial experiments the expression and activity of endogenous Erbb4 in the 
neuronal cell line NG108-15 were studied, with the aim of potentially identifying 
a neuronal cell line that could be utilised to investigate Nrg1-Erbb4 signalling 
(chapter 3).  Western blotting and RT-PCR techniques were used to show that 
NG108-15 cells express murine Erbb4 mRNA and protein, and moreover 
selectively express the JMa/CYT1 and JMa/CYT2 isoforms of Erbb4.  Although 
the levels of Erbb4 endogenous expression appeared to be low in NG108-15 cells, 
optimised siRNA-mediated knockdown of Erbb4 without overt off-target effects 
was achieved at the mRNA level.  Moreover, there was subtle but significant 
activation of Erbb4 and GSK3 following the application of NRG1 to the cells, 
indicative that Erbb4 receptors in NG108-15 cells are functional.  It has been 
previously reported that NG108-15 cells expressed Nrg1 (Pun et al., 2007); 
however, this is, to my knowledge, the first study specifically investigating the 
expression of Erbb4 in this cell line.  As Erbb4 is expressed endogenously in 
NG108-15 cells they offer a superior model for investigating Nrg1-Erbb4 
signalling as compared to cells manipulated to express these genes. Moreover 
since NG108-15 are a neuronal cell line, it is likely that the roles that these 
genes play in this cell line will be more representative of the brain than non-
neuronal cell lines such as HEK-293 cells.   Identifying cell lines, and specifically 
neuronal cell lines, that express schizophrenia candidate genes allowed 
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preliminary investigations of the functions of these genes to be carried out prior 
to in vivo studies. 
7.2 Erbb4 knockdown on schizophrenia-related 
signalling pathways and behaviours 
The pinnacle finding of this PhD study was that knockdown of Erbb4 expression 
exclusively in the mPFC was sufficient for producing selective behavioural 
phenotypes that relate to schizophrenia, such as increasing accuracy in the 5-
CSRTT which translates to increased sustained attention (chapter 6). 
This study utilised the innovative technique of viral-mediated gene manipulation 
which to date has only been used by a small number of groups to study 
schizophrenia-related genes (Mao et al., 2009; Burnet et al., 2011).  Although 
one very recent study has published viral-mediated targeting of Erbb4 (Choi et 
al., 2010), this current project is the first demonstration of the functional 
effects of viral –mediated Erbb4 manipulation in vivo.  Moreover, although 
several studies have elegantly shown behavioural and biochemical changes in 
genetically manipulated rodents that express altered levels of Erbb4, this 
present study is the first to identify the effects of altered Erbb4 expression 
within a distinct brain region. 
By targeting a distinct brain region such as the mPFC, which has been highly 
implicated in the cognitive deficits of schizophrenia, we can identify the 
potential role Erbb4 may have distinctively within this brain region.  These 
findings can then reflect how, if the function of this gene if perturbed in 
schizophrenia, can ultimately lead to these poorly treated symptoms.  
Remarkably Erbb4 knockdown within the mPFC led to an improvement in 
performance of the 5-CSRTT, a measure of attentional processes and processing 
speed (Young et al., 2009). 
These data are not only significant from a technical perspective but also from a 
biological standpoint.  No previous animal models of altered Nrg1 or Erbb4 
expression have utilised the 5-CSRTT or measures of attention and processing 
speed and therefore cannot be compared to the present study, however, the 
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finding of increased accuracy following Erbb4 knockdown parallels human 
studies.  In post-mortem dlPFC tissue from schizophrenia patients expression of 
ERBB4 has repeatedly been found to be increased (Silberberg et al., 2006; Law 
et al., 2007; Chong et al., 2008), and that this increase is selective for this brain 
region (Law et al., 2007).  Moreover, patients with variations in ERBB4 have 
dysfunctional activity in this brain region (Nicodemus et al., 2010).  In rodents 
performance accuracy in the 5-CSRTT has been positively correlated with 
activity of the mPFC (Barbelivien et al., 2001) and lesions of this region result in 
reduced accuracy (Muir et al., 1996).  It can therefore be interpreted that tight 
regulation of ERBB4 within the dlPFC is essential for optimal cognitive 
performance.   
In addition, the reliability of the 5-CSRTT finding is emphasised by the parallel 
finding that Erbb4 knockdown within the mPFC heightens the sensitivity to 
locomotor response to amphetamine at exactly the same time point post-viral 
manipulation – 5 weeks.  Not only does this finding illustrate that the 
behavioural responses occurred at the same time, but also that it is likely that 
they are both a result of altered dopamine transmission.  The locomotor 
response to amphetamine is due to increased dopamine availability (Seiden et 
al., 1993) and dopamine levels in the frontal cortex have been positively 
correlated with choice accuracy in the 5-CSRTT (Puumala & Sirvio, 1998).  These 
findings are consistent with the hypothesis that reduced dopamine levels within 
the PFC of schizophrenia patients are responsible for cognitive deficits. 
Moreover this link between prefrontal Erbb4 expression and dopamine regulation 
was highlighted by a change in the activity of Akt signalling within the PFC 
following Erbb4 knockdown.  Akt signalling has been repeatedly associated with 
dopamine regulation (Beaulieu et al., 2009), so this reduction in Akt signalling 
may reflect an altered dopaminergic modulation of Akt subsequent to Erbb4 
knockdown. The directional of the change in Akt activity in the PFC following 
Erbb4 knockdown is inconsistent with the results of Emamian et al., (2004) who 
reported decreased Akt activity in the PFC of patients with schizophrenia. 
However, the direction of the change is consistent with the data of Beaulieu et 
al. (2009), who reported that dopaminergic modulation of mouse behaviour, in 
behavioural assays such as locomotor activity, involves a suppression of Akt 
activity.   It is tempting to speculate that a reduction in PFC Erbb4 levels 
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facilitates dopaminergic suppression of Akt in the PFC, and thus enhances 
performance in behavioural tasks involving the PFC.  Equally, it should be noted 
that these signalling cascades are very complex and have multiple inputs.  
Moreover, since dopamine has also been reported to stimulate Akt, the 
decreased Akt activity may reflect a compensatory effect to reverse the 
hyperdopaminergic state that is potentially producing the behavioural 
phenotypes. 
This potential compensatory effect of decreased Akt activity is not unwarranted 
as we observed a compensatory increase in the expression of Nrg1 within the 
PFC following Erbb4 knockdown that led to a significant negative correlation 
between Nrg1 and Erbb4 expression.  This finding leads to an interesting query 
that has not been addressed in previous animal models of altered Nrg1 and Erbb4 
expression, of whether this balance of Nrg1 and Erbb4 expression is also 
affected.  Again, increasing the credibility of the findings in this present study to 
the observations of human studies, it has been repetitively found that there is 
an interaction between components of the NRG1-ERBB4-AKT1 signalling cascade 
(Benzel et al., 2007; Nicodemus et al., 2010; Sei et al., 2010).  The findings 
from these previous studies along with those reported in the current study 
emphasise that with the complexity of schizophrenia, it is unlikely that 
expression changes in one gene or protein are solely pathogenic, but instead it is 
a combination of changes in multiple related genes.   Indeed, NRG1 and ERBB4 
have also been associated with other genes including COMT, ESR1 (estrogen 
receptor 1) and DISC1 (Wong & Weickert, 2009; Sei et al., 2010; Seshadri et 
al., 2010). 
As expected Erbb4 knockdown did not lead to widespread behavioural deficits. 
Thus it appears that Erbb4 within the prefrontal cortex does not impact upon 
sensorimotor gating, as there was no effect of Erbb4 knockdown on prepulse 
inhibition performance.  This may reflect the more distributed neuronal network 
thought to be involved in PPI responses.  In addition, the lack of effect of Erbb4 
knockdown within the mPFC on PPI performance may also be due to the small 
area of mPFC transduced by the rAAV particles, or that the amount of Erbb4 
knockdown achieved by the rAAVs was insufficient to cause an effect on PPI.   
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7.3 Further work 
The data generated from this study are very thought-provoking, and if more time 
and funding were available several interesting follow-up studies could be carried 
out.  Although the behavioural changes following Erbb4 knockdown within the 
mPFC provide promising insight into Erbb4 regulating cognitive behaviour which 
points towards altered dopaminergic transmission, it is uncertain as to which 
neurotransmitter systems are altered, as neurotransmitter levels were not 
measured in this study.  It would therefore be of great interest to measure the 
levels of neurotransmitters related to Erbb4 function such as dopamine, 
glutamate, serotonin and GABA within the mPFC following Erbb4 knockdown by a 
technique such as in vivo microdialysis. 
Due to time constraints, one limiting factor of the current study is that gene and 
protein expression were only quantified at one time point post-viral injection.  
Although we successfully identified significant knockdown in Erbb4 expression 
and alterations in the levels of expression several related proteins, it would be 
of great interest to determine when the peak level of knockdown or secondary 
effects occurred by performing a time-line experiment.  However, to carry this 
out and to have a large enough sample size per time point, would require a 
substantial number of animals.  Consequently, it would also be worthwhile to 
assess the behaviours measured in this study at time points beyond 5 weeks post-
viral injection, to determine how long lasting these phenotypes were present 
and if they became more evident over time.   
Since it has been shown that specifically within the PFC it is distinct isoforms of 
ERBB4 that are over-expressed (Silberberg et al., 2006; Law et al., 2007), it 
would be fascinating to use the techniques mastered in this present study to 
knockdown specific isoforms of Erbb4 within the mPFC.  It would be 
hypothesised that knockdown of JMa/CYT1 isoforms alone would produce a more 
distinct behavioural effect that knockdown of JMb/CYT2 isoforms.  Also, as it is 
unlikely that the complex range of symptoms which define schizophrenia result 
from dysfunction in one brain region alone, further studies akin to the present 
study where Erbb4 expression is manipulated in multiple brain regions 
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simultaneously would identify behavioural and biochemical consequences of 
dysfunctional Erbb4 signalling within a complete circuit.   
Finally, it would be appealing to repeat the current studies performed in NG108-
15 cells in cells that had been differentiated, to determine whether the 
expression and activity of Erbb4 in this cell line increases in response to 
differentiation.  This might further validate this cell line as a good in vitro 
model to study Nrg1-Erbb4 signalling. 
7.4 Conclusions 
This thesis presents a number of novel findings that impact on the understanding 
of Erbb4 function within the prefrontal cortex.  The innovative technique of 
using adeno-associated viral-mediated manipulation of Erbb4 with functional 
behavioural and biochemical analyses has been reported here for the first time.  
Following primary in vitro and in vivo validation, viral-mediated Erbb4 
knockdown was achieved within the PFC, which led to increased accuracy 
performance in the 5-CSRTT and heightened sensitivity to the locomotor effects 
of amphetamine, without affecting sensorimotor gating function. 
As well as impacting on behavioural phenotypes, Erbb4 knockdown within the rat 
PFC altered biochemical signalling, with an increase in Nrg1 expression and 
decreased Akt activity observed.  These behavioural and biochemical findings 
point to a tentative link between prefrontal Erbb4 levels and dopamine 
regulation; however, it is likely that numerous other neurotransmitters may also 
be affected.   
Importantly, the data in this study highlight the validity of viral-mediated gene 
manipulation to investigate schizophrenia candidate genes, with the advantage 
of having control over spatial and temporal gene manipulation.  This innovative 
technique has enabled the investigation of the function of Erbb4 specifically 
within the prefrontal cortex in the adult rodent brain, and has led to the 
findings that 1) Erbb4 expression within the PFC is important in cognitive 
function 2) prefrontal Erbb4 is not essential in regulating sensorimotor gating 
and 3) alterations in Erbb4 expression affect multiple components of the Nrg1-
Erbb4 signalling cascade. 
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These findings are a vital stepping stone to a greater understanding of how 
ERBB4 may be potentially pathophysiological in schizophrenia, and with follow 
up studies can prospectively lead to new therapeutic targets for the treatment 
of the cognitive deficits of schizophrenia.   
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